10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

Commission file number 1-34435

EMDEON INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	20-5799664
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
3055 Lebanon Pike, Suite 1000 Nashville, TN	37214
(Address of Principal Executive Offices)	(Zip Code)

(615) 932-3000

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ¨    No  x*

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class	Outstanding as of November 7, 2014
Common Stock, $0.01 par value	100

* The registrant is a voluntary filer of certain reports required to be filed by companies under Section 13 or 15(d) of the Securities and Exchange Act of 1934 and has filed all reports that would have been required to have been filed by the registrant during the preceding 12 months had it been subject to such filing requirements during the entirety of such period.

Emdeon Inc.

Table of Contents

Part I. Financial Information
Item 1. Financial Statements	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	39
Item 3. Quantitative and Qualitative Disclosures About Market Risk	54
Item 4. Controls and Procedures	55
Part II. Other Information
Item 1. Legal Proceedings	55
Item 1A. Risk Factors	55
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	55
Item 3. Defaults Upon Senior Securities	55
Item 4. Mine Safety Disclosures	55
Item 5. Other Information	56
Item 6. Exhibits	56
Signatures	57
Exhibit Index	58

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Emdeon Inc.

Condensed Consolidated Balance Sheets

(unaudited and amounts in thousands, except share and per share amounts)

	September 30, 2014			December 31, 2013
ASSETS
Current assets:
Cash and cash equivalents	$	23,927		$	76,538
Accounts receivable, net of allowance for doubtful accounts of $4,310 and $3,856 at September 30, 2014 and December 31, 2013, respectively		231,950			214,247
Deferred income tax assets		16,974			6,317
Prepaid expenses and other current assets		33,085			27,019
Total current assets		305,936			324,121
Property and equipment, net		239,635			269,470
Goodwill		1,584,655			1,502,434
Intangible assets, net		1,530,775			1,632,688
Other assets, net		19,656			19,169
Total assets	$	3,680,657		$	3,747,882
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	12,263		$	8,367
Accrued expenses		143,807			131,149
Deferred revenues		10,233			10,881
Current portion of long-term debt		24,493			31,330
Total current liabilities		190,796			181,727
Long-term debt, excluding current portion		1,998,569			1,999,026
Deferred income tax liabilities		416,986			436,263
Tax receivable agreement obligations to related parties		159,716			150,496
Other long-term liabilities		13,576			11,824
Commitments and contingencies
Equity:
Common stock (par value, $.01), 100 shares authorized and outstanding at September 30, 2014 and December 31, 2013, respectively		—			—
Additional paid-in capital		1,147,586			1,139,375
Accumulated other comprehensive income (loss)		(1,570	)		(1,343	)
Accumulated deficit		(245,002	)		(169,486	)
Total equity		901,014			968,546
Total liabilities and equity	$	3,680,657		$	3,747,882

See accompanying notes to unaudited condensed consolidated financial statements.

3

Emdeon Inc.

Condensed Consolidated Statements of Operations

(unaudited and amounts in thousands)

	Three Months Ended September 30, 2014			Three Months Ended September 30, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Revenue	$	341,608		$	317,810		$	996,973		$	922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		202,305			191,695			597,843			563,146
Development and engineering		8,156			7,878			24,771			23,201
Sales, marketing, general and administrative		45,031			44,104			150,739			123,469
Depreciation and amortization		48,448			47,181			141,541			137,943
Accretion		4,452			7,112			9,220			18,712
Impairment of long-lived assets		3,114			25			82,689			1,887
Operating income (loss)		30,102			19,815			(9,830	)		54,094
Interest expense, net		36,635			37,000			109,741			116,390
Loss on extinguishment of debt		—			—			—			23,160
Contingent consideration		1,976			1,879			3,646			1,879
Other		—			(2,925	)		(3,968	)		(2,925	)
Income (loss) before income tax provision (benefit)		(8,509	)		(16,139	)		(119,249	)		(84,410	)
Income tax provision (benefit)		4,493			126			(43,733	)		(26,422	)
Net income (loss)	$	(13,002	)	$	(16,265	)	$	(75,516	)	$	(57,988	)

See accompanying notes to unaudited condensed consolidated financial statements.

4

Emdeon Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited and amounts in thousands)

	Three Months Ended September 30, 2014			Three Months Ended September 30, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Net income (loss)	$	(13,002	)	$	(16,265	)	$	(75,516	)	$	(57,988	)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		732			(1,064	)		(127	)		2,511
Foreign currency translation adjustment		(127	)		35			(100	)		(65	)
Other comprehensive income (loss)		605			(1,029	)		(227	)		2,446
Total comprehensive income (loss)	$	(12,397	)	$	(17,294	)	$	(75,743	)	$	(55,542	)

See accompanying notes to unaudited condensed consolidated financial statements.

5

Emdeon Inc.

Condensed Consolidated Statements of Equity

(unaudited and amounts in thousands, except share amounts)

	Common Stock				Additional Paid-in			Retained Earnings			Accumulated Other Comprehensive			Total
	Shares		Amount		Capital			(Deficit)			Income (Loss)			Equity
Balance at January 1, 2013		100	$	—	$	1,130,968		$	(95,028	)	$	(3,789	)	$	1,032,151
Equity compensation expense		—		—		5,637			—			—			5,637
Repurchase of Parent common stock		—		—		(250	)		—			—			(250	)
Net income (loss)		—		—		—			(57,988	)		—			(57,988	)
Foreign currency translation adjustment		—		—		—			—			(65	)		(65	)
Change in fair value of interest rate swap, net of taxes		—		—		—			—			2,511			2,511
Balance at September 30, 2013		100	$	—	$	1,136,355		$	(153,016	)	$	(1,343	)	$	981,996
Balance at January 1, 2014		100	$	—	$	1,139,375		$	(169,486	)	$	(1,343	)	$	968,546
Equity compensation expense		—		—		5,914			—			—			5,914
Issuance of shares in connection with equity compensation plans, net of taxes		—		—		1,257			—			—			1,257
Repurchase of Parent common stock		—		—		(960	)		—			—			(960	)
Capital contribution from Parent		—		—		2,000			—			—			2,000
Net income (loss)		—		—		—			(75,516	)		—			(75,516	)
Foreign currency translation adjustment		—		—		—			—			(100	)		(100	)
Change in fair value of interest rate swap, net of taxes		—		—		—			—			(127	)		(127	)
Balance at September 30, 2014		100	$	—	$	1,147,586		$	(245,002	)	$	(1,570	)	$	901,014

See accompanying notes to unaudited condensed consolidated financial statements.

6

Emdeon Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited and amounts in thousands)

	Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Operating activities
Net income (loss)	$	(75,516	)	$	(57,988	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		141,541			137,943
Accretion		9,220			18,712
Equity compensation		5,914			5,637
Deferred income tax expense (benefit)		(44,886	)		(27,884	)
Amortization of debt discount and issuance costs		5,804			6,585
Contingent consideration		3,646			1,879
Gain on sale of cost method investment		—			(2,925	)
Loss on extinguishment of debt		—			22,828
Impairment of long-lived assets		82,689			1,887
Other		(3,125	)		(819	)
Changes in operating assets and liabilities:
Accounts receivable		(12,656	)		(15,582	)
Prepaid expenses and other		(4,490	)		(1,804	)
Accounts payable		644			685
Accrued expenses, deferred revenue and other liabilities		(375	)		20,985
Tax receivable agreement obligations to related parties		—			(103	)
Net cash provided by (used in) operating activities		108,410			110,036
Investing activities
Purchases of property and equipment		(37,673	)		(52,806	)
Payments for acquisitions, net of cash acquired		(87,909	)		(18,291	)
Proceeds from sale of cost method investment		36			5,820
Other		(133	)		—
Net cash provided by (used in) investing activities		(125,679	)		(65,277	)
Financing activities
Debt principal payments		(9,659	)		(9,692	)
Payment of debt assumed from acquisition		(23,262	)		(218	)
Proceeds from Revolving Facility		65,000			—
Payments on Revolving Facility		(65,000	)		—
Payment of loan costs		—			(2,178	)
Repayment of deferred financing arrangements		(4,717	)		(2,103	)
Repurchase of Parent common stock		(960	)		(250	)
Capital contribution from Parent		3,256			—
Other		—			(518	)
Net cash provided by (used in) financing activities		(35,342	)		(14,959	)
Net increase (decrease) in cash and cash equivalents		(52,611	)		29,800
Cash and cash equivalents at beginning of period		76,538			31,763
Cash and cash equivalents at end of period	$	23,927		$	61,563

See accompanying notes to unaudited condensed consolidated financial statements.

7

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

1. Nature of Business and Organization

Nature of Business

Emdeon Inc. (the “Company”), through its subsidiaries, is a provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers, pharmacies and patients of the United States healthcare system. The Company’s product and service offerings integrate and automate key business and administrative functions for healthcare payers, providers and pharmacies throughout the patient encounter, including pre-care patient eligibility and benefits verification and enrollment, clinical information exchange, claims management and adjudication, payment integrity, payment distribution, payment posting and denial management and patient billing and payment processing.

Organization

The Company was formed as a Delaware limited liability company in September 2006 and converted into a Delaware corporation in September 2008 in anticipation of the Company’s August 2009 initial public offering (the “IPO”). On November 2, 2011, pursuant to an Agreement and Plan of Merger among the Company, Beagle Parent Corp. (“Parent”) and Beagle Acquisition Corp. (“Merger Sub”), Merger Sub merged with and into the Company with the Company surviving the merger (the “Merger”). Subsequent to the Merger, the Company became an indirect wholly-owned subsidiary of Parent, which is controlled by affiliates of The Blackstone Group L.P. (“Blackstone”).

2. Basis of Presentation

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) Guidelines, Rules and Regulations (“Regulation S-X”) and, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of results for the unaudited interim periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The results of operations for the interim period are not necessarily indicative of the results to be obtained for the full fiscal year. All material intercompany accounts and transactions have been eliminated in the unaudited condensed consolidated financial statements.

Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The Company changed the classification of rebate payments to its channel partners from cost of operations to a reduction of revenue to the extent that such rebate payments for any given channel partner were less than or equal to revenue otherwise earned from the respective channel partner. To conform to the current period presentation, rebate payments to channel partners resulted in a reduction of revenue of $6,096 and $18,641 for the three and nine months ended September 30, 2013, respectively.

Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors and various other assumptions that the Company believes are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses and disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in the Company’s business environment; therefore, actual results could differ materially from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the reported results of operations; and if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Estimates and assumptions by management affect: the allowance for doubtful

8

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

accounts; the fair value assigned to assets acquired and liabilities assumed in business combinations; tax receivable agreement obligations; the fair value of interest rate swap obligations; contingent consideration; loss accruals; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses; revenue recognition; contingencies; and the value attributed to equity awards.

During the three months ended September 30, 2014, the Company recognized a change in estimate related to its accounts receivable, the effect of which reduced revenue and increased pretax loss by $4,098.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, which changes the requirements for reporting discontinued operations. Following adoption of this update, discontinued operations generally will be reported for the disposal by sale or otherwise of a component or a group of components that represents a strategic shift that has or will have a major effect on an entity’s operations and financial results. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2014, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, which replaces most prior general and industry specific revenue recognition guidance with a principles-based comprehensive revenue recognition framework. Under this revised framework, a company will recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2016. Early adoption is not permitted. Upon adoption, a company may elect to either retrospectively restate each prior reporting period or reflect the cumulative effect of initially applying the update with an adjustment to retained earnings. The Company is currently assessing the potential effects this update may have on its consolidated financial statements.

In June 2014, the FASB issued ASU No. 2014-12, which clarifies, in the context of share-based payment awards, that a performance target that affects vesting and could be achieved after the requisite service period has been rendered should be treated as a performance condition. Prior to this update, because there was no explicit guidance, there was diversity in practice among companies. This update is effective for fiscal years and interim periods within those years beginning after December 15, 2015, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

3. Concentration of Credit Risk

The Company’s revenue is primarily generated in the United States. Changes in economic conditions, government regulations or demographic trends, among other matters, in the United States could adversely affect the Company’s revenue and results of operations.

The Company maintains its cash and cash equivalent balances in either insured depository accounts or money market mutual funds. The money market mutual funds are limited to investments in low-risk securities such as United States or government agency obligations, or repurchase agreements secured by such securities.

4. Business Combinations

In July 2014, the Company acquired all of the equity interests of Capario, Inc. (“Capario”), a technology-enabled provider of revenue cycle management solutions.

In February 2014, the Company acquired all of the equity interests of Vieosoft, Inc. (“Vieosoft”), a development stage enterprise.

9

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

In June 2013, the Company acquired all of the equity interests of Goold Health Systems (“Goold”), a technology-enabled provider of pharmacy benefit and related services primarily to state Medicaid agencies across the nation.

The following table summarizes certain information related to these acquisitions. The preliminary values of the consideration transferred, assets acquired and liabilities assumed in the Capario acquisition, including related tax effects, are subject to receipt of a final valuation and a final working capital settlement.

	Capario			Vieosoft			Goold
Total Consideration Fair Value at Acquisition Date:
Cash paid at closing	$	89,422		$	800		$	19,391
Contingent consideration		—			6,015			5,553
Other		(227	)		—			(5	)
	$	89,195		$	6,815		$	24,939
Allocation of the Consideration Transferred:
Cash	$	2,292		$	21		$	1,101
Accounts receivable		5,046			—			3,435
Deferred income tax assets		275			—			—
Prepaid expenses and other current assets		1,112			—			647
Property and equipment		9,580			—			7,695
Identifiable intangible assets:
Tradename		900			—			—
Noncompetition agreements		2,740			1,320			280
Customer relationships		38,510			—			5,160
Backlog and other		—			2,060			460
Goodwill		76,062			6,159			14,300
Accounts payable		(2,020	)		—			(541	)
Accrued expenses		(9,068	)		(194	)		(2,076	)
Deferred revenues		—			—			(101	)
Current maturities of long-term debt		(2,600	)		(1,877	)		(218	)
Deferred income tax liabilities		(14,642	)		(674	)		(5,203	)
Long-term debt		(18,785	)		—			—
Other long-term liabilities		(207	)		—			—
Total consideration transferred	$	89,195		$	6,815		$	24,939
Acquisition costs in sales, marketing, general and administrative expense:
For the three months ended September 30, 2014	$	234		$	—		$	—
For the three months ended September 30, 2013	$	—		$	—		$	18
For the nine months ended September 30, 2014	$	862		$	111		$	—
For the nine months ended September 30, 2013	$	—		$	—		$	280

10

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

	Capario		Vieosoft		Goold
Other Information:
Gross contractual accounts receivable	$	5,112	$	—	$	3,435
Amount not expected to be collected	$	66	$	—	$	—
Goodwill expected to be deductible for tax purposes	$	—	$	—	$	—
Contingent Consideration Information:
Contingent consideration range		N/A	$	0 - $43,104	$	0 - 15,000
Measurement period				February 12, 2014 to December 31, 2017		July 1, 2013 to September 30, 2014
Basis of measurement		N/A		Milestone achievement, revenue performance		Award of contracts with annual revenue exceeding targeted amount
Type of measurement		N/A		Level 3		Level 3
Key assumptions at the acquisition date:
Probability of achieving milestone objectives		N/A		90%		N/A
Probability of achieving minimum gross profit margin		N/A		5% for 2015 - 90% for 2017		N/A
Probability of winning new contracts		N/A		N/A		10%-50%
Probability of retaining contracts that expire during the measurement period		N/A		N/A		90%
Range of baseline revenue retention for existing customers		N/A		N/A		75%-125%
Expected payment date(s)		N/A		2015-2017		12/15/2014
Discount rate(s)		N/A		5.2% to 53.2%		15.4%
Increase (decrease) to net loss:
For the three months ended September 30, 2014		N/A	$	647	$	1,329
For the nine months ended September 30, 2014		N/A	$	1,305	$	2,341
For the three months ended September 30, 2013		N/A		N/A	$	1,879
For the nine months ended September 30, 2013		N/A		N/A	$	1,879

The Company generally recognizes goodwill attributable to the assembled workforce and expected synergies among the operations of acquired entities and the Company’s existing operations. In the case of the Company’s acquisitions of operating companies, synergies generally have resulted from the elimination of duplicative facilities and personnel costs and cross selling opportunities among the Company’s existing customer base.

Goodwill is generally deductible for federal income tax purposes when a business combination is treated as an asset purchase. Goodwill is generally not deductible for federal income tax purposes when the business combination is treated as a stock purchase.

5. Goodwill and Intangible Assets

Goodwill activity during the nine months ended September 30, 2014 was as follows:

	Payer		Provider		Pharmacy		All Other		Total
Balance at December 31, 2013	$	827,455	$	401,845	$	160,561	$	112,573	$	1,502,434
Acquisitions		18,792		34,211		6,159		23,059		82,221
Balance at September 30, 2014	$	846,247	$	436,056	$	166,720	$	135,632	$	1,584,655

11

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Intangible assets subject to amortization as of September 30, 2014 consisted of the following:

	Weighted Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net
Customer relationships	16.2	$	1,602,232	$	(232,575	)	$	1,369,657
Trade names	16.2		157,430		(23,235	)		134,195
Non-compete agreements	2.2		17,140		(8,260	)		8,880
Data sublicense agreement	3.0		31,000		(15,275	)		15,725
Other	6.0		2,653		(335	)		2,318
Total		$	1,810,455	$	(279,680	)	$	1,530,775

Amortization expense was $75,286 and $78,140 for the nine months ended September 30, 2014 and 2013, respectively. Aggregate future amortization expense for intangible assets is estimated to be:

2014 (remainder)	$	25,574
2015		101,888
2016		101,301
2017		97,399
2018		92,788
Thereafter		1,111,825
	$	1,530,775

During the nine months ended September 30, 2014, the Company recognized an impairment charge related to the pending partial loss of a customer contract. See Note 8 to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report.

6. Long-Term Debt

In November 2011, the Company entered into a credit agreement which was comprised of a senior secured term loan facility (the “Term Loan Facility”), a revolving credit facility (the “Revolving Facility”; together with the Term Loan Facility, the “Senior Credit Facilities”), 11% senior notes due 2019 (the “2019 Notes”) and 11.25% senior notes due 2020 (the “2020 Notes”; together with the 2019 Notes, the “Senior Notes”).

12

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Long-term debt as of September 30, 2014 and December 31, 2013, consisted of the following:

	September 30,			December 31,
	2014			2013
Senior Credit Facilities
$1,301 million Senior Secured Term Loan facility, due November 2, 2018, net of unamortized discount of $13,520 and $15,826 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 4.21%)	$	1,255,092		$	1,262,445
$125 million Senior Secured Revolving Credit facility, expiring on November 2, 2016 and bearing interest at a variable base rate plus a spread rate		—			—
Senior Notes
$375 million 11% Senior Notes due December 31, 2019, net of unamortized discount of $6,966 and $7,664 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.53%)		368,034			367,336
$375 million 11.25% Senior Notes due December 31, 2020, net of unamortized discount of $8,868 and $9,560 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.86%)		366,132			365,440
Obligation under data sublicense agreement		22,543			22,543
Other		11,261			12,592
Less current portion		(24,493	)		(31,330	)
Long-term debt	$	1,998,569		$	1,999,026

Senior Credit Facilities

The credit agreement governing the Senior Credit Facilities (the “Senior Credit Agreement”) provides that, subject to certain conditions, the Company may request additional tranches of term loans, increase commitments under the Revolving Facility or the Term Loan Facility or add one or more incremental revolving credit facility tranches (provided that the revolving credit commitments outstanding at any time have no more than three different maturity dates) in an aggregate amount not to exceed (a) $300,000 plus (b) an unlimited amount at any time, subject to compliance on a pro forma basis with a first lien net leverage ratio of no greater than 4.00:1.00. Availability of such additional tranches of term loans or revolving credit facilities and/or increased commitments is subject to, among other conditions, the absence of any default under the Senior Credit Agreement and the receipt of commitments by existing or additional financial institutions. Proceeds of the Revolving Facility, including up to $30,000 in the form of borrowings on same-day notice, referred to as swingline loans, and up to $50,000 in the form of letters of credits, are available to provide financing for working capital and general corporate purposes.

Borrowings under the Senior Credit Facilities bear interest at an annual rate equal to an applicable margin plus, at the Company’s option, either (a) a base rate determined by reference to the highest of (i) the applicable prime rate, (ii) the federal funds rate plus 0.50% and (iii) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00%, which base rate, in the case of the Term Loan Facility only, shall be no less than 2.25%, or (b) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, which, in the case of the Term Loan Facility only, shall be no less than 1.25%.

In April 2012, the Company amended the Senior Credit Agreement to reprice the Senior Credit Facilities and borrow $80,000 of additional term loans. Following this amendment, the LIBOR-based interest rate on the Term Loan Facility was LIBOR plus 3.75%, compared to the previous interest rate of LIBOR plus 5.50%. The new LIBOR-based interest rate on the Revolving Facility was LIBOR plus 3.50% (with a potential step-down to LIBOR plus 3.25% based on the Company’s first lien net leverage ratio), compared to the previous interest rate of LIBOR plus 5.25% (with a potential step-down to LIBOR plus 5.00% based on the Company’s first lien net leverage ratio).

In April 2013, the Company again amended the Senior Credit Agreement to further reprice, and also to modify certain financial covenants under, the Senior Credit Facilities. Following this amendment, the interest rate on the Term Loan Facility is LIBOR plus 2.50%, compared to the previous interest rate of LIBOR plus 3.75%. The new interest rate on the Revolving Facility is LIBOR plus

13

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

2.50%, compared to the previous interest rate of LIBOR plus 3.50% (or 3.25% based on a specified first lien net leverage ratio). The Term Loan Facility remains subject to a LIBOR floor of 1.25%, and there continues to be no LIBOR floor on the Revolving Facility. In connection with the April 2013 repricing, the Senior Credit Agreement also was amended to, among other things, eliminate the financial covenant related to the consolidated cash interest coverage ratio and modify the financial covenant related to the net leverage test by maintaining the required first lien net leverage ratio at 5.35 to 1.00 for the remaining term of the Senior Credit Facilities.

These amendments to the Senior Credit Agreement resulted in a loss on extinguishment of debt of $23,160 and other expenses related to fees paid to third parties of $1,151 for the nine months ended September 30, 2013, which have been reflected within sales, marketing, general and administrative expense in the accompanying consolidated statements of operations.

In addition to paying interest on outstanding principal under the Senior Credit Facilities, the Company is required to pay customary agency fees, letter of credit fees and a 0.50% commitment fee in respect of the unutilized commitments under the Revolving Facility.

The Senior Credit Agreement requires that the Company prepay outstanding loans under the Term Loan Facility, subject to certain exceptions, with (a) 100% of the net cash proceeds of any incurrence of debt other than debt permitted under the Senior Credit Agreement, (b) commencing with the fiscal year ended December 31, 2012, 50% (which percentage will be reduced to 25% and 0% based on the Company’s first lien net leverage ratio) of the Company’s annual excess cash flow and (c) 100% of the net cash proceeds of certain asset sales and casualty and condemnation events, subject to reinvestment rights and certain other exceptions.

The Company generally may voluntarily prepay outstanding loans under the Senior Credit Facilities at any time without premium or penalty other than breakage costs with respect to LIBOR loans.

The Company is required to make quarterly payments equal to 0.25% of the aggregate principal amount of the loans under the Term Loan Facility, with the balance due and payable on November 2, 2018. Any principal amount outstanding under the Revolving Facility is due and payable on November 2, 2016.

Certain of the Company’s United States wholly-owned restricted subsidiaries, together with the Company, are co-borrowers and jointly and severally liable for all obligations under the Senior Credit Facilities. Such obligations of the co-borrowers are unconditionally guaranteed by Beagle Intermediate Holdings, Inc. (a direct wholly-owned subsidiary of Parent), the Company and each of its existing and future United States wholly-owned restricted subsidiaries (with certain exceptions including immaterial subsidiaries). These obligations are secured by a perfected security interest in substantially all of the assets of the co-borrowers and guarantors now owned or later acquired, including a pledge of all of the capital stock of the Company and its United States wholly-owned restricted subsidiaries and 65% of the capital stock of its foreign restricted subsidiaries, subject in each case to the exclusion of certain assets and additional exceptions.

The Senior Credit Agreement requires the Company to comply with a maximum first lien net leverage ratio financial maintenance covenant, to be tested on the last day of each fiscal quarter. A breach of the first lien net leverage ratio covenant is subject to certain equity cure rights. In addition, the Senior Credit Facilities contain a number of negative covenants that, among other things and subject to certain exceptions, restrict the Company’s ability and the ability of its subsidiaries to:

• incur additional indebtedness or guarantees;

• incur liens;

• make investments, loans and acquisitions;

• consolidate or merge;

• sell assets, including capital stock of subsidiaries;

• pay dividends on capital stock or redeem, repurchase or retire capital stock of the Company or any restricted subsidiary, subject to customary covenants, including compliance with leverage ratios and subject to limitation based on net income generated during the term of the Senior Credit Agreement;

• alter the business of the Company;

• amend, prepay, redeem or purchase subordinated debt;

14

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

• engage in transactions with affiliates; and

• enter into agreements limiting dividends and distributions of certain subsidiaries.

The Senior Credit Agreement also contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default (including upon change of control).

As of September 30, 2014, the Company believes it was in compliance with all of the applicable debt covenants under the Senior Credit Agreement.

Senior Notes

The 2019 Notes bear interest at an annual rate of 11.00% with interest payable semi-annually on June 30 and December 31 of each year. The 2019 Notes mature on December 31, 2019. The 2020 Notes bear interest at an annual rate of 11.25% with interest payable quarterly on March 31, June 30, September 30 and December 31 of each year. The 2020 Notes mature on December 31, 2020.

The Company may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at any time on or after December 31, 2015 at the applicable redemption price, plus accrued and unpaid interest. In addition, at any time prior to December 31, 2014, the Company may, at its option and on one or more occasions, redeem up to 35% of the aggregate principal amount of the 2019 Notes or the 2020 Notes, at a redemption price equal to 100% of the aggregate principal amount, plus a premium equal to the stated interest rate on the 2019 Notes or the 2020 Notes, respectively, plus accrued and unpaid interest with the net cash proceeds of certain equity offerings; provided that at least 50% of the sum of the aggregate principal amount of the 2019 Notes or 2020 Notes, respectively, originally issued (including any additional notes) remain outstanding immediately after such redemption and the redemption occurs within 180 days of the equity offering. At any time prior to December 31, 2015, the Company may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at its option and on one or more occasions, at a redemption price equal to 100% of the principal amount, plus an applicable premium and accrued and unpaid interest. If the Company experiences specific kinds of changes in control, it must offer to purchase the Senior Notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest.

The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of the Company’s existing and future indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness. The Company’s obligations under the Senior Notes are guaranteed on a senior basis by all of its existing and subsequently acquired or organized wholly-owned United States restricted subsidiaries that guarantee the Senior Credit Facilities or its other indebtedness or indebtedness of any affiliate guarantor. The Senior Notes and the related guarantees are effectively subordinated to the Company’s existing and future secured obligations and that of its affiliate guarantors to the extent of the value of the collateral securing such obligations, and are structurally subordinated to all existing and future indebtedness and other liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Notes.

The indentures governing the Senior Notes (the “Indentures”) contain customary covenants that restrict the ability of the Company and its restricted subsidiaries to:

• pay dividends on their capital stock or redeem, repurchase or retire their capital stock, subject to customary covenants, including compliance with a fixed charge coverage ratio and subject to limitation based on net income generated during the term of the Indentures;

• incur additional indebtedness or issue certain capital stock;

• incur certain liens;

• make investments, loans, advances and acquisitions;

• consolidate, merge or transfer all or substantially all of their assets and the assets of their subsidiaries;

• prepay subordinated debt;

• engage in certain transactions with affiliates; and

• enter into agreements restricting the subsidiaries’ ability to pay dividends.

The Indentures also contain certain customary affirmative covenants and events of default.

15

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

As of September 30, 2014, the Company believes it was in compliance with all of the applicable debt covenants under the Senior Notes.

Obligation Under Data Sublicense Agreement

In October 2009 and April 2010, the Company acquired certain additional rights to specified uses of its data from the former owner of the Company’s business in order to broaden the Company’s ability to pursue business intelligence and data analytics solutions for payers and providers. The Company previously licensed exclusive rights to this data to the former owner of the Company’s business. In connection with these data rights acquisitions, the Company recorded amortizable intangible assets and corresponding obligations at inception based on the present value of the scheduled annual payments through 2018, which totaled $65,000 in the aggregate (approximately $30,000 remained payable at September 30, 2014). In connection with the Merger, the Company was required to adjust this obligation to its fair value.

Other

From time to time, the Company enters into deferred financing arrangements with certain vendors. The obligations under such arrangements are recorded at the present value of the scheduled payments. Such future payments totaled $12,081 at September 30, 2014.

7. Interest Rate Swap

Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During the three and nine months ended September 30, 2014, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt pursuant to the Term Loan Facility. As of September 30, 2014, the Company had three outstanding interest rate derivatives with a combined notional amount of $640,000 that were designated as cash flow hedges of interest rate risk.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an additional $2,570 will be reclassified as an increase to interest expense.

16

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

The following table summarizes the fair value of the Company’s derivative instruments at September 30, 2014 and December 31, 2013:

	Fair Values of Derivative Instruments
	Asset (Liability) Derivatives
	Balance Sheet Location	September 30, 2014			December 31, 2013
Derivatives designated as hedging instruments:
Interest rate swaps	Other assets	$	679		$	899
Interest rate swaps	Accrued expenses		(2,570	)		(2,575	)
		$	(1,891	)	$	(1,676	)

Tabular Disclosure of the Effect of Derivative Instruments on the Statement of Operations

The effect of the derivative instruments on the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013, respectively, is summarized in the following table:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Derivatives in Cash Flow Hedging Relationships
Gain/ (loss) related to effective portion of derivative recognized in other comprehensive loss	$	595		$	(2,305	)	$	(2,150	)	$	2,096
Gain/ (loss) related to effective portion of derivative reclassified from accumulated other comprehensive loss to interest expense	$	(652	)	$	(652	)	$	(1,935	)	$	(1,935	)

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where if the Company defaults on any of its indebtedness, including default where repayment of the indebtedness has not been accelerated by the lender, then the Company also could be declared in default on its derivative obligations.

As of September 30, 2014, the termination value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $2,595. If the Company had breached any of these provisions at September 30, 2014, the Company could have been required to settle its obligations under the agreements at this termination value. The Company does not offset any derivative instruments and the derivative instruments are not subject to collateral posting requirements.

8. Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company’s assets and liabilities that are measured at fair value on a recurring basis consist of the Company’s derivative financial instruments and contingent consideration associated with business combinations. The table below summarizes these items as of September 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

Description	Balance at September 30, 2014			Quoted in Markets Identical (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Interest rate swaps	$	(1,891	)	$	—	$	(1,891	)	$	—
Contingent consideration obligations		(15,145	)		—		—			(15,145	)
Total	$	(17,036	)	$	—	$	(1,891	)	$	(15,145	)

17

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

The valuation of the Company’s derivative financial instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivative, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair value of the interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments) using the overnight index swap rate as the discount rate.

The Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements and measures the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs to evaluate the likelihood of default by itself and by its counterparties. As of September 30, 2014, the Company determined that the credit valuation adjustments are not significant to the overall valuation of its derivatives. As a result, the Company determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

The valuation of the Company’s contingent consideration obligations is estimated as the present value of total expected contingent consideration payments which are determined using a Monte Carlo simulation. This analysis reflects the contractual terms of the purchase agreements and utilizes assumptions with regard to future sales, probabilities of achieving such future sales, the likelihood and timing of expected payments and a discount rate. Significant increases with respect to assumptions as to future sales and probabilities of achieving such future sales would result in a higher fair value measurement, while an increase in the discount rate would result in a lower fair value measurement.

The table below presents a reconciliation of the fair value of the liabilities that use significant unobservable inputs (Level 3).

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Balance at beginning of period	$	(13,169	)	$	(5,887	)	$	(5,484	)	$	(296	)
Adjustment of provisional amounts		—			223			—			—
Issuance of contingent consideration		—			—			(6,015	)		(5,495	)
Settlement of contingent consideration		—			105			—			232
Total changes included in contingent consideration		(1,976	)		(1,879	)		(3,646	)		(1,879	)
Balance at end of period	$	(15,145	)	$	(7,438	)	$	(15,145	)	$	(7,438	)

Assets and Liabilities Measured at Fair Value on a Non-recurring Basis

During the nine months ended September 30, 2014, the Company’s pharmacy services segment received notice that its existing contract with a customer would not be renewed in full upon its expiration. As a result, the Company abandoned a customer related project that was under development and assessed the recoverability of the net assets included in the relevant asset group. The Company recognized an impairment charge to write off the abandoned project and to adjust the carrying value of the asset group to its fair value. This latter impairment charge was generally allocated to the affected long-lived assets on a pro rata basis. Additionally, the Company abandoned certain pharmacy services and provider services segment development projects in connection with execution of certain strategic initiatives during the nine months ended September 30, 2014.

18

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

The following table summarizes the affected financial statement captions, the allocation of the impairment charges among those captions and provides certain quantitative information associated with the required fair value measurements.

	Range of Inputs		Fair Value		Impairment
Long-lived assets to be held and used
Relevant asset group		N/A	$	13,066	$	73,220
Balance sheet account:
Customer relationships		N/A		N/A	$	72,290
Property and equipment		N/A		N/A	$	930
Unobservable inputs (discounted cash flow method):
Probability of contract extension		80%		N/A		N/A
Probability of new contract execution		20%-90%		N/A		N/A
Expected annual revenue range	$	3,080-$3,590		N/A		N/A
Risk free interest rate		1.6%		N/A		N/A
Long-lived assets to be disposed of
Property and Equipment		N/A	$	—	$	8,848

Assets and Liabilities Measured at Fair Value upon Initial Recognition

The carrying amount and the estimated fair value of financial instruments held by the Company as of September 30, 2014 were:

	Carrying Amount		Fair Value
Cash and cash equivalents	$	23,927	$	23,927
Accounts receivable	$	231,950	$	231,950
Senior Credit Facilities (Level 1)	$	1,255,092	$	1,255,926
Senior Notes (Level 2)	$	734,166	$	830,861

The carrying amounts of cash equivalents and accounts receivable approximate fair value because of their short-term maturities. The fair value of long-term debt is based upon market quotes and trades by investors in partial interests of these instruments.

9. Legal Proceedings

The Company finalized and paid $8,000 related to the settlement of a vendor fee dispute during the three months ended September 30, 2014, with $500 and $3,000 of this amount recognized within sales, general, marketing and administrative expense during the three and nine months ended September 30, 2014, respectively.

Additionally, in the normal course of business, the Company is involved in various claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the Company does not believe that their outcomes will have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

10. Income Taxes

In January 2014, the Company effected a change in the tax status of EBS Master LLC (“EBS Master”) from a partnership to a corporation. Prior to the tax status change, the Company recognized a deferred tax liability for the difference in the book and tax basis of its investment in EBS Master (i.e. outside basis). Following the tax status change, the Company’s deferred tax balances reflect the differences in the book and tax bases of the individual assets and liabilities included in the corporation. In addition, as a result of the change in tax status, the Company was required to revise the apportionment of its income taxes among various state taxing jurisdictions.

Income taxes were also affected by the establishment of a valuation allowance related to state deferred tax assets for three of the Company’s subsidiaries.

19

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

After giving effect to this change in tax status and these other items, income taxes for the nine months ended September 30, 2014 amounted to an income tax benefit of $43,733 and an effective tax rate of 36.7%. The income tax benefit for the nine months ended September 30, 2013, which does not reflect the change in tax status, was $26,422 and resulted in an effective tax rate of 31.3%.

11. Tax Receivable Agreement Obligation to Related Parties

In connection with the IPO, the Company entered into tax receivable agreements which obligated the Company to make payments to certain current and former owners of the Company, including affiliates of Hellman and Friedman (“H&F”) and certain members of management, equal to 85% of the applicable cash savings that the Company realizes as a result of tax attributes arising from certain previous transactions. The Company will retain the benefit of the remaining 15% of these tax savings.

In November 2011, H&F and certain current and former members of management exchanged all of their remaining EBS Master Units (“EBS Units”) for cash and a combination of cash and shares of Parent, respectively, and the former majority owner of the Company assigned its rights under the tax receivable agreements to affiliates of Blackstone (Blackstone, together with H&F and certain current and former members of management are sometimes referred to collectively as the “TRA Members”). Additionally, effective December 31, 2011, the Company simplified its corporate structure. The tax attributes of the exchange of EBS Units and corporate restructuring are expected to provide the Company with additional cash savings, 85% of which are payable to the TRA Members. Collectively, the Company expects the tax attributes of the above referenced events to result in cumulative payments under the tax receivable agreements of approximately $352,521. $160,690 of this amount, which reflected the initial fair value of the tax receivable agreement obligations plus recognized accretion, was reflected as an obligation on the accompanying unaudited condensed consolidated balance sheet at September 30, 2014.

During the nine months ended September 30, 2014, the Company changed its estimate of the timing and amount of future cash flows attributable to the tax receivable agreements as a result of the effective tax rate change resulting from the change in tax status of EBS Master from a partnership to a corporation and the acquisitions of Vieosoft and Capario. These revised estimates resulted in a decrease to pretax net loss of $5,756 for the nine months ended September 30, 2014.

12. Segment Reporting

Effective January 1, 2014, the Company completed an internal reorganization of its reporting structure which resulted in a change in the composition of its operating segments. Additionally, the Company periodically makes other changes to the composition of its operating segments. Prior period segment information is restated to reflect the organizational structure and any other changes made.

Management views the Company’s operating results in three reportable segments: (a) payer services, (b) provider services and (c) pharmacy services. Listed below are the results of operations for each of the reportable segments. In addition to these reportable segments, the Company reports financial information for two additional operating segments that is presented on an aggregate basis. This information is reflected in the manner utilized by management to make operating decisions, assess performance and allocate resources. Segment assets are not presented to management for purposes of operational decision making, and therefore are not included in the accompanying tables. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies in the notes to the Company’s audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the SEC.

Payer Services Segment

The payer services segment provides payment cycle solutions that simplify the administration of healthcare related to insurance eligibility and benefit verification, claims management, payment integrity and payment distribution. Additionally, the payer services segment provides patient billing and payment and consulting services.

20

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Provider Services Segment

The provider services segment provides revenue cycle management solutions, government program eligibility and enrollment services and revenue optimization solutions primarily to hospitals, physician practices, laboratories and other healthcare providers that simplify providers’ revenue cycle and workflow, reduce related costs and improve cash flow.

Pharmacy Services Segment

The pharmacy services segment provides electronic prescribing services, other electronic solutions and benefit administration services to pharmacies, pharmacy benefit management companies, government agencies and other payers related to prescription benefit claim filing, adjudication and management.

All Other

All Other consists of two operating segments, one of which provides revenue cycle management solutions through channel partners and one of which provides revenue cycle solutions, either directly or through channel partners, to dental practices.

Corporate and Eliminations

Inter-segment revenue and expenses primarily represent claims management and patient billing and payment services provided between segments.

Corporate and eliminations includes management, administrative and other shared corporate services functions such as information technology, legal, finance, human resources, marketing and product management, as well as eliminations to remove inter-segment revenue and expenses. These administrative and other shared services costs are excluded from the adjusted EBITDA measure for each respective operating segment.

21

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

The revenue and adjusted EBITDA for the operating segments are as follows:

	Three Months Ended September 30, 2014
	Payer		Provider			Pharmacy			All Other		Corporate and Eliminations			Consolidated
Revenue from external customers:
Claims management	$	73,314	$	—		$	—		$	—	$	—		$	73,314
Payment distribution services		73,703		—			—			—		—			73,703
Patient billing and payment services		68,360		—			—			—		—			68,360
Revenue cycle technology		—		32,343			—			—		—			32,343
Revenue cycle services		—		34,979			—			—		—			34,979
Physician services		—		12,041			—			—		—			12,041
Pharmacy		—		—			31,649			—		—			31,649
Channel Partner		—		—			—			13,152		(6,200	)		6,952
Dental		—		—			—			8,267		—			8,267
Inter-segment revenue		2,490		—			90			—		(2,580	)		—
Net revenue	$	217,867	$	79,363		$	31,739		$	21,419	$	(8,780	)	$	341,608
Income (loss) before income taxes		51,103		26,565			9,846			11,742		(107,765	)	$	(8,509	)
Interest expense		—		(159	)		(5	)		—		36,799			36,635
Depreciation and amortization		16,843		12,178			3,254			41		16,132			48,448
EBITDA		67,946		38,584			13,095			11,783		(54,834	)		76,574
Equity compensation		254		265			77			21		1,615			2,232
Acquisition accounting adjustments		18		7			152			—		12			189
Acquisition-related costs		461		12			—			8		906			1,387
Transaction-related costs and advisory fees		—		—			—			—		1,683			1,683
Strategic initiatives, duplicative and transition costs		—		7			96			—		303			406
Severance costs		321		801			13			—		767			1,902
Accretion		—		—			—			—		4,452			4,452
Impairment of long-lived assets		—		—			(90	)		—		3,204			3,114
Contingent consideration		—		—			1,976			—		—			1,976
Other non-routine, net		523		106			37			—		(529	)		137
EBITDA Adjustments		1,577		1,198			2,261			29		12,413			17,478
Adjusted EBITDA	$	69,523	$	39,782		$	15,356		$	11,812	$	(42,421	)	$	94,052

22

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

	Three Months Ended September 30, 2013
	Payer			Provider		Pharmacy			All Other		Corporate and Eliminations			Consolidated
Revenue from external customers:
Claims management	$	78,292		$	—	$	—		$	—	$	—		$	78,292
Payment distribution services		63,942			—		—			—		—			63,942
Patient billing and payment services		62,911			—		—			—		—			62,911
Revenue cycle technology		—			29,678		—			—		—			29,678
Revenue cycle services		—			31,172		—			—		—			31,172
Physician services		—			9,237		—			—		—			9,237
Pharmacy		—			—		30,363			—		—			30,363
Channel Partner		—			—		—			10,230		(6,095	)		4,135
Dental		—			—		—			8,080		—			8,080
Inter-segment revenue		1,625			—		77			—		(1,702	)		—
Net revenue	$	206,770		$	70,087	$	30,440		$	18,310	$	(7,797	)	$	317,810
Income (loss) before income taxes		51,815			20,052		9,725			8,509		(106,240	)	$	(16,139	)
Interest expense		(2	)		—		(3	)		—		37,005			37,000
Depreciation and amortization		16,333			11,579		4,309			43		14,917			47,181
EBITDA		68,146			31,631		14,031			8,552		(54,318	)		68,042
Equity compensation		285			315		62			292		1,135			2,089
Acquisition accounting adjustments		65			76		94			4		12			251
Acquisition-related costs		884			29		41			2		563			1,519
Transaction-related costs and advisory fees		—			—		—			—		1,500			1,500
Strategic initiatives, duplicative and transition costs		—			—		223			16		2,188			2,427
Severance costs		84			105		18			—		3,302			3,509
Accretion		—			—		—			—		7,112			7,112
Impairment of long-lived assets		—			25		—			—		—			25
Contingent consideration		—			—		1,879			—		—			1,879
Other non-routine, net		101			136		2			—		(3,344	)		(3,105	)
EBITDA Adjustments		1,419			686		2,319			314		12,468			17,206
Adjusted EBITDA	$	69,565		$	32,317	$	16,350		$	8,866	$	(41,850	)	$	85,248

23

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

	Nine Months Ended September 30, 2014
	Payer			Provider			Pharmacy			All Other		Corporate and Eliminations			Consolidated
Revenue from external customers:
Claims management	$	215,614		$	—		$	—		$	—	$	—		$	215,614
Payment distribution services		213,766			—			—			—		—			213,766
Patient billing and payment services		205,921			—			—			—		—			205,921
Revenue cycle technology		—			95,254			—			—		—			95,254
Revenue cycle services		—			101,491			—			—		—			101,491
Physician services		—			30,619			—			—		—			30,619
Pharmacy		—			—			92,808			—		—			92,808
Channel Partner		—			—			—			34,659		(17,618	)		17,041
Dental		—			—			—			24,459		—			24,459
Inter-segment revenue		7,062			—			271			—		(7,333	)		—
Net revenue	$	642,363		$	227,364		$	93,079		$	59,118	$	(24,951	)	$	996,973
Income (loss) before income taxes		146,600			67,797			(40,942	)		31,170		(323,874	)	$	(119,249	)
Interest expense		(9	)		(159	)		(6	)		—		109,915			109,741
Depreciation and amortization		49,921			36,127			11,479			159		43,855			141,541
EBITDA		196,512			103,765			(29,469	)		31,329		(170,104	)		132,033
Equity compensation		769			759			198			66		4,122			5,914
Acquisition accounting adjustments		85			57			546			3		34			725
Acquisition-related costs		1,368			273			(72	)		9		3,895			5,473
Transaction-related costs and advisory fees		—			—			—			—		4,799			4,799
Strategic initiatives, duplicative and transition costs		59			230			192			—		9,205			9,686
Severance costs		851			1,227			18			30		3,626			5,752
Accretion		—			—			—			—		9,220			9,220
Impairment of long-lived assets		—			448			73,751			—		8,490			82,689
Contingent consideration		—			—			3,646			—		—			3,646
Other non-routine, net		3,156			465			206			6		(1,085	)		2,748
EBITDA Adjustments		6,288			3,459			78,485			114		42,306			130,652
Adjusted EBITDA	$	202,800		$	107,224		$	49,016		$	31,443	$	(127,798	)	$	262,685

24

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

	Nine Months Ended September 30, 2013
	Payer		Provider		Pharmacy			All Other		Corporate and Eliminations			Consolidated
Revenue from external customers:
Claims management	$	215,933	$	—	$	—		$	—	$	—		$	215,933
Payment distribution services		194,174		—		—			—		—			194,174
Patient billing and payment services		189,396		—		—			—		—			189,396
Revenue cycle technology		—		87,777		—			—		—			87,777
Revenue cycle services		—		92,273		—			—		—			92,273
Physician services		—		27,030		—			—		—			27,030
Pharmacy		—		—		80,331			—		—			80,331
Channel Partner		—		—		—			29,689		(18,642	)		11,047
Dental		—		—		—			24,491		—			24,491
Inter-segment revenue		4,399		—		256			—		(4,655	)		—
Net revenue	$	603,902	$	207,080	$	80,587		$	54,180	$	(23,297	)	$	922,452
Income (loss) before income taxes		144,726		54,987		30,740			25,039		(339,902	)	$	(84,410	)
Interest expense		1		33		(8	)		—		116,364			116,390
Depreciation and amortization		48,355		35,607		11,573			88		42,320			137,943
EBITDA		193,082		90,627		42,305			25,127		(181,218	)		169,923
Equity compensation		865		906		140			844		2,882			5,637
Acquisition accounting adjustments		236		402		53			15		35			741
Acquisition-related costs		1,821		91		47			4		494			2,457
Transaction-related costs and advisory fees		—		—		—			—		4,825			4,825
Strategic initiatives, duplicative and transition costs		130		—		781			85		3,359			4,355
Severance costs		434		319		252			263		3,870			5,138
Loss on extinguishment of debt and other related costs		—		—		—			—		24,311			24,311
Accretion		—		—		—			—		18,712			18,712
Impairment of long-lived assets		—		—		—			—		1,887			1,887
Contingent consideration		—		—		1,879			—		—			1,879
Other non-routine, net		218		544		7			6		(2,200	)		(1,425	)
EBITDA Adjustments		3,704		2,262		3,159			1,217		58,175			68,517
Adjusted EBITDA	$	196,786	$	92,889	$	45,464		$	26,344	$	(123,043	)	$	238,440

13. Accumulated Other Comprehensive Income (Loss)

The following is a summary of the accumulated other comprehensive income (loss) balances, net of taxes, as of and for the nine months ended September 30, 2014.

	Foreign Currency Translation Adjustment			Cash Flow Hedge			Accumulated Other Comprehensive Income (Loss)
Balance at January 1, 2014	$	(264	)	$	(1,079	)	$	(1,343	)
Change associated with foreign currency translation		(100	)		—			(100	)
Change associated with current period hedging		—			(2,062	)		(2,062	)
Reclassification into earnings		—			1,935			1,935
Balance at September 30, 2014	$	(364	)	$	(1,206	)	$	(1,570	)

25

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

14. Supplemental Condensed Consolidating Financial Information

In lieu of providing separate annual and interim financial statements for each guarantor of the Senior Notes, Regulation S-X provides companies, if certain criteria are satisfied, with the option to instead provide condensed consolidating financial information for its issuers, guarantors and non-guarantors. In the case of the Company, the applicable criteria include the following: (i) the Senior Notes are fully and unconditionally guaranteed on a joint and several basis, (ii) each of the guarantors of the Senior Notes is a direct or indirect wholly-owned subsidiary of the Company and (iii) any non-guarantors are considered minor as that term is defined in Regulation S-X. Because each of these criteria has been satisfied by the Company, condensed consolidating balance sheets as of September 30, 2014 and December 31, 2013, condensed consolidating statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2014 and 2013, respectively, and condensed consolidating cash flows for the nine months ended September 30, 2014 and 2013, respectively, for the Company, segregating the issuer, the subsidiary guarantors and consolidating adjustments, are reflected below. Prior period amounts have been reclassified to conform to the current year presentation.

26

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Balance Sheet

	As of September 30, 2014
	Emdeon Inc.		Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	740	$	23,187	$	—		$	23,927
Accounts receivable, net of allowance for doubtful accounts		—		231,950		—			231,950
Deferred income tax assets		100		16,874		—			16,974
Prepaid expenses and other current assets		3,972		29,113		—			33,085
Total current assets		4,812		301,124		—			305,936
Property and equipment, net		7		239,628		—			239,635
Due from affiliates		—		138,176		(138,176	)		—
Investment in consolidated subsidiaries		1,718,809		—		(1,718,809	)		—
Goodwill		—		1,584,655		—			1,584,655
Intangible assets, net		135,750		1,395,025		—			1,530,775
Other assets, net		138,648		16,030		(135,022	)		19,656
Total assets	$	1,998,026	$	3,674,638	$	(1,992,007	)	$	3,680,657
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	12,263	$	—		$	12,263
Accrued expenses		16,589		127,218		—			143,807
Deferred revenues		—		10,233		—			10,233
Current portion of long-term debt		5,577		18,916		—			24,493
Total current liabilities		22,166		168,630		—			190,796
Due to affiliates		138,176		—		(138,176	)		—
Long-term debt, excluding current portion		776,954		1,221,615		—			1,998,569
Deferred income tax liabilities		—		552,008		(135,022	)		416,986
Tax receivable agreement obligations to related parties		159,716		—		—			159,716
Other long-term liabilities		—		13,576		—			13,576
Commitments and contingencies
Equity		901,014		1,718,809		(1,718,809	)		901,014
Total liabilities and equity	$	1,998,026	$	3,674,638	$	(1,992,007	)	$	3,680,657

27

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Balance Sheet

	As of December 31, 2013
	Emdeon Inc.		Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	2,794	$	73,744	$	—		$	76,538
Accounts receivable, net of allowance for doubtful accounts		—		214,247		—			214,247
Deferred income tax assets		—		6,317		—			6,317
Prepaid expenses and other current assets		3,441		23,578		—			27,019
Total current assets		6,235		317,886		—			324,121
Property and equipment, net		10		269,460		—			269,470
Due from affiliates		—		69,142		(69,142	)		—
Investment in subsidiaries		1,764,213		—		(1,764,213	)		—
Goodwill		—		1,502,434		—			1,502,434
Intangible assets, net		142,500		1,490,188		—			1,632,688
Other assets, net		64,536		14,949		(60,316	)		19,169
Total assets	$	1,977,494	$	3,664,059	$	(1,893,671	)	$	3,747,882
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	8,367	$	—		$	8,367
Accrued expenses		8,205		122,944		—			131,149
Deferred revenues		—		10,881		—			10,881
Current portion of long-term debt		5,775		25,555		—			31,330
Total current liabilities		13,980		167,747		—			181,727
Due to affiliates		69,142		—		(69,142	)		—
Long-term debt, excluding current portion		775,330		1,223,696		—			1,999,026
Deferred income tax liabilities		—		496,579		(60,316	)		436,263
Tax receivable agreement obligations to related parties		150,496		—		—			150,496
Other long-term liabilities		—		11,824		—			11,824
Commitments and contingencies		—		—		—			—
Total equity		968,546		1,764,213		(1,764,213	)		968,546
Total liabilities and equity	$	1,977,494	$	3,664,059	$	(1,893,671	)	$	3,747,882

28

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2014
	Emdeon Inc.			Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
Revenue	$	—		$	341,608	$	—		$	341,608
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—			202,305		—			202,305
Development and engineering		—			8,156		—			8,156
Sales, marketing, general and administrative		1,290			43,741		—			45,031
Depreciation and amortization		2,251			46,197		—			48,448
Accretion		4,452			—		—			4,452
Impairment of long-lived assets		—			3,114		—			3,114
Operating income (loss)		(7,993	)		38,095		—			30,102
Equity in earnings of consolidated subsidiaries		(10,110	)		—		10,110			—
Interest expense, net		23,418			13,217		—			36,635
Contingent consideration		—			1,976		—			1,976
Income (loss) before income tax provision (benefit)		(21,301	)		22,902		(10,110	)		(8,509	)
Income tax provision (benefit)		(8,299	)		12,792		—			4,493
Net income (loss)	$	(13,002	)	$	10,110	$	(10,110	)	$	(13,002	)

29

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2013
	Emdeon Inc.			Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
Revenue	$	—		$	317,810	$	—		$	317,810
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—			191,695		—			191,695
Development and engineering		—			7,878		—			7,878
Sales, marketing, general and administrative		1,997			42,107		—			44,104
Depreciation and amortization		2,251			44,930		—			47,181
Accretion		7,112			—		—			7,112
Impairment of long-lived assets		—			25		—			25
Operating income (loss)		(11,360	)		31,175		—			19,815
Equity in earnings of consolidated subsidiaries		(3,766	)		—		3,766			—
Interest expense, net		23,579			13,421		—			37,000
Contingent consideration		—			1,879		—			1,879
Other		(2,925	)		—		—			(2,925	)
Income (loss) before income tax provision (benefit)		(28,248	)		15,875		(3,766	)		(16,139	)
Income tax provision (benefit)		(11,983	)		12,109		—			126
Net income (loss)	$	(16,265	)	$	3,766	$	(3,766	)	$	(16,265	)

30

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2014
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments			Consolidated
Revenue	$	—		$	996,973		$	—		$	996,973
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—			597,843			—			597,843
Development and engineering		—			24,771			—			24,771
Sales, marketing, general and administrative		13,775			136,964			—			150,739
Depreciation and amortization		6,753			134,788			—			141,541
Accretion		9,220			—			—			9,220
Impairment of long-lived assets		—			82,689			—			82,689
Operating income (loss)		(29,748	)		19,918			—			(9,830	)
Equity in earnings of consolidated subsidiaries		51,018			—			(51,018	)		—
Interest expense, net		70,224			39,517			—			109,741
Contingent consideration		—			3,646			—			3,646
Other		(111	)		(3,857	)		—			(3,968	)
Income (loss) before income tax provision (benefit)		(150,879	)		(19,388	)		51,018			(119,249	)
Income tax provision (benefit)		(75,363	)		31,630			—			(43,733	)
Net income (loss)	$	(75,516	)	$	(51,018	)	$	51,018		$	(75,516	)

31

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2013
	Emdeon Inc.			Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
Revenue	$	—		$	922,452	$	—		$	922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—			563,146		—			563,146
Development and engineering		—			23,201		—			23,201
Sales, marketing, general and administrative		7,023			116,446		—			123,469
Depreciation and amortization		6,753			131,190		—			137,943
Accretion		18,712			—		—			18,712
Impairment of long-lived assets		—			1,887		—			1,887
Operating income (loss)		(32,488	)		86,582		—			54,094
Equity in earnings of consolidated subsidiaries		(6,216	)		—		6,216			—
Interest expense, net		70,621			45,769		—			116,390
Loss on extinguishment of debt		485			22,675		—			23,160
Contingent consideration		—			1,879		—			1,879
Other		(2,925	)		—		—			(2,925	)
Income (loss) before income tax provision (benefit)		(94,453	)		16,259		(6,216	)		(84,410	)
Income tax provision (benefit)		(36,465	)		10,043		—			(26,422	)
Net income (loss)	$	(57,988	)	$	6,216	$	(6,216	)	$	(57,988	)

32

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2014
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments			Consolidated
Net income (loss)	$	(13,002	)	$	10,110		$	(10,110	)	$	(13,002	)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		732			—			—			732
Foreign currency translation adjustment		—			(127	)		—			(127	)
Equity in other comprehensive earnings		(127	)		—			127			—
Other comprehensive income (loss)		605			(127	)		127			605
Total comprehensive income (loss)	$	(12,397	)	$	9,983		$	(9,983	)	$	(12,397	)

33

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2013
	Emdeon Inc.			Guarantor Subsidiaries		Consolidating Adjustments			Consolidated
Net income (loss)	$	(16,265	)	$	3,766	$	(3,766	)	$	(16,265	)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(1,064	)		—		—			(1,064	)
Foreign currency translation adjustment		—			35		—			35
Equity in other comprehensive earnings		35			—		(35	)		—
Other comprehensive income (loss)		(1,029	)		35		(35	)		(1,029	)
Total comprehensive income (loss)	$	(17,294	)	$	3,801	$	(3,801	)	$	(17,294	)

34

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2014
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments		Consolidated
Net income (loss)	$	(75,516	)	$	(51,018	)	$	51,018	$	(75,516	)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(127	)		—			—		(127	)
Foreign currency translation adjustment		—			(100	)		—		(100	)
Equity in other comprehensive earnings		(100	)		—			100		—
Other comprehensive income (loss)		(227	)		(100	)		100		(227	)
Total comprehensive income (loss)	$	(75,743	)	$	(51,118	)	$	51,118	$	(75,743	)

35

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2013
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments			Consolidated
Net income (loss)	$	(57,988	)	$	6,216		$	(6,216	)	$	(57,988	)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		2,511			—			—			2,511
Foreign currency translation adjustment		—			(65	)		—			(65	)
Equity in other comprehensive earnings		(65	)		—			65			—
Other comprehensive income (loss)		2,446			(65	)		65			2,446
Total comprehensive income (loss)	$	(55,542	)	$	6,151		$	(6,151	)	$	(55,542	)

36

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2014
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments			Consolidated
Operating activities
Net income (loss)	$	(75,516	)	$	(51,018	)	$	51,018		$	(75,516	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		6,753			134,788			—			141,541
Accretion		9,220			—			—			9,220
Equity compensation		255			5,659			—			5,914
Deferred income tax expense (benefit)		(74,817	)		29,931			—			(44,886	)
Amortization of debt discount and issuance costs		2,003			3,801			—			5,804
Contingent consideration		—			3,646			—			3,646
Impairment of long lived assets		—			82,689			—			82,689
Equity in earnings of consolidated subsidiaries		51,018			—			(51,018	)		—
Other		(1,094	)		(2,031	)		—			(3,125	)
Changes in operating assets and liabilities:
Accounts receivable		—			(12,656	)		—			(12,656	)
Prepaid expenses and other		(462	)		(4,028	)		—			(4,490	)
Accounts payable		—			644			—			644
Accrued expenses, deferred revenue, and other liabilities		9,377			(9,752	)		—			(375	)
Due to/from affiliates		69,034			(69,034	)		—			—
Net cash provided (used in) by operating activities		(4,229	)		112,639			—			108,410
Investing activities
Purchases of property and equipment		—			(37,673	)		—			(37,673	)
Payments for acquisitions, net of cash acquired		—			(87,909	)		—			(87,909	)
Proceeds from sale of cost method investment		36			—			—			36
Other		—			(133	)		—			(133	)
Investment in subsidiary		50			—			(50	)		—
Net cash provided by (used in) investing activities		86			(125,715	)		(50	)		(125,679	)
Financing activities
Distributions from (to) Emdeon Inc. net		—			(50	)		50			—
Debt principal payments		(207	)		(9,452	)		—			(9,659	)
Payment of debt assumed from acquisition		—			(23,262	)		—			(23,262	)
Proceeds from Revolving Facility		—			65,000			—			65,000
Payments on Revolving Facility		—			(65,000	)		—			(65,000	)
Repayment of deferred financing arrangements		—			(4,717	)		—			(4,717	)
Repurchase of Parent common stock		(960	)		—			—			(960	)
Capital contribution from Parent		3,256			—			—			3,256
Net cash provided by (used in) financing activities		2,089			(37,481	)		50			(35,342	)
Net decrease in cash and cash equivalents		(2,054	)		(50,557	)		—			(52,611	)
Cash and cash equivalents at beginning of period		2,794			73,744			—			76,538
Cash and cash equivalents at end of period	$	740		$	23,187		$	—		$	23,927

37

Emdeon Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited and amounts in thousands, except share and per share amounts)

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2013
	Emdeon Inc.			Guarantor Subsidiaries			Consolidating Adjustments			Consolidated
Operating activities
Net income (loss)	$	(57,988	)	$	6,216		$	(6,216	)	$	(57,988	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		6,753			131,190			—			137,943
Accretion expense		18,712			—			—			18,712
Equity compensation expense		178			5,459			—			5,637
Deferred income tax expense (benefit)		(33,425	)		5,541			—			(27,884	)
Amortization of debt discount and issuance costs		1,865			4,720			—			6,585
Contingent consideration		—			1,879			—			1,879
Loss on extinguishment of debt		478			22,350			—			22,828
Impairment of long lived assets		—			1,887			—			1,887
Gain on sale of cost method investment		(2,925	)		—			—			(2,925	)
Equity in earnings of consolidated subsidiaries		(6,216	)		—			6,216			—
Other		(819	)		—			—			(819	)
Changes in operating assets and liabilities:
Accounts receivable		—			(15,582	)		—			(15,582	)
Prepaid expenses and other		(4,732	)		2,928			—			(1,804	)
Accounts payable		—			685			—			685
Accrued expenses, deferred revenue, and other liabilities		14,509			6,476			—			20,985
Tax receivable agreement obligations to related parties		(103	)		—			—			(103	)
Due to/from affiliates		1,923			(1,923	)		—			—
Net cash provided by (used in) operating activities		(61,790	)		171,826			—			110,036
Investing activities
Purchases of property and equipment		—			(52,806	)		—			(52,806	)
Payments for acquisitions, net of cash acquired		—			(18,291	)		—			(18,291	)
Proceeds from sale of cost method investment		5,820			—			—			5,820
Investment in subsidiaries, net		56,149			—			(56,149	)		—
Net cash provided by (used in) investing activities		61,969			(71,097	)		(56,149	)		(65,277	)
Financing activities
Distributions from (to) Emdeon Inc., net		—			(56,149	)		56,149			—
Debt principal payments		(211	)		(9,481	)		—			(9,692	)
Payment of debt assumed from acquisition		—			(218	)		—			(218	)
Payment of loan costs		—			(2,178	)		—			(2,178	)
Repayment of deferred financing arrangements		—			(2,103	)		—			(2,103	)
Repurchase of Parent common stock		—			(250	)		—			(250	)
Other		—			(518	)		—			(518	)
Net cash provided by (used in) financing activities		(211	)		(70,897	)		56,149			(14,959	)
Net increase (decrease) in cash and cash equivalents		(32	)		29,832			—			29,800
Cash and cash equivalents at beginning of period		754			31,009			—			31,763
Cash and cash equivalents at end of period	$	722		$	60,841		$	—		$	61,563

38

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes in Part I, Item 1 of this Quarterly Report on Form 10-Q (“Quarterly Report”), together with the risk factors contained in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013 (“Form 10-K”) on file with the Securities and Exchange Commission (“SEC”).

Unless stated otherwise or the context otherwise requires, references in this Quarterly Report to “we”, “us”, “our”, “Emdeon” and “the Company” refer to Emdeon Inc. and its subsidiaries.

Forward-Looking Statements

This Quarterly Report includes certain forward-looking statements within the meaning of the federal securities laws regarding, among other things, our or our management’s intentions, plans, beliefs, expectations or predictions of future events, which are considered forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements often include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based upon assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. As you read this Quarterly Report, you should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our Form 10-K. Although we believe that these forward-looking statements are based upon reasonable assumptions, you should be aware that many factors, including those described under the heading “Risk Factors” in our Form 10-K, could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements.

Our forward-looking statements made herein speak only as of the date on which made. We expressly disclaim any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this Quarterly Report.

Overview

We are a leading provider of revenue and payment cycle management and clinical information exchange solutions connecting payers, providers, pharmacies and patients in the United States healthcare system. Our solutions integrate and automate key business and administrative functions of our payer, provider and pharmacy customers throughout the patient encounter, including pre-care patient eligibility and benefits verification and enrollment, clinical information exchange capabilities, claims management and adjudication, payment integrity, payment distribution, payment posting and denial management and patient billing and payment services. Our customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes by using our comprehensive suite of solutions.

We deliver our solutions and operate our business in three reportable segments: (i) payer services, which provides solutions primarily to commercial insurance companies, third party administrators and governmental payers; (ii) provider services, which provides solutions primarily to hospitals, physician practices, laboratories and other healthcare providers; and (iii) pharmacy services, which provides solutions to pharmacies, pharmacy benefit management companies, government agencies and other payers. Through our payer services segment, we provide payment cycle solutions that simplify the administration of healthcare related to insurance eligibility and benefit verification, claims management, payment integrity and payment distribution. Additionally, we provide patient billing and payment and consulting services through our payer services segment. Through our provider services segment, we provide revenue cycle management solutions, government program eligibility and enrollment services and revenue optimization solutions that simplify providers’ revenue cycle and workflow, reduce related costs and improve cash flow. Through our pharmacy services segment, we provide electronic prescribing, other electronic solutions and benefit administration services related to prescription benefit claim filing, adjudication and management.

39

There are a number of company-specific initiatives and industry trends that may affect our business volumes, revenues, cost of operations and margins. As part of our strategy, we encourage our customers to migrate from paper-based claim, patient billing and payment, payment distribution and other transaction processing to electronic, automated processing in order to improve efficiency. Our business is aligned with our customers to support this transition, and as they migrate from paper-based processing to electronic processing, even though our revenues for an applicable customer generally will decline, our margins and profitability will typically increase. For example, because the cost of postage is included in our revenues for patient billing and payment services (which is then also deducted as a cost of operations), when our customers transition to electronic processing, our revenues and costs of operations are expected to decrease as we will no longer incur or be required to charge for postage. As another example, as our payer customers migrate to comprehensive management services agreements with us, our electronic transaction volume usually increases while the rebates we pay and the per transaction rates we charge under these agreements are typically reduced.

Part of our strategy also includes the development and introduction of new solutions. Our new and updated solutions are likely to require us to incur development and engineering expenditures, both operating and capital, and related sales and marketing costs at levels greater than recent years’ expenditures in order to successfully develop and achieve market acceptance of such solutions. We also may acquire, or enter into agreements with third parties to assist us in providing, new solutions. For example, we offer our electronic payment solutions through banks or vendors who contract with banks and other financial service firms. The costs of these initiatives or the failure to achieve broad penetration in target markets with respect to new or updated solutions may negatively affect our results of operations, margins and cash flow. Because newly introduced solutions generally will have lower margins initially as compared to our existing and more mature solutions, our margins and margin growth may be adversely affected on a percentage basis until these new solutions achieve scale and maturity.

In addition to our internal development efforts, we actively evaluate opportunities to improve and expand our solutions through strategic acquisitions. Our acquisition strategy focuses on identifying acquisitions that improve and streamline the business and administrative functions of healthcare. We believe our broad customer footprint allows us to deploy acquired solutions into our installed base, which, in turn, can help accelerate growth of our acquired businesses. We also believe our management team’s ability to identify acquisition opportunities that are complementary and synergistic to our business, and to integrate them into our existing operations with minimal disruption, will continue to play an important role in the expansion of our business and growth. Our success in acquiring and integrating acquired businesses into our existing operations, the associated costs of such acquisitions, including integration costs, and the operating characteristics of the acquired businesses also may impact our results of operations and margins. Because the businesses we acquire sometimes have lower margins than our existing businesses, primarily as a result of their lack of scale and maturity, our margins on a percentage basis may be adversely affected in the periods subsequent to an acquisition from revenue mix changes and integration activities associated with these acquisitions.

We also expect to continue to be affected by general economic, regulatory and demographic factors affecting the healthcare industry. For several years, there has been pricing pressure in our industry, particularly as it relates to our claims management solutions, which has led and is expected to continue to lead to reduced prices for the same services. We have sought in the past and will continue to seek to mitigate pricing pressure by providing additional value-added solutions, increasing the volume of solutions we provide and managing our costs. In addition, significant changes in regulatory schemes, such as the updated Health Insurance Portability and Accountability Act of 1996, American Recovery and Reinvestment Act of 2009, the Patient Protection and Affordable Care Act (“ACA”) and other federal healthcare policy initiatives, impact our customers’ healthcare activities and can result in increased operating costs and capital expenditures for us. In particular, we believe the ACA will significantly affect the regulatory environment in which we and our customers operate by changing how healthcare services are covered, delivered and reimbursed through expanded coverage of previously uninsured individuals, increased efforts to link federal healthcare program payments to quality and efficiency and insurance market reforms. Also, changes in federal and state reimbursement patterns and rates can impact the revenues in certain of our business lines, particularly our government program eligibility and enrollment solutions. We are unable to predict how providers, payers, pharmacies and other healthcare market participants will respond to the various reform provisions of the ACA, and we cannot be sure that the markets for our solutions will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in those markets.

Demographic trends affecting the healthcare industry, such as population growth and aging or unemployment rates, also could affect the frequency and nature of our customers’ healthcare transactional activity. The impact of such changes could impact our revenues, cost of operations and infrastructure expenses and thereby affect our results of operations and the way we operate our business. For example, an increase in the United States population, if such increase is accompanied by an increase in the United States population that has health insurance benefits, or the aging of the United States population, which requires an overall increased need for healthcare services, may result in an increase in our business volumes which, in turn,

40

may increase our revenues and cost of operations. Alternatively, a general economic downturn, which reduces the number of discretionary health procedures by patients, or a persistent high unemployment rate, which lessens healthcare utilization, may decrease or offset other growth in our volumes, which, in turn, may adversely impact our revenues and cost of operations.

Recent Developments

In January 2014, we reorganized our reportable segments as payer services, provider services and pharmacy services. In addition to these reportable segments, we report financial information for two additional operating segments that is presented on an aggregate basis. This discussion and analysis related to prior periods has been restated to reflect our current organizational structure.

In January 2014, we effected a change in the tax status of EBS Master LLC (“EBS Master”) from a partnership to a corporation. Prior to the tax status change, we recognized a deferred tax liability for the difference in the book and tax basis of our investment in EBS Master (i.e. outside basis). Following the tax status change, our deferred tax balances reflect the differences in the book and tax bases of the individual assets and liabilities included in the corporation. In addition, as a result of the change in tax status, we were required to revise the apportionment of our income taxes among various state taxing jurisdictions.

In February 2014, we acquired all of the equity interests of Vieosoft, Inc. (“Vieosoft”), a development stage enterprise, for initial cash consideration, contingent cash consideration that varies based on the performance of the acquired business in each of the four years following the acquisition and the assumption of certain liabilities.

In July 2014, we acquired all of the equity interests of Capario, Inc. (“Capario”), a technology-enabled provider of revenue cycle management solutions, for cash consideration and the assumption of certain liabilities.

Our Revenues and Expenses

We generate virtually all of our revenue by using technology solutions to provide our customers services that automate and simplify business and administrative functions for payers, providers and pharmacies generally on either a per transaction, per document, per communication, per member per month, monthly flat-fee, contingent fee or hourly basis.

Cost of operations consists primarily of costs related to services we provide to customers and costs associated with the operation and maintenance of our networks. These costs primarily include postage and materials costs related to our patient billing and payment and payment distribution services, rebates paid to our channel partners (net of rebates to certain customers that offset revenue) and data communications costs, all of which generally vary with our revenues and/or volumes. Cost of operations also includes personnel costs associated with production, network operations, customer support and other personnel, facilities expenses and equipment maintenance, all of which vary less directly with our revenue and/or volumes due to the fixed or semi-fixed nature of these expenses.

The largest component of our cost of operations is postage, which is incurred in our patient billing and payment and payment distribution services businesses and which is also a component of our revenue in those businesses. Our postage costs increase as our patient billing and payment services volumes increase and also when the United States Postal Service (“USPS”) increases postage rates. Postage rate increases, while generally billed as pass-through costs to our customers, affect our cost of operations as a percentage of revenue. In prior years, we have offset the impact of postage rate increases on cost of operations as a percentage of revenue through cost reductions from efficiency measures, including data communication expense reductions and production efficiencies. Though we plan to implement additional efficiency measures, we may not be able to offset the impact of postage rate increases in the future and, as a result, cost of operations as a percentage of revenue may increase if postage rate increases continue. Although the USPS historically has increased postage rates annually in most recent years, including in January 2013 and 2014, the frequency and nature of such annual increases may not occur as regularly in the future.

Rebates are paid to channel partners for electronic and other volumes delivered through our network to certain payers and can be impacted by the number of comprehensive management services agreements we execute with payers, the associated rate structure with our payer customers, the success of our direct sales efforts to providers and the extent to which direct connections to payers are developed by our channel partners. While these rebates are generally a component of our cost of operations, in cases where the channel partners are also our customers, these rebates generally are recognized as an offset to revenue.

Our data communication expense consists of telecommunication and transaction processing charges.

41

Our material costs relate primarily to our patient statements and payment services volumes, and consist primarily of paper and printing costs.

Development and engineering expense consists primarily of personnel costs related to the development, management and maintenance of our current and future solutions. We may invest more in this area in the future as we develop new and enhance existing solutions.

Sales, marketing, general and administrative expense consists primarily of personnel costs associated with our sales, account management and marketing functions, as well as management, administrative and other shared corporate services related to the operations of our operating segments and overall business operations.

Our development and engineering expense, sales, marketing, general and administrative expense and corporate expense, while related to our current operations, also are affected and influenced by our future plans including the development of new solutions, business strategies and enhancement and maintenance of our infrastructure.

Our depreciation and amortization expense is related to depreciation of our property and equipment, including technology assets, and amortization of intangible assets acquired and recorded in conjunction with acquisition method accounting. As a result, the amount of depreciation and amortization expense is affected by the level of our recent investment in property and equipment and the level of our recent acquisition activity.

Our interest expense consists principally of cash interest associated with our long-term debt obligations and non-cash interest associated with the amortization of borrowing costs and discounts related to debt issuance. If market interest rates on the variable portion of our long-term debt increase in the future, our interest expense may increase.

Our income taxes consist of federal and state income taxes. These amounts include current income taxes payable, as well as income taxes for which the payment is deferred to future periods and dependent on the occurrence of future events. Our income taxes are affected by the recognition of valuation allowances, our tax status and other items. For additional information, see the discussion of income taxes in the section “Significant Items Affecting Comparability-Income Taxes”.

Significant Items Affecting Comparability

Certain significant items or events should be considered to better understand differences in our results of operations from period to period. We believe that the following items or events have had a significant impact on our results of operations for the periods discussed below or may have a significant impact on our results of operations in future periods:

Acquisitions and Divestitures

We actively evaluate opportunities to improve and expand our business through targeted acquisitions that are consistent with our strategy. On occasion, we also may dispose of certain components of our business that no longer fit within our overall strategy. Because of our acquisition activity, our results of operations may not be directly comparable among periods. The following summarizes our acquisition transactions since January 1, 2013 and affected segments:

Date	Business	Description	Affected Segment
June 2013	Goold Health Systems (“Goold”)	Technology-enabled provider of pharmacy benefit and related services primarily to State Medicaid agencies	Pharmacy Services
February 2014	Vieosoft	Development stage enterprise	Pharmacy Services
July 2014	Capario	Technology-enabled provider of revenue cycle management solutions	Payer Services and Provider Services

Efficiency Measures

We evaluate and implement efficiency measures and other cost savings initiatives on an ongoing basis to improve our financial and operating performance through reorganization, cost savings, productivity improvements, product development and other process improvements. For instance, we continue to evaluate measures to consolidate our data centers, operations and networks, to outsource certain information technology and operations functions and to streamline product development. The implementation of these measures often involves upfront cash costs related to severance, professional fees, contractor costs and/or capital expenditures, with the cost savings or other improvements not realized until the measures are successfully completed. Additionally, we may recognize impairment charges as a result of such initiatives.

42

Income Taxes

Our blended statutory federal and state income tax rate ranges from 37% to 40%. Our effective income tax rate, however, can be affected by several factors, including the change in tax status of EBS Master from a partnership to a corporation in January 2014. The following table and subsequent commentary reconcile our federal statutory rate to our effective income tax rate, and the subsequent commentary describes the more significant of the reconciling factors:

	Nine Months Ended
	September 30,
	2014			2013
Statutory United States federal tax rate		35.0	%		35.0	%
State income taxes (net of federal benefit)		2.4			(3.5	)
Change in tax status		(.4	)		—
Other		(.3	)		(0.2	)
Effective income tax rate		36.7	%		31.3	%

State Income Taxes—Our effective tax rate for state income taxes is generally impacted by changes in our apportionment. In addition, our effective tax rate for state income taxes for the nine months ended September 30, 2014 was affected by the change in tax status of EBS Master from a partnership to a corporation.

Change in Tax Status—Prior to the change in tax status of EBS Master from a partnership to a corporation, we recognized a deferred tax liability for the difference in the book and tax basis of our investment in EBS Master (i.e. outside basis). The outside tax basis of the investment in EBS Master excluded consideration of goodwill within EBS Master that otherwise would have no tax basis. Following the tax status change, our deferred tax balances reflect only the difference in the book and tax bases of the individual assets and liabilities included in the corporation.

Amendments of the Senior Credit Agreement

Our interest expense primarily is affected by the amount of debt funding and the applicable variable interest rates, including a fixed spread, under our credit agreement (the “Senior Credit Agreement”) governing our senior secured term loan facility (the “Term Loan Facility”) and senior secured revolving credit facility (the “Revolving Facility”) (collectively, the “Senior Credit Facilities”). In April 2013, we amended the Senior Credit Agreement to reduce the LIBOR-based interest rate by 125 basis points, and also to modify certain financial covenants.

Impairment of Long-lived Assets

During the nine months ended September 30, 2014, our pharmacy services segment received notice that its existing contract with a customer would not be renewed in full upon its expiration. As a result, we abandoned a customer related project that was under development and assessed the recoverability of the net assets included in the relevant asset group. We recognized a $73.2 million impairment charge to write off the abandoned project and to adjust the carrying value of the asset group to its fair value.

Additionally, we abandoned certain pharmacy services and provider services segment development projects in connection with execution of certain strategic initiatives. We recognized impairment charges of $3.1 million and $9.5 million during the three and nine months ended September 30, 2014, respectively, related to these abandoned projects.

43

Critical Accounting Estimates

The preparation of financial statements in accordance with United States generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

• it requires assumptions to be made that were uncertain at the time the estimate was made; and

• changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations and financial condition.

We believe the current assumptions and other considerations used to estimate amounts reflected in our unaudited condensed consolidated financial statements are appropriate. However, if actual experience differs from the assumptions and other considerations used in estimating amounts reflected in our unaudited condensed consolidated financial statements, the resulting changes could have a material adverse effect on our unaudited condensed consolidated results of operations and financial condition.

We believe there have been no significant changes during the nine months ended September 30, 2014 to the items we disclosed as our critical accounting estimates in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K.

Results of Operations

The following table summarizes our consolidated results of operations for the three and nine months ended September 30, 2014 and 2013, respectively (amounts in thousands).

	Three Months Ended												Nine Months Ended
	September 30, 2014						September 30, 2013						September 30, 2014						September 30, 2013
				% of						% of						% of						% of
	Amount			Revenue			Amount			Revenue			Amount			Revenue			Amount			Revenue
Revenues	$	341,608			100.0	%	$	317,810			100.0	%	$	996,973			100.0	%	$	922,452			100.0	%
Cost and expenses:
Cost of operations (exclusive of depreciation and amortization below)		202,305			59.2			191,695			60.3			597,843			60.0			563,146			61.0
Development and engineering		8,156			2.4			7,878			2.5			24,771			2.5			23,201			2.5
Sales, marketing, general and administrative		45,031			13.2			44,104			13.9			150,739			15.1			123,469			13.4
Depreciation and amortization		48,448			14.2			47,181			14.8			141,541			14.2			137,943			15.0
Accretion		4,452			1.3			7,112			2.2			9,220			0.9			18,712			2.0
Impairment of long-lived assets		3,114			0.9			25			0.0			82,689			8.3			1,887			0.2
Operating income		30,102			8.8			19,815			6.2			(9,830	)		(1.0	)		54,094			5.9
Interest expense, net		36,635			10.7			37,000			11.6			109,741			11.0			116,390			12.6
Loss on extinguishment of debt		—			—			—			—			—			—			23,160			2.5
Contingent consideration		1,976			0.6			1,879			0.6			3,646			0.4			1,879			0.2
Other		—			—			(2,925	)		(0.9	)		(3,968	)		(0.4	)		(2,925	)		(0.3	)
Income (loss) before income tax provision (benefit)		(8,509	)		(2.5	)		(16,139	)		(5.1	)		(119,249	)		(12.0	)		(84,410	)		(9.2	)
Income tax provision (benefit)		4,493			1.3			126			0.0			(43,733	)		(4.4	)		(26,422	)		(2.9	)
Net income (loss)	$	(13,002	)		(3.8	)%	$	(16,265	)		(5.1	)%	$	(75,516	)		(7.6	)%	$	(57,988	)		(6.3	)%

Three Months Ended September 30, 2014 Compared to Three Months Ended September 30, 2013

Revenues

Our total revenues were $341.6 million for the three months ended September 30, 2014 as compared to $317.8 million for the three months ended September 30, 2013, an increase of $23.8 million, or 7.5%. Factors affecting our revenues are described in the various segment discussions below.

44

Cost of Operations

Our total cost of operations was $202.3 million for the three months ended September 30, 2014 as compared to $191.7 million for the three months ended September 30, 2013, an increase of $10.6 million, or 5.5%. As a percentage of revenue, our cost of operations was 59.2% for the three months ended September 30, 2014 as compared to 60.3% the three months ended September 30, 2013. The increase in our cost of operations is primarily due to volume growth, including approximately $2.4 million related to the impact of the USPS postage rate increase effective in January 2014, approximately $3.1 million related to the inclusion of the acquired Capario business and increased strategic growth initiative costs. The decrease in our cost of operations as a percentage of revenue is primarily due to changes in revenue mix and increased productivity.

Development and Engineering Expense

Our total development and engineering expense was $8.2 million for the three months ended September 30, 2014 as compared to $7.9 million for the three months ended September 30, 2013, an increase of $0.3 million, or 3.5%, reflecting generally consistent levels of activity.

Sales, Marketing, General and Administrative Expense

Our total sales, marketing, general and administrative expense was $45.0 million for the three months ended September 30, 2014 as compared to $44.1 million for the three months ended September 30, 2013, an increase of $0.9 million, or 2.1%. The increase in our sales, marketing, general and administrative expense was primarily due to overall business growth, partially offset by cost containment initiatives.

Depreciation and Amortization Expense

Our depreciation and amortization expense was $48.4 million for the three months ended September 30, 2014 as compared to $47.2 million for the three months ended September 30, 2013, an increase of $1.3 million, or 2.7%. This increase was primarily due to increased capital expenditures and acquisition activity, partially offset by the effects of the impairment charge related to the pending partial loss of a customer contract.

Accretion

Our accretion was $4.5 million for the three months ended September 30, 2014 as compared to $7.1 million for the three months ended September 30, 2013. The amount recognized as accretion can vary significantly from period to period due to changes in estimates related to the amount or timing of our tax receivable agreement obligation payments. Such changes can result from a variety of factors, including changes in tax rates and the expected timing of prior net operating loss utilization, which can be affected by business combinations, changes in corporate structure, leverage, operations or other factors.

Interest Expense

Our interest expense was $36.6 million for the three months ended September 30, 2014 as compared to $37.0 million for the three months ended September 30, 2013, a decrease of $0.4 million, or 1.0%. Interest expense for the three months ended September 30, 2014 and 2013 reflect generally consistent interest rates and levels of outstanding debt.

Income Taxes

Our income tax provision was $4.5 million for the three months ended September 30, 2014 as compared to an income tax benefit of $0.1 million for the three months ended September 30, 2013. Our effective tax rate was 52.8% for the three months ended September 30, 2014 as compared to 0.8% for the three months ended September 30, 2013. The effective tax rate for the three months ended September 30, 2014 was affected by the change in tax status, a decrease in state income tax rates and valuation allowances related to net operating losses in state tax jurisdictions for which we recognized no income tax benefit.

45

Segment Revenues and Adjusted EBITDA

We operate our business in three reportable segments: payer services, provider services and pharmacy services. In addition to these reportable segments, we report financial information for two additional operating segments on an aggregate basis, one of which provides revenue cycle management solutions through channel partners and the other of which provides revenue cycle solutions, either directly or through channel partners, to dental practices. We also maintain a corporate function which includes management, administrative and other shared corporate services such as information technology, legal, finance, human resources, marketing and product management.

The segment profit measure primarily utilized by management is adjusted EBITDA which is defined as EBITDA (defined as net income (loss) before net interest expense, income tax provision (benefit) and depreciation and amortization), plus certain other non-cash or non-operating items. The non-cash or other non-operating items affecting the segment profit measure generally include equity compensation; acquisition accounting adjustments; acquisition-related costs; strategic initiatives, duplicative and transition costs; impairment of long lived assets; and contingent consideration adjustments. Adjusted EBITDA for the respective segments excludes all costs and adjustments associated with the above-referenced corporate functions. Financial information, including details of our adjustments to EBITDA, for each of our segments is set forth in Note 12 to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report.

Payer Services

Our payer services segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Claims management	$	73,314	$	78,292	$	(4,978	)
Payment distribution services		73,703		63,942		9,761
Patient billing and payment services		68,360		62,911		5,449
Intersegment revenue		2,490		1,625		865
	$	217,867	$	206,770	$	11,097
Adjusted EBITDA	$	69,523	$	69,565	$	(42	)

Claims management revenue for the three months ended September 30, 2014 decreased by $5.0 million, or 6.4%, as compared to the prior year period. Claims management revenue for the three months ended September 30, 2014 includes a one-time reduction of revenue of $4.1 million related to inaccurate data supplied by one of our customers, partially offset by $2.4 million of revenue from the Capario acquisition.

Payment distribution services revenues for the three months ended September 30, 2014 increased by $9.8 million, or 15.3%, as compared to the prior year period. This increase was primarily driven by new sales and implementations and the impact of the USPS postage rate increase effective in January 2014, partially offset by customer attrition.

Patient billing and payment services revenue for the three months ended September 30, 2014 increased by $5.4 million, or 8.7%, as compared to the prior year period. This increase was primarily driven by the impact of the USPS postage rate increase effective in January 2014 and new sales and implementations, partially offset by customer attrition.

Payer services adjusted EBITDA for the three months ended September 30, 2014 was generally consistent with the prior year period. As a percentage of revenue, payer services adjusted EBITDA was 31.9% for the three months ended September 30, 2014 as compared to 33.6% for the three months ended September 30, 2013. The decrease in our payer services adjusted EBITDA as a percentage of revenue is primarily due to the impact of the one-time reduction of claims management revenue described above and the USPS postage rate increase effective in January 2014.

46

Provider Services

Our provider services segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Revenue cycle technology	$	32,343	$	29,678	$	2,665
Revenue cycle services		34,979		31,172		3,807
Physician services		12,041		9,237		2,804
	$	79,363	$	70,087	$	9,276
Adjusted EBITDA	$	39,782	$	32,317	$	7,465

Revenue cycle technology revenue for the three months ended September 30, 2014 increased by $2.7 million, or 9.0%, as compared to the prior year period primarily due to new sales and implementations, partially offset by customer attrition.

Revenue cycle services revenue for the three months ended September 30, 2014 increased by $3.8 million, or 12.2%, as compared to the prior year period primarily due to new sales and implementations and improved reimbursement patterns of federal and state payers related to our government eligibility and enrollment services, partially offset by customer attrition.

Physician services revenue for the three months ended September 30, 2014 increased by $2.8 million, or 30.4%, as compared to the prior year period primarily due to $2.6 million of revenue from the Capario acquisition and new sales and implementations, partially offset by customer attrition.

Provider services adjusted EBITDA for the three months ended September 30, 2014 increased by $7.5 million, or 23.1%, as compared to the prior year period. As a percentage of revenue, provider services adjusted EBITDA was 50.1% for the three months ended September 30, 2014 as compared to 46.1% for the three months ended September 30, 2013. The increase in provider services adjusted EBITDA and as a percentage of revenue was primarily due to the impact of revenue items described above and efficiency measures, partially offset by increased strategic growth initiative costs.

Pharmacy Services

Our pharmacy services segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Pharmacy services	$	31,649	$	30,363	$	1,286
Intersegment revenue		90		77		13
	$	31,739	$	30,440	$	1,299
Adjusted EBITDA	$	15,356	$	16,350	$	(994	)

Pharmacy services revenue for the three months ended September 30, 2014 increased by $1.3 million, or 4.2%, as compared to the prior year period primarily due to new sales and implementations.

Pharmacy services adjusted EBITDA for the three months ended September 30, 2014 decreased by $1.0 million, or 6.1%, as compared to the prior year period. As a percentage of revenue, pharmacy services adjusted EBITDA was 48.4% for the three months ended September 30, 2014 as compared to 53.7% for the prior year period. The decrease in pharmacy services adjusted EBITDA and as a percentage of revenue is primarily due to increased strategic growth initiative and channel partner costs, changes in revenue mix and the impact of the Vieosoft acquisition.

Nine Months Ended September 30, 2014 Compared to Nine Months Ended September 30, 2013

Revenues

Our total revenues were $997.0 million for the nine months ended September 30, 2014 as compared to $922.5 million for the nine months ended September 30, 2013, an increase of $74.5 million, or 8.1%. Factors affecting our revenues are described in the various segment discussions below.

47

Cost of Operations

Our total cost of operations was $597.8 million for the nine months ended September 30, 2014 as compared to $563.1 million for the nine months ended September 30, 2013, an increase of $34.7 million, or 6.2%. As a percentage of revenue, our cost of operations was 60.0% for the nine months ended September 30, 2014 as compared to 61.0% for the nine months ended September 30, 2013. The increase in our cost of operations is primarily due to volume growth, including approximately $7.1 million related to the impact of the United States postage rate increase effective in January 2014, approximately $10.2 million related to the inclusion of the acquired Goold, Vieosoft and Capario businesses and increased labor and strategic growth initiative costs. The decrease in our cost of operations as a percentage of revenue is primarily due to changes in revenue mix and increased productivity.

Development and Engineering Expense

Our total development and engineering expense was $24.8 million for the nine months ended September 30, 2014 as compared to $23.2 million for the nine months ended September 30, 2013, an increase of $1.6 million, or 6.8%. The increase in our development and engineering expense is primarily due to strategic growth initiative and labor costs.

Sales, Marketing, General and Administrative Expense

Our total sales, marketing, general and administrative expense was $150.7 million for the nine months ended September 30, 2014 as compared to $123.5 million for the nine months ended September 30, 2013, an increase of $27.3 million, or 22.1%. The increase in our sales, marketing, general and administrative expense was primarily due to approximately $9.1 million related to increased strategic growth initiatives, labor-related and acquisition-related costs, approximately $1.9 million related to canceling product development projects, approximately $3.0 million related to the settlement of a vendor dispute and approximately $2.9 million related to the inclusion of the acquired Vieosoft and Capario businesses.

Depreciation and Amortization Expense

Our depreciation and amortization expense was $141.5 million for the nine months ended September 30, 2014 as compared to $137.9 million for the nine months ended September 30, 2013, an increase of $3.6 million, or 2.6%. This increase was primarily due to increased capital expenditures and acquisition activity, partially offset by the effects of the impairment charge related to the pending partial loss of a customer contract.

Accretion Expense

Our accretion expense was $9.2 million for the nine months ended September 30, 2014 as compared to $18.7 million for the nine months ended September 30, 2013. The amount recognized as accretion expense can vary significantly from period to period due to changes in estimates related to the amount or timing of our tax receivable agreement obligation payments. Such changes can result from a variety of factors, including changes in tax rates and the expected timing of prior net operating loss utilization, which can be affected by business combinations, changes in leverage, operations or other factors.

Interest Expense

Our interest expense was $109.7 million for the nine months ended September 30, 2014 as compared to $116.4 million for the nine months ended September 30, 2013, a decrease of $6.6 million, or 5.7%. Interest expense for the nine months ended September 30, 2014 includes the effect of lower interest rates on the Senior Credit Facilities as a result of the April 2013 repricing transaction.

Income Taxes

Our income tax benefit was $43.7 million for the nine months ended September 30, 2014 as compared to an income tax benefit of $26.4 million for the nine months ended September 30, 2013. Our effective tax rate was 36.7% for the nine months ended September 30, 2014 as compared to 31.3% for the nine months ended September 30, 2013. Differences between the federal statutory rate and the effective income tax rates for these periods principally relate to the change in tax status of EBS Master from a partnership to a corporation in January 2014, a decrease in state income tax rates, as well as valuation allowances related to net operating losses in state tax jurisdictions for which we recognized no income tax benefit.

48

Segment Revenues and Adjusted EBITDA

Payer Services

Our payer services segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Claims management	$	215,614	$	215,933	$	(319	)
Payment distribution services		213,766		194,174		19,592
Patient billing and payment services		205,921		189,396		16,525
Intersegment revenue		7,062		4,399		2,663
	$	642,363	$	603,902	$	38,461
Adjusted EBITDA	$	202,800	$	196,786	$	6,014

Claims management revenue for the nine months ended September 30, 2014 decreased by $0.3 million, or 0.1%, as compared to the prior year period. Claims management revenue for the nine months ended September 30, 2014 includes a one-time reduction of revenue of $4.1 million related to inaccurate data supplied by one of our customers. Excluding this one-time reduction, claims management revenue increased by $3.8 million or 1.8% which was primarily due to revenue of $2.4 million from the Capario acquisition and new sales and implementations.

Payment distribution services revenues for the nine months ended September 30, 2014 increased by $19.6 million, or 10.1%, as compared to the prior year period. This increase was primarily driven by new sales and implementations and the impact of the USPS postage rate increase effective in January 2014, partially offset by customer attrition.

Patient billing and payment services revenue for the nine months ended September 30, 2014 increased by $16.5 million, or 8.7%, as compared to the prior year period. This increase was primarily driven by the impact of the USPS postage rate increase effective in January 2014 and new sales and implementations, partially offset by customer attrition.

Payer services adjusted EBITDA for the nine months ended September 30, 2014 increased by $6.0 million, or 3.1%, as compared to the prior year period. As a percentage of revenue, payer services adjusted EBITDA was 31.6% for the nine months ended September 30, 2014 as compared to 32.6% for the nine months ended September 30, 2013. The increase in payer services adjusted EBITDA was primarily due to the impact of the revenue items described above, partially offset by strategic growth initiative costs. The decrease in our payer services adjusted EBITDA as a percentage of revenue is primarily due to the impact of the one-time reduction of claims management revenue described above and the USPS postage rate increase effective in January 2014.

Provider Revenue Cycle Solutions

Our provider revenue cycle solutions segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Revenue cycle technology	$	95,254	$	87,777	$	7,477
Revenue cycle services		101,491		92,273		9,218
Physician services		30,619		27,030		3,589
	$	227,364	$	207,080	$	20,284
Adjusted EBITDA	$	107,224	$	92,889	$	14,335

Revenue cycle technology revenue for the nine months ended September 30, 2014 increased by $7.5 million, or 8.5%, as compared to the prior year period primarily due to new sales and implementations, partially offset by customer attrition.

Revenue cycle services revenue for the nine months ended September 30, 2014 increased by $9.2 million, or 10.0%, as compared to the prior year period primarily due to new sales and implementations and improved reimbursement patterns of federal and state payers related to our government eligibility and enrollment services, partially offset by customer attrition.

49

Physician services revenue for the nine months ended September 30, 2014 increased by $3.6 million, or 13.3%, as compared to the prior year period primarily due to $2.6 million of revenue from the Capario acquisition and new sales and implementations, partially offset by customer attrition.

Provider services adjusted EBITDA for the nine months ended September 30, 2014 increased by $14.3 million, or 15.4%, as compared to the prior year period. As a percentage of revenue, provider services adjusted EBITDA was 47.2% for the nine months ended September 30, 2014 as compared to 44.9% for the nine months ended September 30, 2013. The increase in provider services adjusted EBITDA and as a percentage of revenue was primarily due to the impact of the revenue items described above and efficiency measures, partially offset by increased strategic growth initiative costs.

Pharmacy Services

Our pharmacy services segment revenue and adjusted EBITDA is summarized in the following table (in thousands):

	September 30, 2014		September 30, 2013		$ Change
Revenue:
Pharmacy services	$	92,808	$	80,331	$	12,477
Intersegment revenue		271		256		15
	$	93,079	$	80,587	$	12,492
Adjusted EBITDA	$	49,016	$	45,464	$	3,552

Pharmacy services revenue for the nine months ended September 30, 2014 increased by $12.5 million, or 15.5%, as compared to the prior year period. Pharmacy services revenue for the nine months ended September 30, 2014 and 2013 included $17.6 million and $6.5 million, respectively, related to the Goold acquisition. Excluding this revenue, pharmacy services revenue for the nine months ended September 30, 2014 increased by $1.4 million, or 1.8%, as compared to the prior year period. This increase was primarily due to new sales and implementations, offset by customer attrition.

Pharmacy services adjusted EBITDA for the nine months ended September 30, 2014 increased by $3.6 million, or 7.8%, as compared to the prior year period. The increase in pharmacy services adjusted EBITDA is primarily due to the impact of the revenue items described above. As a percentage of revenue, pharmacy services adjusted EBITDA was 52.7% for the nine months ended September 30, 2014 as compared to 56.4% for the nine months ended September 30, 2013. The decrease in pharmacy services adjusted EBITDA as a percentage of revenue was primarily due to increased strategic growth initiative and channel partner costs, changes in revenue mix and the impact of the Goold and Vieosoft acquisitions.

Liquidity and Capital Resources

General

We are a holding company with no material business operations. Our principal assets are the equity interests we own in our subsidiaries. We conduct all of our business operations through our direct and indirect subsidiaries. Accordingly, our only material sources of cash are borrowings under our Senior Credit Facilities and dividends or other distributions or payments that are derived from earnings and cash flow generated by our subsidiaries.

We anticipate cash generated by operations, the funds available under our Senior Credit Facilities, including the Revolving Facility, and existing cash and equivalents will be sufficient to meet working capital requirements, service our debt and finance capital expenditures. There can be no assurance, however, that our business will generate sufficient cash flow from operations or that future borrowings will be available to us under our Senior Credit Facilities in amounts sufficient to enable us to repay our indebtedness, or to fund other liquidity needs.

We and our subsidiaries, affiliates or significant stockholders may from time to time seek to retire or purchase our outstanding debt (including our senior notes) through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

50

Cash Flows

Operating Activities

Cash provided by operating activities for the nine months ended September 30, 2014 was $108.4 million as compared to $110.0 million for nine months ended September 30, 2013, a decrease of $1.6 million, reflecting generally consistent levels of activity.

Cash provided by operating activities can be significantly impacted by our non-cash working capital assets and liabilities, which may vary based on the timing of cash receipts that fluctuate by day of week and/or month and also may be impacted by cash management decisions.

Investing Activities

Cash used in investing activities for the nine months ended September 30, 2014 was $125.7 million as compared to $65.3 million for the nine months ended September 30, 2013. Cash used in investing activities for each of the nine months ended September 30, 2014 and 2013 consisted of capital expenditures for property and equipment and cash consideration paid for acquisitions, including the July 2014 Capario acquisition.

Financing Activities

Cash used in financing activities for the nine months ended September 30, 2014 was $35.3 million as compared to $15.0 million for the nine months ended September 30, 2013. Cash used in financing activities for each of the nine months ended September 30, 2014 and 2013 primarily consisted of principal payments under our Senior Credit Facilities and deferred financing arrangements. Additionally, cash used in financing activities for the nine months ended September 30, 2014 included the payment of debt assumed in the Capario acquisition.

Long-term Debt

In November 2011, we entered into the Senior Credit Agreement which was comprised of the Term Loan Facility and the Revolving Facility, $375.0 million of 11% senior notes due 2019 (the “2019 Notes”) and $375.0 million 11.25% senior notes due 2020 (the “2020 Notes”; together with the 2019 Notes, the “Senior Notes”).

Long-term debt as of September 30, 2014 and December 31, 2013, consisted of the following:

	September 30, 2014			December 31, 2013
Senior Credit Facilities
$1,301 million Senior Secured Term Loan facility, due November 2, 2018, net of unamortized discount of $13,520 and $15,826 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 4.21%)	$	1,255,092		$	1,262,445
$125 million Senior Secured Revolving Credit facility, expiring on November 2, 2016 and bearing interest at a variable base rate plus a spread rate		—			—
Senior Notes
$375 million 11% Senior Notes due December 31, 2019, net of unamortized discount of $6,966 and $7,664 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.53%)		368,034			367,336
$375 million 11.25% Senior Notes due December 31, 2020, net of unamortized discount of $8,868 and $9,560 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.86%)		366,132			365,440
Obligation under data sublicense agreement		22,543			22,543
Other		11,261			12,592
Less current portion		(24,493	)		(31,330	)
Long-term debt	$	1,998,569		$	1,999,026

51

Senior Credit Facilities

The Senior Credit Agreement provides that, subject to certain conditions, we may request additional tranches of term loans, increase commitments under the Revolving Facility or the Term Loan Facility or add one or more incremental revolving facility tranches (provided that the revolving credit commitments outstanding at any time have no more than three different maturity dates) in an aggregate amount not to exceed (a) $300.0 million plus (b) an unlimited amount at any time, subject to compliance on a pro forma basis with a first lien net leverage ratio of no greater than 4.00:1.00. Availability of such additional tranches of term loans or revolving facilities and/or increased commitments is subject to, among other conditions, the absence of any default under the Senior Credit Agreement and the receipt of commitments by existing or additional financial institutions. Proceeds of the Revolving Facility, including up to $30.0 million in the form of borrowings on same-day notice, referred to as swingline loans, and up to $50.0 million in the form of letters of credit, are available to provide financing for working capital and general corporate purposes.

Borrowings under the Senior Credit Facilities bear interest at an annual rate equal to an applicable margin plus, at our option, either (a) a base rate determined by reference to the highest of (i) the applicable prime rate, (ii) the federal funds rate plus 0.50% and (iii) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00%, which base rate, in the case of the Term Loan Facility only, shall be no less than 2.25% or (b) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, which, in the case of the Term Loan Facility only, shall be no less than 1.25%.

In April 2012, we amended the Senior Credit Agreement to reprice the Senior Credit Facilities and borrow $80.0 million of additional term loans for general corporate purposes, including acquisitions. Following this amendment, the LIBOR-based interest rate on the Term Loan Facility was LIBOR plus 3.75%, compared to the previous interest rate of LIBOR plus 5.50%. The new LIBOR-based interest rate on the Revolving Facility was LIBOR plus 3.50% (with a potential step-down to LIBOR plus 3.25% based on our first lien net leverage ratio), compared to the previous interest rate of LIBOR plus 5.25% (with a potential step-down to LIBOR plus 5.00% based on our first lien net leverage ratio).

In April 2013, we again amended the Senior Credit Agreement to further reprice, and also to modify certain financial covenants under, the Senior Credit Facilities. Following this amendment, the interest rate on the Term Loan Facility is LIBOR plus 2.50%, compared to the previous interest rate of LIBOR plus 3.75%. The new interest rate on the Revolving Facility is LIBOR plus 2.50%, compared to the previous interest rate of LIBOR plus 3.50% (or 3.25% based on a specified first lien net leverage ratio). The Term Loan Facility remains subject to a LIBOR floor of 1.25%, and there continues to be no LIBOR floor on the Revolving Facility. In connection with the April 2013 repricing, the Senior Credit Agreement also was amended to, among other things, eliminate the financial covenant in the Senior Credit Facilities related to the consolidated cash interest coverage ratio and modify the financial covenant related to the net leverage test by maintaining the required first lien net leverage ratio at 5.35 to 1.00 for the remaining term of the Senior Credit Facilities.

These amendments to the Senior Credit Agreement resulted in a loss on extinguishment of debt of $23.2 million and other expenses related to fees paid to third parties of $1.2 million for the nine months ended September 30, 2013, which have been reflected within sales, marketing, general and administrative expense in the accompanying consolidated statements of operations.

In addition to paying interest on outstanding principal under the Senior Credit Facilities, we are required to pay customary agency fees, letter of credit fees and a 0.50% commitment fee in respect of the unutilized commitments under the Revolving Facility.

The Senior Credit Agreement requires that we prepay outstanding loans under the Term Loan Facility, subject to certain exceptions, with (a) 100% of the net cash proceeds of any incurrence of debt other than debt permitted under the Senior Credit Agreement, (b) commencing with the fiscal year ended December 31, 2012, 50% (which percentage will be reduced to 25% and 0% based on our first lien net leverage ratio) of our annual excess cash flow and (c) 100% of the net cash proceeds of certain asset sales and casualty and condemnation events, subject to reinvestment rights and certain other exceptions.

We generally may voluntarily prepay outstanding loans under the Senior Credit Facilities at any time without premium or penalty other than breakage costs with respect to LIBOR loans.

We are required to make quarterly payments equal to 0.25% of the aggregate principal amount of the loans under the Term Loan Facility, with the balance due and payable on November 2, 2018. Any principal amount outstanding under the Revolving Facility is due and payable on November 2, 2016.

52

Certain of our United States wholly-owned restricted subsidiaries, together with the Company, are co-borrowers and jointly and severally liable for all obligations under the Senior Credit Facilities. Such obligations of the co-borrowers are unconditionally guaranteed by Beagle Intermediate Holdings, Inc., a direct wholly-owned subsidiary of Beagle Parent Corp., the Company and each of our existing and future United States wholly-owned restricted subsidiaries (with certain exceptions including immaterial subsidiaries). These obligations are secured by a perfected security interest in substantially all of the assets of the co-borrowers and guarantors now owned or later acquired, including a pledge of all of the capital stock of the Company and our United States wholly-owned restricted subsidiaries and 65% of the capital stock of our foreign restricted subsidiaries, subject in each case to the exclusion of certain assets and additional exceptions.

The Senior Credit Agreement requires us to comply with a maximum first lien net leverage ratio financial maintenance covenant, to be tested on the last day of each fiscal quarter. A breach of the first lien net leverage ratio covenant is subject to certain equity cure rights. In addition, the Senior Credit Facilities contain a number of negative covenants that, among other things and subject to certain exceptions, restrict our ability and the ability of our subsidiaries to:

• incur additional indebtedness or guarantees;

• incur liens;

• make investments, loans and acquisitions;

• consolidate or merge;

• sell assets, including capital stock of subsidiaries;

• pay dividends on capital stock or redeem, repurchase or retire capital stock of the Company or any restricted subsidiary, subject to customary covenants, including compliance with leverage ratios and subject to limitation based on net income generated during the term of the Senior Credit Agreement;

• alter the business of the Company;

• amend, prepay, redeem or purchase subordinated debt;

• engage in transactions with affiliates; and

• enter into agreements limiting dividends and distributions of certain subsidiaries.

The Senior Credit Agreement also contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default (including upon change of control).

As of September 30, 2014, we believe we were in compliance with all of the applicable debt covenants under the Senior Credit Agreement.

Senior Notes

The 2019 Notes bear interest at an annual rate of 11% with interest payable semi-annually on June 30 and December 31 of each year. The 2019 Notes mature on December 31, 2019. The 2020 Notes bear interest at an annual rate of 11.25% with interest payable quarterly on March 31, June 30, September 30 and December 31 of each year. The 2020 Notes mature on December 31, 2020.

We may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at any time on or after December 31, 2015 at the applicable redemption price, plus accrued and unpaid interest. In addition, at any time prior to December 31, 2014, we may, at our option and on one or more occasions, redeem up to 35% of the aggregate principal amount of the 2019 Notes or the 2020 Notes, at a redemption price equal to 100% of the aggregate principal amount, plus a premium equal to the stated interest rate on the 2019 Notes or the 2020 Notes, respectively, plus accrued and unpaid interest with the net cash proceeds of certain equity offerings; provided that at least 50% of the sum of the aggregate principal amount of the 2019 Notes or 2020 Notes, respectively, originally issued (including any additional notes) remain outstanding immediately after such redemption and the redemption occurs within 180 days of the equity offering. At any time prior to December 31, 2015, we may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at our option and on one or more occasions, at a redemption price equal to 100% of the principal amount, plus an applicable premium and accrued and unpaid interest. If we experience specific kinds of changes in control, we must offer to purchase the Senior Notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest.

The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of our existing and future indebtedness and senior in right of payment to all of our existing and future subordinated indebtedness. Our obligations under the Senior Notes are guaranteed on a senior basis by all of our existing and subsequently acquired or organized wholly-owned United States restricted subsidiaries that guarantee our Senior Credit Facilities or our other

53

indebtedness or indebtedness of any affiliate guarantor. The Senior Notes and the related guarantees are effectively subordinated to our existing and future secured obligations and that of our affiliate guarantors to the extent of the value of the collateral securing such obligations, and are structurally subordinated to all existing and future indebtedness and other liabilities of any of our subsidiaries that do not guarantee the Senior Notes.

The indentures governing the Senior Notes (the “Indentures”) contain covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to:

• pay dividends on our capital stock or redeem, repurchase or retire our capital stock, subject to customary covenants, including compliance with a fixed charge coverage ratio and subject to limitation based on net income generated during the term of the Indentures;

• incur additional indebtedness or issue certain capital stock;

• incur certain liens;

• make investments, loans, advances and acquisitions;

• consolidate, merge or transfer all or substantially all of our assets and the assets of our subsidiaries;

• prepay subordinated debt;

• engage in certain transactions with our affiliates; and

• enter into agreements restricting our restricted subsidiaries’ ability to pay dividends.

The Indentures also contain certain affirmative covenants and events of default.

As of September 30, 2014, we believe we were in compliance with all of the applicable debt covenants under the Senior Notes.

Off-Balance Sheet Arrangements

As of the filing of this Quarterly Report, we had no off-balance sheet arrangements or obligations, other than those related to surety bonds of an insignificant amount.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have interest rate risk primarily related to borrowings under the Senior Credit Agreement. Borrowings under the Senior Credit Facilities bear interest at an annual rate equal to an applicable margin plus, at our option, either (a) a base rate determined by reference to the highest of (i) the applicable prime rate, (ii) the federal funds rate plus 0.50% and (iii) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00%, which base rate, in the case of the Term Loan Facility only, shall be no less than 2.25% or (b) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, which, in the case of the Term Loan Facility only, shall be no less than 1.25%.

As of September 30, 2014, we had outstanding borrowings of $1,269 million (before unamortized debt discount) under the Senior Credit Agreement. As of September 30, 2014, the LIBOR-based interest rate on the Term Loan Facility and Revolving Facility were each LIBOR plus 2.50%. The Term Loan Facility is subject to a LIBOR floor of 1.25% and there is no LIBOR floor on the Revolving Facility.

We manage economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of our debt funding and the use of derivative financial instruments. Specifically, we enter into interest rate swap agreements to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. Our interest rate swap agreements are used to manage differences in the amount, timing and duration of our known or expected cash receipts and our known or expected cash payments principally related to our borrowings.

In January 2012, we executed three interest rate swap agreements with an aggregate notional amount of $640 million to reduce the variability of interest payments associated with the Term Loan Facility. For the quarter ended September 30, 2014, our interest rate swap agreements were designated as a cash flow hedge so that changes in the fair market value of the interest rate swap agreements were included within other comprehensive income.

54

A change in interest rates on variable rate debt may impact our pretax earnings and cash flows. However, due to a floor on the floating rate index of 1.25% under the Term Loan Facility, as of September 30, 2014, our interest rates must increase by more than 100 basis points before our interest expense or cash flows are affected. Based on our outstanding debt as of September 30, 2014, and assuming that our mix of debt instruments, interest rate swaps and other variables remain the same, the annualized effect of a one percentage point change in variable interest rates would have minimal impact on our earnings and cash flows.

In the future, in order to manage our interest rate risk, we may refinance our existing debt, enter into additional interest rate swap agreements, modify our existing interest rate swap agreements or make changes that may impact our ability to treat our interest rate swaps as a cash flow hedge. However, we do not intend or expect to enter into derivative or interest rate swap transactions for speculative purposes.

ITEM 4. CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2014. Based upon that evaluation, our CEO and CFO concluded that, as of September 30, 2014, our disclosure controls and procedures were effective to ensure that the information that we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes to our internal control over financial reporting that occurred during the three months ended September 30, 2014, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. While it is not possible to ascertain the ultimate outcome of such matters, in management’s opinion, the liabilities, if any, in excess of amounts provided or covered by insurance, are not expected to have a material adverse effect on our consolidated financial position, results of operations or liquidity.

ITEM 1A. RISK FACTORS

The discussion of the Company’s business and operations should be read together with the risk factors contained under the heading “Risk Factors” in our Form 10-K, which describes various risks and uncertainties to which we are or may be subject. These risks and uncertainties have the potential to affect our business, financial condition and results of operations, cash flows and prospects in a material adverse manner. As of the date hereof, there have been no material changes to the risk factors set forth in our Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

55

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits listed on the accompanying Exhibit Index are filed, furnished or incorporated by reference (as stated therein) as part of this Quarterly Report.

56

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	EMDEON INC.
Date: November 7, 2014	By:	/s/ Neil E. de Crescenzo
		Neil E. de Crescenzo, Chief Executive Officer and Director
		(Principal Executive Officer)
Date: November 7, 2014	By:	/s/ Randy P. Giles
		Randy P. Giles, Chief Financial Officer
		(Principal Financial and Accounting Officer)

57

Exhibit Index

Exhibit     No.
4.1	2019 Notes Supplemental Indenture, dated as of September 16, 2014, between Capario, Inc. and Wilmington Trust, National Association, as trustee (filed herewith).
4.2	2020 Notes Supplemental Indenture, dated as of September 16, 2014, between Capario, Inc. and Wilmington Trust, National Association, as trustee (filed herewith).
10.1	Separation Agreement and General Release, dated September 19, 2014, among T. Ulrich Brechbuhl and Emdeon Business Services LLC (filed herewith).
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith).
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith).
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Scheme Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.DEF	XBRL Taxonomy Definition Linkbase Document
101.LAB	XBRL Taxonomy Label Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document

58

EX-4.1

Exhibit 4.1

Supplemental Indenture (this “Supplemental Indenture”), dated as of September 16, 2014, between Capario, Inc., a Delaware corporation (the “Guaranteeing Subsidiary”), a subsidiary of Emdeon Inc., a Delaware corporation (the “Issuer”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”).

W I T N E S S E T H

WHEREAS, Beagle Acquisition Corp. (“Beagle”) has heretofore executed and delivered to the Trustee an Indenture (the “Indenture”), dated as of November 2, 2011, providing for the issuance of an unlimited aggregate principal amount of 11.00% Senior Notes due 2019 (the “Notes”);

WHEREAS, the Notes were issued and sold in connection with the merger of Beagle with and into the Issuer (the “Merger”), whereby, upon consummation of the Merger, the Issuer continued as the surviving corporation;

WHEREAS, upon consummation of the Merger, and simultaneously with the execution of the Indenture, the Issuer, certain Guarantors party thereto and the Trustee entered into a supplemental indenture, under which the Issuer and the Guarantors became party to the Indenture;

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Guarantee”); and

WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

(1) Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

(2) Agreement to Guarantee. The Guaranteeing Subsidiary acknowledges that it has received and reviewed a copy of the Indenture and all other documents it deems necessary to review in order to enter into this Supplemental Indenture, and acknowledges and agrees to (i) join and become a party to the Indenture as indicated by its signature below; (ii) be bound by the Indenture, as of the date hereof, as if made by, and with respect to, each signatory hereto; and (iii) perform all obligations and duties required of a Guarantor pursuant to the Indenture. The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Indenture, including, but not limited to, Article 10 thereof.

(3) Execution and Delivery. The Guaranteeing Subsidiary agrees that the Guarantee shall remain in full force and effect notwithstanding the absence of the endorsement of any notation of such Guarantee on the Notes.

(4) No Recourse Against Others. No past, present or future director, officer, employee, incorporator, member, partner or stockholder of the Issuer or any Guaranteeing Subsidiary (other than the Issuer and the Guarantors) shall have any liability for any obligations of the Issuer or the Guarantors (including the Guaranteeing Subsidiary) under the Notes, any Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder by accepting Notes waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes.

(5) Governing Law. THIS SUPPLEMENTAL INDENTURE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

(6) Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. This Supplemental Indenture may be executed in multiple counterparts which, when taken together, shall constitute one instrument. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmissions shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

(7) Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

(8) The Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary.

(9) Benefits Acknowledged. The Guaranteeing Subsidiary’s Guarantee is subject to the terms and conditions set forth in the Indenture. The Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to this Guarantee are knowingly made in contemplation of such benefits.

(10) Successors. All agreements of the Guaranteeing Subsidiary in this Supplemental Indenture shall bind its Successors, except as otherwise provided in this Supplemental Indenture. All agreements of the Trustee in this Supplemental Indenture shall bind its successors.

2

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the date first above written.

CAPARIO, INC.
By:	/s/ Gregory T. Stevens
Name:	Gregory T. Stevens
Title:	Secretary
WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee
By:	/s/ Joseph P. O’Donnell
Name:	Joseph P. O’Donnell
Title:	Vice President

Supplemental Indenture (11.00% Senior Notes Due 2019)

EX-4.2

Exhibit 4.2

Supplemental Indenture (this “Supplemental Indenture”), dated as of September 16, 2014, between Capario, Inc., a Delaware corporation (the “Guaranteeing Subsidiary”), a subsidiary of Emdeon Inc., a Delaware corporation (the “Issuer”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”).

W I T N E S S E T H

WHEREAS, Beagle Acquisition Corp. (“Beagle”) has heretofore executed and delivered to the Trustee an Indenture (the “Indenture”), dated as of November 2, 2011, providing for the issuance of an unlimited aggregate principal amount of 11 ¹⁄₄% Senior Notes due 2020 (the “Notes”);

WHEREAS, the Notes were issued and sold in connection with the merger of Beagle with and into the Issuer (the “Merger”), whereby, upon consummation of the Merger, the Issuer continued as the surviving corporation;

WHEREAS, upon consummation of the Merger, and simultaneously with the execution of the Indenture, the Issuer, certain Guarantors party thereto and the Trustee entered into a supplemental indenture, under which the Issuer and the Guarantors became party to the Indenture;

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein and under the Indenture (the “Guarantee”); and

WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties mutually covenant and agree for the equal and ratable benefit of the Holders as follows:

(1) Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

(2) Agreement to Guarantee. The Guaranteeing Subsidiary acknowledges that it has received and reviewed a copy of the Indenture and all other documents it deems necessary to review in order to enter into this Supplemental Indenture, and acknowledges and agrees to (i) join and become a party to the Indenture as indicated by its signature below; (ii) be bound by the Indenture, as of the date hereof, as if made by, and with respect to, each signatory hereto; and (iii) perform all obligations and duties required of a Guarantor pursuant to the Indenture. The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Indenture, including, but not limited to, Article 10 thereof.

(3) Execution and Delivery. The Guaranteeing Subsidiary agrees that the Guarantee shall remain in full force and effect notwithstanding the absence of the endorsement of any notation of such Guarantee on the Notes.

(4) No Recourse Against Others. No past, present or future director, officer, employee, incorporator, member, partner or stockholder of the Issuer or any Guaranteeing Subsidiary (other than the Issuer and the Guarantors) shall have any liability for any obligations of the Issuer or the Guarantors (including the Guaranteeing Subsidiary) under the Notes, any Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder by accepting Notes waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes.

(5) Governing Law. THIS SUPPLEMENTAL INDENTURE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

(6) Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. This Supplemental Indenture may be executed in multiple counterparts which, when taken together, shall constitute one instrument. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmissions shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

(7) Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

(8) The Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary.

(9) Benefits Acknowledged. The Guaranteeing Subsidiary’s Guarantee is subject to the terms and conditions set forth in the Indenture. The Guaranteeing Subsidiary acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by the Indenture and this Supplemental Indenture and that the guarantee and waivers made by it pursuant to this Guarantee are knowingly made in contemplation of such benefits.

(10) Successors. All agreements of the Guaranteeing Subsidiary in this Supplemental Indenture shall bind its Successors, except as otherwise provided in this Supplemental Indenture. All agreements of the Trustee in this Supplemental Indenture shall bind its successors.

2

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the date first above written.

CAPARIO, INC.
By:	/s/ Gregory T. Stevens
Name:	Gregory T. Stevens
Title:	Secretary
WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee
By:	/s/ Joseph P. O’Donnell
Name:	Joseph P. O’Donnell
Title:	Vice President

Supplemental Indenture (11.25% Senior Notes Due 2020)

EX-10.1

Exhibit 10.1

SEPARATION AGREEMENT AND GENERAL RELEASE

THIS SEPARATION AGREEMENT AND GENERAL RELEASE (this “Release”) is made as of September 19, 2014 (the “Execution Date”) by and between T. Ulrich Brechbuhl, an individual (“Executive”), and Emdeon Business Services LLC, a Delaware limited liability company (“Emdeon”). In consideration of the payments and benefits described in Section 2 below be provided to Executive, the sufficiency of which is acknowledged hereby, Executive and Emdeon agree as follows:

1. Termination Date. Executive and Emdeon agree that Executive’s employment will terminate on November 4, 2014 (the “Termination Date”). During the period through the Termination Date, Executive will be compensated in accordance with Emdeon’s regular payroll processes up to and including the Termination Date and will complete certain tasks and transition his responsibilities as determined by management and be in compliance with Emdeon’s policies and procedures. Executive hereby resigns from all positions as an officer or director with Emdeon and its affiliates as of the Termination Date. Executive shall not take any actions on behalf of the Company and its Affiliates after the Termination Date.

2. Cash Severance; Reimbursements. Subject to the revocation period referred to in Section 9(c) below having expired without the Executive’s having revoked this Release and subject to Executive’s execution of the release attached as Exhibit A following the Termination Date (the “Termination Date Release”) and the revocation period set forth therein expiring without a revocation of the Termination Date Release, and in consideration of Executive’s general release of claims, and Executive’s other promises set forth herein, Emdeon shall pay to Executive the following severance compensation:

(a) $365,000, payable in equal installments over 12 months in accordance with Emdeon’s regular payroll dates;

(b) payment of the prorated portion of Executive’s Annual Bonus in respect of the 2014 year based on actual performance as though Executive remained employed with Emdeon through the payment date of the Annual Bonus, payable when annual bonuses generally are paid to Emdeon’s senior executives (but no later than March 15, 2015);

(c) a lump sum cash payment representing that portion of the health insurance premium that Emdeon would have paid for active employees with similar coverage for twelve months; and

(d) Emdeon shall reimburse Executive for reasonable business expenses incurred prior to the Termination Date and submitted for reimbursement within 30 days following the Termination Date and otherwise in compliance with Emdeon’s reimbursement policies.

3. Stock Options. (a) Executive acknowledges that Executive holds 240 options (collectively, the “Rollover Options”) with an exercise price per share of $250 to purchase shares of common stock of Beagle Parent Corp. (“Parent”) that Executive received pursuant to the Option Rollover Agreement (the “Option Rollover Agreement”) dated as of November 2, 2011 between Parent and Executive. The Rollover Options shall remain outstanding and exercisable in accordance with their terms.

1

(b) Executive acknowledges that Executive holds the following outstanding options (collectively, the “Options”) to purchase shares of common stock of Parent that Executive received pursuant to the Nonqualified Stock Option Agreement (the “Option Agreement”) under the Beagle Parent Corp. Amended and Restated 2009 Equity Incentive Plan (as amended from time to time, the “Plan”):

(i) 2,740 time-vesting options with an exercise price of $1,000 per share (the “Tier I Options”), of which 1,644 will be vested as of the Termination Date (the “Vested Tier I Options”);

(ii) 1,700 time-vesting options with an exercise price of $2,500 per share (the “Tier II Options”), of which 1,020 will be vested as of the Termination Date (the “Vested Tier II Options”);

(iii) 1,370 options with an exercise price of $1,000 per share, which vest upon the satisfaction of the 2x MOIC Hurdle or 20% IRR Hurdle (each as defined in the Option Agreement) (the “2.0 MOIC Options”), of which none are currently vested;

(iv) 1,370 options with an exercise price of $1,000 per share, which vest upon the satisfaction of the 2.5x MOIC Hurdle or 25% IRR Hurdle (the “2.5 MOIC Options”, and together with the 2.0 MOIC Options, the “MOIC Options”), of which none are currently vested.

(c) Executive and Emdeon (on behalf of Parent) acknowledge and agree that (i) Vested Tier I Options will remain outstanding until fourteen months after the Termination Date (rather than expiring pursuant to original terms in connection with Executive’s termination of employment); (ii) Vested Tier II Options shall expire on the Termination Date; (iii) all other Tier I Options and Tier II Options shall be forfeited by Executive and cancelled without consideration as of the Termination Date; and (iv) the MOIC Options shall remain outstanding and eligible to vest until eight months after the Termination Date (rather than expiring pursuant to original terms in connection with Executive’s termination of employment), and subject to expiration without consideration as set forth in the Option Agreements.

4. Company Property. On or as promptly as practicable after the Termination Date, Executive shall return to Emdeon Executive’s corporate credit cards, electronic building access cards, keys and all other property of Emdeon. Executive shall not take, retain, or copy in any form or manner any Emdeon files, financial information, lists of customers, prices, or any other confidential and proprietary materials or information of Emdeon or any of its subsidiaries or affiliates.

5. No Admission. Neither this Release nor anything in this Release shall be construed to be or shall be admissible in any proceeding as evidence of an admission by Emdeon or Executive of any violation of Emdeon’s policies or procedures, or state or federal laws or regulations. This Release may be introduced, however, in any proceeding to enforce the Release.

Such introduction shall be pursuant to an order protecting its confidentiality, except insofar as a court declines to enter any such Order.

2

6. Release. Except for (a) those obligations created by or arising out of this Release, (b) any rights Executive may have under the agreements related to Executive’s Options (after giving effect to Section 3), and any retirement, 401(k), or similar qualified benefit plans of Emdeon, and (c) any continuing right to indemnification as provided by (i) any indemnification agreements entered into by and between Executive and Parent or any of its subsidiaries (collectively, the “Indemnification Agreements”), (ii) any applicable law or (iii) in Emdeon’s bylaws and articles of incorporation in connection with acts, suits or proceedings by reason of the fact that Executive was an officer or employee of Emdeon where the basis of the claims against Executive consists of acts or omissions taken or made in such capacity, Executive on behalf of Executive, Executive’s descendants, dependents, heirs, executors, administrators, assigns, and successors, and each of them, hereby covenants not to sue and fully releases and discharges Emdeon, and its predecessors, subsidiaries and affiliates, past and present, and each of them, as well as its and their respective trustees, directors, officers, agents, attorneys, insurers, employees, stockholders (including any direct or indirect stockholder that beneficially owns more than 10% of the capital stock of Emdeon), representatives, assigns, and successors, past and present, and each of them, hereinafter together and collectively (including Emdeon) referred to as the “Emdeon Releasees”, with respect to and from any and all claims, wages, demands, rights, liens, agreements, contracts, covenants, actions, suits, causes of action, obligations, debts, costs, expenses, attorneys’ fees, damages, judgments, orders and liabilities of whatever kind or nature in law, equity or otherwise, whether now known or unknown, suspected or unsuspected, and whether or not concealed or hidden, which Executive now owns or holds or Executive has at any time heretofore owned or held as against the Emdeon Releasees, up to and including the date of Executive’s execution of this Release, arising out of or in any way connected with Executive’s employment relationship with any Emdeon Releasee, or the termination of Executive’s employment with the Emdeon Releasees or any other transactions, occurrences, actions, omissions, claims, losses, damages or injuries whatsoever, known or unknown, suspected or unsuspected, resulting from any act or omission by or on the part of any Emdeon Releasee committed or omitted prior to the date of this Release, including, without limiting the generality of the foregoing, any claim under Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Family and Medical Leave Act of 1993, the Fair Employment Practices Act, the Equal Pay Laws, the Workers’ Compensation Act, the Family and Medical Leave Act, the Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the United States Code, the Employee Retirement Income Security Act of 1974, the Tennessee Human Rights Act, the Tennessee Disability Act, the Tennessee Whistleblower’s Act, the Tennessee Wage Regulation Act, the state and federal Worker Adjustment and Retraining Notification Act, or any common law or statutory claim whatsoever whether for fraud, wrongful termination, violation of public policy or defamation or otherwise, except as expressly set forth herein, any claim for compensation, severance pay, bonus, sick leave, holiday pay, vacation pay, life insurance, health or medical insurance or any other fringe benefit, workers’ compensation or disability benefits.

7. Release of Unknown Claims. It is the intention of Executive in executing this Release that the same shall be effective as a bar to each and every claim, demand and cause of action hereinabove specified. Executive acknowledges that Executive may hereafter discover

3

claims or facts in addition to or different from those which Executive now knows or believes to exist with respect to the subject matter of this Release and which, if known or suspected at the time of executing this Release, may have materially affected this settlement. Nevertheless, Executive hereby waives any right, claim or cause of action that might arise as a result of such different or additional claims or facts. Executive acknowledges that Executive understands the significance and consequence of such release.

8. Confidential. The terms and conditions of this Release shall remain confidential as between the parties and professional advisers to the parties and neither of them shall disclose them to any other person, except as provided herein or as required by the rules and regulations of the Securities and Exchange Commission (“SEC”) or as otherwise may be required by law or court order. Executive may disclose pertinent information concerning this Release to Executive’s attorney, tax advisor, financial planner, current spouse and adult children, provided they have been previously informed of and have agreed to keep confidential the terms of this Release. Without limiting the generality of the foregoing, neither Emdeon nor Executive will respond to or in any way participate in or contribute to any public discussion concerning, or in any way relating to, the execution of this Release or the events which led to its execution. Except as provided above with respect to SEC rules and regulations or as otherwise may be required by law or court order, if inquiry is made of Emdeon concerning any request for reference information about Executive, or relating to Executive’s employment with Emdeon, Emdeon shall provide to third parties Executive’s dates of employment with Emdeon and its predecessors and Executive’s job titles during such employment, in accordance with the normal practices of Emdeon’s human resources department.

9. Waiver; Effective Date. Executive expressly acknowledges and agrees that, by entering into this Release, Executive is waiving any and all rights or claims that may have arisen under the Age Discrimination in Employment Act of 1967, as amended, which have arisen on or before the date of execution of this Release. Executive further expressly acknowledges that:

(a) Executive is hereby advised in writing by this Release to consult with an attorney before signing this Release;

(b) Executive was given a copy of this Release on September 18, 2014, and informed that Executive has 21 calendar days from that date to consider this Release, although Executive is free to execute this Release any time prior to that date as indicated in Section 18 below; and

(c) Executive was informed that Executive has seven days following the date of Executive’s execution of this Release in which to revoke this Release, which revocation may be effected by means of a written notice actually delivered to the office of the General Counsel of Emdeon at Emdeon’s corporate headquarters within such seven day period, provided that in all events any revocation must be received by Emdeon during the seven-day revocation period.

(d) Emdeon and Executive agree that this Release will not become effective or enforceable until the seven-day revocation period has expired without Executive’s having revoked this Release (the “Effective Date”), and no obligations upon Emdeon set forth in this Release shall be operative or binding upon it until the Effective Date. Moreover, without limiting the generality of the foregoing, if this Release is revoked, all unvested Options shall immediately be forfeited and canceled with no further action required by any party.

4

10. Employment Relationship. Emdeon and Executive acknowledge that any employment relationship between them (including with any other Emdeon Releasee) shall terminate on the Termination Date, that thereafter they have no further employment relationship except as may arise out of this Release and that Executive waives any right or claim to reinstatement as an employee of any Emdeon Releasee and will not seek employment in the future with Emdeon, unless by mutual consent. Nothing herein shall be construed as voiding Executive’s entitlement to post-termination payments pursuant to Sections 2 and 3 above or Emdeon’s (or any of its affiliates as the case may be) rights pursuant to Section 4 of the Employment Agreement. Executive agrees that, following the termination of Executive’s employment with Emdeon, (a) Executive will cooperate with any reasonable request Emdeon may make for information or assistance with respect to any matter involving Executive during Executive’s period of employment, including reasonable cooperation with Emdeon with respect to any pending or future proceedings, lawsuits, or investigations concerning Emdeon and/or its affiliates; provided that Emdeon will reimburse Executive for any reasonable out of pocket expenses incurred as a result of such cooperation, as long as such expenses are supported with receipts or other acceptable documentation in accordance with Emdeon’s corporate travel and expense policies; and (b) Executive will not at any time, directly or indirectly, disparage or make any untruthful statements about Emdeon or any Emdeon Releasee or take any action with the intention of injuring the business, prospects or reputation of Emdeon or any Emdeon Releasee, provided, however, that nothing contained herein shall restrict in any way Executive’s communications with law enforcement or government officials, or in Executive giving of any testimony. Emdeon, on behalf of itself and the Emdeon Releasees, agrees that it will instruct its officers and directors not to disparage or make any untruthful statements about Executive.

11. Entire Agreement. This Release shall be incorporated into and made a part of the Employment Agreement, the Indemnification Agreements, and legal documentation related to the Rollover Options and Options (the “Option Documents”) as of the date hereof. This Release, together with the Employment Agreement and the Option Documents, sets forth the entire agreement and understanding between the parties as to the subject matter hereof and supersedes all prior and contemporaneous oral and written discussions, agreements and understandings of any kind or nature. This Release shall inure to the benefit of and be binding upon the parties hereto and their respective permitted successors and assigns.

12. Severability. If any provision of this Release or the application thereof is held invalid, the invalidity shall not affect the other provisions or applications of this Release which can be given effect without the invalid provisions or applications and to this end the provisions of this Release are declared to be severable.

13. Governing Law. This Release and the rights and obligations of the parties hereunder shall be construed and enforced in accordance with, and governed by, the laws of the State of Tennessee without regard to principles of conflict of laws.

14. Counterparts. This Release may be executed in counterparts, and each counterpart, when executed, shall have the efficacy of a signed original. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.

5

15. No Waiver. No waiver of any breach of any term or provision of this Release shall be construed to be, or shall be, a waiver of any other breach of this Release. No waiver shall be binding unless in writing and signed by the party waiving the breach.

16. Reliance on Counsel. In entering this Release, Executive represents that Emdeon advised Executive to consult legal counsel and that Executive had the opportunity to seek the advice of Executive’s legal counsel of Executive’s own choice, and that Executive has read the Release and had the opportunity to have the Release explained to Executive by legal counsel, and that those terms are fully understood and voluntarily accepted by Executive.

17. Cooperation. All parties agree to cooperate fully and to execute any and all supplementary documents and to take all additional actions that may be necessary or appropriate to give full force to the terms and intent of this Release and which are not inconsistent with its terms.

18. Declaration. Executive hereby declares as follows:

I, T. Ulrich Brechbuhl, hereby acknowledge that I was given 21 calendar days to consider the foregoing Release and voluntarily chose to sign the Release prior to that date.

I have read the foregoing Release and I accept and agree to the provisions it contains and hereby execute it voluntarily with full understanding of its consequences.

[Signature page follows]

6

IN WITNESS WHEREOF, the undersigned have executed and delivered this Release this 19th day of September, 2014.

/s/ T. Ulrich Brechbuhl

Name: T. Ulrich Brechbuhl

7

EMDEON BUSINESS SERVICES LLC
By:	/s/ Gregory T. Stevens

8

EXHIBIT A—TERMINATION DATE RELEASE

This Termination Date Release, dated as of November 4, 2014, (this “Termination Date Release”), is entered into by and between T. Ulrich Brechbuhl, an individual (“Executive”), and Emdeon Business Services LLC, a Delaware limited liability company (“Emdeon”).

WHEREAS, Executive until recently has been employed with Emdeon; and

WHEREAS, Executive’s employment with Emdeon has terminated effective November 4, 2014;

NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Termination Date Release and other good and valuable consideration, Executive and Emdeon hereby agree as follows:

1. Release. Except for (a) those obligations created by or arising out of the Separation Agreement and Release, effective as of September 19, 2014 by and between Executive and Emdeon (the “Release”), (b) any rights Executive may have under the agreements related to Executive’s Options (after giving effect to Section 3 of the Release), and any retirement, 401(k), or similar qualified benefit plans of Emdeon, and (c) any continuing right to indemnification as provided by (i) any indemnification agreements entered into by and between Executive and Parent or any of its subsidiaries (collectively, the “Indemnification Agreements”), (ii) any applicable law or (iii) in Emdeon’s bylaws and articles of incorporation in connection with acts, suits or proceedings by reason of the fact that Executive was an officer or employee of Emdeon where the basis of the claims against Executive consists of acts or omissions taken or made in such capacity, Executive on behalf of Executive, Executive’s descendants, dependents, heirs, executors, administrators, assigns, and successors, and each of them, hereby covenants not to sue and fully releases and discharges Emdeon, and its predecessors, subsidiaries and affiliates, past and present, and each of them, as well as its and their respective trustees, directors, officers, agents, attorneys, insurers, employees, stockholders (including any direct or indirect stockholder that beneficially owns more than 10% of the capital stock of Emdeon), representatives, assigns, and successors, past and present, and each of them, hereinafter together and collectively (including Emdeon) referred to as the “Emdeon Releasees”, with respect to and from any and all claims, wages, demands, rights, liens, agreements, contracts, covenants, actions, suits, causes of action, obligations, debts, costs, expenses, attorneys’ fees, damages, judgments, orders and liabilities of whatever kind or nature in law, equity or otherwise, whether now known or unknown, suspected or unsuspected, and whether or not concealed or hidden, which Executive now owns or holds or Executive has at any time heretofore owned or held as against the Emdeon Releasees, up to and including the date of Executive’s execution of this Release, arising out of or in any way connected with Executive’s employment relationship with any Emdeon Releasee, or the termination of Executive’s employment with the Emdeon Releasees or any other transactions, occurrences, actions, omissions, claims, losses, damages or injuries whatsoever, known or unknown, suspected or unsuspected, resulting from any act or omission by or on the part of any Emdeon Releasee committed or omitted prior to the date of this Release, including, without limiting the generality of the foregoing, any claim under Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Family and Medical

9

Leave Act of 1993, the Fair Employment Practices Act, the Equal Pay Laws, the Workers’ Compensation Act, the Family and Medical Leave Act, the Civil Rights Act of 1991, Sections 1981 through 1988 of Title 42 of the United States Code, the Employee Retirement Income Security Act of 1974, the Tennessee Human Rights Act, the Tennessee Disability Act, the Tennessee Whistleblower’s Act, the Tennessee Wage Regulation Act, the state and federal Worker Adjustment and Retraining Notification Act, or any common law or statutory claim whatsoever whether for fraud, wrongful termination, violation of public policy or defamation or otherwise, except as expressly set forth herein, any claim for compensation, severance pay, bonus, sick leave, holiday pay, vacation pay, life insurance, health or medical insurance or any other fringe benefit, workers’ compensation or disability benefits.

2. Release of Unknown Claims. It is the intention of Executive in executing this Termination Date Release that the same shall be effective as a bar to each and every claim, demand and cause of action hereinabove specified. Executive acknowledges that Executive may hereafter discover claims or facts in addition to or different from those which Executive now knows or believes to exist with respect to the subject matter of this Release and which, if known or suspected at the time of executing this Termination Date Release, may have materially affected this settlement. Nevertheless, Executive hereby waives any right, claim or cause of action that might arise as a result of such different or additional claims or facts. Executive acknowledges that Executive understands the significance and consequence of such release.

3. Waiver; Effective Date. Executive expressly acknowledges and agrees that, by entering into this Termination Date Release, Executive is waiving any and all rights or claims that may have arisen under the Age Discrimination in Employment Act of 1967, as amended, which have arisen on or before the date of execution of this Release. Executive further expressly acknowledges that:

(a) Executive is hereby advised in writing by this Termination Date Release to consult with an attorney before signing this Termination Date Release;

(b) Executive was given a copy of this Termination Date Release on November 4, 2014, and informed that Executive has 21 calendar days from that date to consider this Release, although Executive is free to execute this Termination Date Release any time prior to that date as indicated in Section 5 below; and

(c) Executive was informed that Executive has seven days following the date of Executive’s execution of this Termination Date Release in which to revoke this Termination Date Release, which revocation may be effected by means of a written notice actually delivered to the office of the General Counsel of Emdeon at Emdeon’s corporate headquarters within such seven day period, provided that in all events any revocation must be received by Emdeon during the seven-day revocation period.

(d) Emdeon and Executive agree that this Termination Date Release will not become effective or enforceable until the seven-day revocation period has expired without Executive’s having revoked this Release (the “Effective Date”), and no obligations upon Emdeon set forth in this Release shall be operative or binding upon it until the Effective Date. Moreover, without limiting the generality of the foregoing, if this Termination Date Release is revoked, all unvested Options shall immediately be forfeited and canceled with no further action required by any party.

10

4. Governing Law. This Termination Date Release and the rights and obligations of the parties hereunder shall be construed and enforced in accordance with, and governed by, the laws of the State of Tennessee without regard to principles of conflict of laws.

5. Declaration. Executive hereby declares as follows:

I, T. Ulrich Brechbuhl, hereby acknowledge that I was given 21 calendar days to consider the foregoing Termination Date Release and voluntarily chose to sign the Termination Date Release prior to that date.

I have read the foregoing Termination Date Release and I accept and agree to the provisions it contains and hereby execute it voluntarily with full understanding of its consequences.

IN WITNESS WHEREOF, the undersigned have executed and delivered this Termination Date Release this 4^th day of November, 2014.

/s/ T. Ulrich Brechbuhl

Name: T. Ulrich Brechbuhl

11

EX-31.1

Exhibit 31.1

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Neil E. de Crescenzo, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Emdeon Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014	By:	/s/ Neil E. de Crescenzo
	Name:	Neil E. de Crescenzo
	Title	Chief Executive Officer of Emdeon Inc.

EX-31.2

Exhibit 31.2

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Randy P. Giles, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Emdeon Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014	By:	/s/ Randy P. Giles
	Name:	Randy P. Giles
	Title	Chief Financial Officer of Emdeon Inc.

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Emdeon Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Neil E. de Crescenzo, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2014	By:	/s/ Neil E. de Crescenzo
	Name:	Neil E. de Crescenzo
	Title	Chief Executive Officer of Emdeon Inc.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Emdeon Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Randy P. Giles, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company, that, to my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2014	By:	/s/ Randy P. Giles
	Name:	Randy P. Giles
	Title	Chief Financial Officer of Emdeon Inc.

XML

Long-Term Debt (Schedule Of Long-Term Debt) (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Less current portion	$ (24,493,000)	$ (31,330,000)
Other	11,261,000	12,592,000
Long-term debt	1,998,569,000	1,999,026,000
Data Sublicense Agreement [Member]
Debt Instrument [Line Items]
Long-term debt	22,543,000	22,543,000
Senior Secured Term Loan Facility, Due November 2, 2018 [Member] | Senior Credit Facilities [Member]
Debt Instrument [Line Items]
Long-term debt	1,255,092,000	1,262,445,000
Long-term debt, face amount	1,301,000,000
Maturity date	Nov. 02, 2018
Long-term debt, unamortized discount	13,520,000	15,826,000
Long-term debt, effective interest rate	4.21%
Senior Secured Revolving Credit Facility, Expiring On November 2, 2016 [Member] | Senior Credit Facilities [Member]
Debt Instrument [Line Items]
Long-term debt, face amount	125,000,000
Maturity date	Nov. 02, 2016
11% Senior Notes Due December 31, 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	368,034,000	367,336,000
Long-term debt, face amount	375,000,000
Long-term debt, stated interest rate	11.00%
Maturity date	Dec. 31, 2019
Long-term debt, unamortized discount	6,966,000	7,664,000
Long-term debt, effective interest rate	11.53%
11.25% Senior Notes Due December 31, 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt	366,132,000	365,440,000
Long-term debt, face amount	375,000,000
Long-term debt, stated interest rate	11.25%
Maturity date	Dec. 31, 2020
Long-term debt, unamortized discount	$ 8,868,000	$ 9,560,000
Long-term debt, effective interest rate	11.86%

XML

Supplemental Condensed Consolidating Financial Information (Condensed Consolidating Statement Of Comprehensive Income (Loss)) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Statement of Comprehensive Income (Loss) [Line Items]
Net income (loss)	$ (13,002)	$ (16,265)	$ (75,516)	$ (57,988)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes	732	(1,064)	(127)	2,511
Foreign currency translation adjustment	(127)	35	(100)	(65)
Other comprehensive income (loss)	605	(1,029)	(227)	2,446
Total comprehensive income (loss)	(12,397)	(17,294)	(75,743)	(55,542)
Emdeon Inc. [Member]
Condensed Statement of Comprehensive Income (Loss) [Line Items]
Net income (loss)	(13,002)	(16,265)	(75,516)	(57,988)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes	732	(1,064)	(127)	2,511
Equity in other comprehensive earnings	(127)	35	(100)	(65)
Other comprehensive income (loss)	605	(1,029)	(227)	2,446
Total comprehensive income (loss)	(12,397)	(17,294)	(75,743)	(55,542)
Guarantor Subsidiaries [Member]
Condensed Statement of Comprehensive Income (Loss) [Line Items]
Net income (loss)	10,110	3,766	(51,018)	6,216
Other comprehensive income (loss):
Foreign currency translation adjustment	(127)	35	(100)	(65)
Other comprehensive income (loss)	(127)	35	(100)	(65)
Total comprehensive income (loss)	9,983	3,801	(51,118)	6,151
Consolidating Adjustments [Member]
Condensed Statement of Comprehensive Income (Loss) [Line Items]
Net income (loss)	(10,110)	(3,766)	51,018	(6,216)
Other comprehensive income (loss):
Equity in other comprehensive earnings	127	(35)	100	65
Other comprehensive income (loss)	127	(35)	100	65
Total comprehensive income (loss)	$ (9,983)	$ (3,801)	$ 51,118	$ (6,151)

XML

Income Taxes (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Taxes [Abstract]
Income tax provision (benefit)	$ 4,493	$ 126	$ (43,733)	$ (26,422)
Effective income tax rate			36.70%	31.30%

XML

Supplemental Condensed Consolidating Financial Information (Condensed Consolidating Statement Of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net income (loss)	$ (75,516)	$ (57,988)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	141,541	137,943
Accretion	9,220	18,712
Equity compensation expense	5,914	5,637
Deferred income tax expense (benefit)	(44,886)	(27,884)
Amortization of debt discount and issuance costs	5,804	6,585
Contingent consideration	3,646	1,879
Loss on extinguishment of debt		22,828
Impairment of long-lived assets	82,689	1,887
Gain on sale of cost method investment		(2,925)
Other	(3,125)	(819)
Changes in operating assets and liabilities:
Accounts receivable	(12,656)	(15,582)
Prepaid expenses and other	(4,490)	(1,804)
Accounts payable	644	685
Accrued expenses, deferred revenue, and other liabilities	(375)	20,985
Tax receivable agreement obligations to related parties		(103)
Net cash provided by (used in) operating activities	108,410	110,036
Investing activities
Purchases of property and equipment	(37,673)	(52,806)
Payments for acquisitions, net of cash acquired	(87,909)	(18,291)
Proceeds from sale of cost method investment	36	5,820
Other	(133)
Net cash provided by (used in) investing activities	(125,679)	(65,277)
Financing activities
Debt principal payments	(9,659)	(9,692)
Payment of debt assumed from acquisition	(23,262)	(218)
Proceeds from Revolving Facility	65,000
Payments on Revolving Facility	(65,000)
Payment of loan costs		(2,178)
Repayment of deferred financing arrangements	(4,717)	(2,103)
Repurchase of Parent common stock	(960)	(250)
Capital contribution from Parent	3,256
Other		(518)
Net cash provided by (used in) financing activities	(35,342)	(14,959)
Net increase (decrease) in cash and cash equivalents	(52,611)	29,800
Cash and cash equivalents at beginning of period	76,538	31,763
Cash and cash equivalents at end of period	23,927	61,563
Emdeon Inc. [Member]
Operating activities
Net income (loss)	(75,516)	(57,988)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	6,753	6,753
Accretion	9,220	18,712
Equity compensation expense	255	178
Deferred income tax expense (benefit)	(74,817)	(33,425)
Amortization of debt discount and issuance costs	2,003	1,865
Loss on extinguishment of debt		478
Gain on sale of cost method investment		(2,925)
Equity in earnings of consolidated subsidiaries	51,018	(6,216)
Other	(1,094)	(819)
Changes in operating assets and liabilities:
Prepaid expenses and other	(462)	(4,732)
Accrued expenses, deferred revenue, and other liabilities	9,377	14,509
Tax receivable agreement obligations to related parties		(103)
Due to/from affiliates	69,034	1,923
Net cash provided by (used in) operating activities	(4,229)	(61,790)
Investing activities
Proceeds from sale of cost method investment	36	5,820
Investment in subsidiaries, net	50	56,149
Net cash provided by (used in) investing activities	86	61,969
Financing activities
Debt principal payments	(207)	(211)
Repurchase of Parent common stock	(960)
Capital contribution from Parent	3,256
Net cash provided by (used in) financing activities	2,089	(211)
Net increase (decrease) in cash and cash equivalents	(2,054)	(32)
Cash and cash equivalents at beginning of period	2,794	754
Cash and cash equivalents at end of period	740	722
Guarantor Subsidiaries [Member]
Operating activities
Net income (loss)	(51,018)	6,216
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	134,788	131,190
Equity compensation expense	5,659	5,459
Deferred income tax expense (benefit)	29,931	5,541
Amortization of debt discount and issuance costs	3,801	4,720
Contingent consideration	3,646	1,879
Loss on extinguishment of debt		22,350
Impairment of long-lived assets	82,689	1,887
Other	(2,031)
Changes in operating assets and liabilities:
Accounts receivable	(12,656)	(15,582)
Prepaid expenses and other	(4,028)	2,928
Accounts payable	644	685
Accrued expenses, deferred revenue, and other liabilities	(9,752)	6,476
Due to/from affiliates	(69,034)	(1,923)
Net cash provided by (used in) operating activities	112,639	171,826
Investing activities
Purchases of property and equipment	(37,673)	(52,806)
Payments for acquisitions, net of cash acquired	(87,909)	(18,291)
Other	(133)
Net cash provided by (used in) investing activities	(125,715)	(71,097)
Financing activities
Distributions to Emdeon Inc., net	(50)	(56,149)
Debt principal payments	(9,452)	(9,481)
Payment of debt assumed from acquisition	(23,262)	(218)
Proceeds from Revolving Facility	65,000
Payments on Revolving Facility	(65,000)
Payment of loan costs		(2,178)
Repayment of deferred financing arrangements	(4,717)	(2,103)
Repurchase of Parent common stock		(250)
Other		(518)
Net cash provided by (used in) financing activities	(37,481)	(70,897)
Net increase (decrease) in cash and cash equivalents	(50,557)	29,832
Cash and cash equivalents at beginning of period	73,744	31,009
Cash and cash equivalents at end of period	23,187	60,841
Consolidating Adjustments [Member]
Operating activities
Net income (loss)	51,018	(6,216)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in earnings of consolidated subsidiaries	(51,018)	6,216
Investing activities
Investment in subsidiaries, net	(50)	(56,149)
Net cash provided by (used in) investing activities	(50)	(56,149)
Financing activities
Distributions to Emdeon Inc., net	50	56,149
Net cash provided by (used in) financing activities	$ 50	$ 56,149

XML

Fair Value Measurements (Carrying Amount And The Estimated Fair Value Of Financial Instruments) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Carrying Amount	$ 23,927	$ 76,538	$ 61,563	$ 31,763
Accounts receivable, net of allowance for doubtfull accounts	231,950	214,247
Cash and cash equivalents, Fair Value	23,927
Accounts receivable, Fair Value	231,950
Quoted in Markets Indentical (Level 1) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Senior Credit Facilities Carrying Amount (Level 1)	1,255,092
Senior Credit Facilities, Fair Value (Level 1)	1,255,926
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Senior Notes, Carrying Amount (Level 2)	734,166
Senior Notes, Fair Value (Level 2)	$ 830,861

XML

Business Combinations (Summary of Other and Contingent Consideration Information Related to Acquisitions) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Information:
Contingent consideration	$ 1,976	$ 1,879	$ 3,646	$ 1,879
Goold [Member]
Other Information:
Gross contractual accounts receivable	3,435		3,435
Contingent consideration range, Max	15,000		15,000
Contingent consideration range, Min	0		0
Basis of Measurement			Award of contracts with annual revenue exceeding targeted amount
Type of measurement			Level 3
Probability of retaining contracts that expire during the measurement period			90.00%
Expected payment date			Dec. 15, 2014
Discount Rate			15.40%
Increase (decrease) to net loss	1,329	1,879	2,341	1,879
Goold [Member] | Maximum [Member]
Other Information:
Measurement period			Sep. 30, 2014
Probability of winning new contracts			50.00%
Range of baseline revenue retention for existing customers			125.00%
Goold [Member] | Minimum [Member]
Other Information:
Measurement period			Jul. 01, 2013
Probability of winning new contracts			10.00%
Range of baseline revenue retention for existing customers			75.00%
Vieosoft [Member]
Other Information:
Contingent consideration range, Max	43,104		43,104
Contingent consideration range, Min	0		0
Basis of Measurement			Milestone achievement, revenue performance
Type of measurement			Level 3
Probability of achieving milestone objectives			90.00%
Increase (decrease) to net loss	647		1,305
Vieosoft [Member] | Maximum [Member]
Other Information:
Measurement period			Dec. 31, 2017
Probability of achieving minimum gross profit margin, year			2017
Probability of achieving minimum gross profit margin			90.00%
Expected Payment Date, Year			2017
Discount Rate			53.20%
Vieosoft [Member] | Minimum [Member]
Other Information:
Measurement period			Feb. 12, 2014
Probability of achieving minimum gross profit margin, year			2015
Probability of achieving minimum gross profit margin			5.00%
Expected Payment Date, Year			2015
Discount Rate			5.20%
Capario [Member]
Other Information:
Gross contractual accounts receivable	5,112		5,112
Amount not expected to be collected	$ 66		$ 66

XML

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2014

Long-Term Debt [Abstract]

Schedule of Long-Term Debt

	September 30,		December 31,
	2014		2013
Senior Credit Facilities
$1,301 million Senior Secured Term Loan facility, due November 2, 2018, net of unamortized discount of $13,520 and $15,826 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 4.21%)	$	1,255,092	$	1,262,445
$125 million Senior Secured Revolving Credit facility, expiring on November 2, 2016 and bearing interest at a variable base rate plus a spread rate		—		—
Senior Notes
$375 million 11% Senior Notes due December 31, 2019, net of unamortized discount of $6,966 and $7,664 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.53%)		368,034		367,336
$375 million 11.25% Senior Notes due December 31, 2020, net of unamortized discount of $8,868 and $9,560 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.86%)		366,132		365,440
Obligation under data sublicense agreement		22,543		22,543
Other		11,261		12,592
Less current portion		(24,493)		(31,330)
Long-term debt	$	1,998,569	$	1,999,026

XML

Segment Reporting (Revenue And Total Segment Contribution For The Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from external customers
Net revenue	$ 341,608	$ 317,810	$ 996,973	$ 922,452
Income (loss) before income taxes	(8,509)	(16,139)	(119,249)	(84,410)
Interest expense, net	36,635	37,000	109,741	116,390
Depreciation and amortization	48,448	47,181	141,541	137,943
EBITDA	76,574	68,042	132,033	169,923
Equity compensation	2,232	2,089	5,914	5,637
Acquisition accounting adjustments	189	251	725	741
Acquisition-related costs	1,387	1,519	5,473	2,457
Transaction-related costs and advisory fees	1,683	1,500	4,799	4,825
Strategic initiatives, duplicative and transition costs	406	2,427	9,686	4,355
Severance costs	1,902	3,509	5,752	5,138
Loss on extinguishment of debt and other related costs				24,311
Accretion expense	4,452	7,112	9,220	18,712
Impairment of long-lived assets	3,114	25	82,689	1,887
Contingent consideration	1,976	1,879	3,646	1,879
Other non-routine, net	137	(3,105)	2,748	(1,425)
EBITDA Adjustments	17,478	17,206	130,652	68,517
Adjusted EBITDA	94,052	85,248	262,685	238,440
Payer [Member]
Revenue from external customers
Net revenue	217,867	206,770	642,363	603,902
Income (loss) before income taxes	51,103	51,815	146,600	144,726
Interest expense, net		(2)	(9)	1
Depreciation and amortization	16,843	16,333	49,921	48,355
EBITDA	67,946	68,146	196,512	193,082
Equity compensation	254	285	769	865
Acquisition accounting adjustments	18	65	85	236
Acquisition-related costs	461	884	1,368	1,821
Strategic initiatives, duplicative and transition costs			59	130
Severance costs	321	84	851	434
Other non-routine, net	523	101	3,156	218
EBITDA Adjustments	1,577	1,419	6,288	3,704
Adjusted EBITDA	69,523	69,565	202,800	196,786
Provider [Member]
Revenue from external customers
Net revenue	79,363	70,087	227,364	207,080
Income (loss) before income taxes	26,565	20,052	67,797	54,987
Interest expense, net	(159)		(159)	33
Depreciation and amortization	12,178	11,579	36,127	35,607
EBITDA	38,584	31,631	103,765	90,627
Equity compensation	265	315	759	906
Acquisition accounting adjustments	7	76	57	402
Acquisition-related costs	12	29	273	91
Strategic initiatives, duplicative and transition costs	7		230
Severance costs	801	105	1,227	319
Impairment of long-lived assets		25	448
Other non-routine, net	106	136	465	544
EBITDA Adjustments	1,198	686	3,459	2,262
Adjusted EBITDA	39,782	32,317	107,224	92,889
Pharmacy [Member]
Revenue from external customers
Net revenue	31,739	30,440	93,079	80,587
Income (loss) before income taxes	9,846	9,725	(40,942)	30,740
Interest expense, net	(5)	(3)	(6)	(8)
Depreciation and amortization	3,254	4,309	11,479	11,573
EBITDA	13,095	14,031	(29,469)	42,305
Equity compensation	77	62	198	140
Acquisition accounting adjustments	152	94	546	53
Acquisition-related costs		41	(72)	47
Strategic initiatives, duplicative and transition costs	96	223	192	781
Severance costs	13	18	18	252
Impairment of long-lived assets	(90)		73,751
Contingent consideration	1,976	1,879	3,646	1,879
Other non-routine, net	37	2	206	7
EBITDA Adjustments	2,261	2,319	78,485	3,159
Adjusted EBITDA	15,356	16,350	49,016	45,464
All Other [Member]
Revenue from external customers
Net revenue	21,419	18,310	59,118	54,180
Income (loss) before income taxes	11,742	8,509	31,170	25,039
Depreciation and amortization	41	43	159	88
EBITDA	11,783	8,552	31,329	25,127
Equity compensation	21	292	66	844
Acquisition accounting adjustments		4	3	15
Acquisition-related costs	8	2	9	4
Strategic initiatives, duplicative and transition costs		16		85
Severance costs			30	263
Other non-routine, net			6	6
EBITDA Adjustments	29	314	114	1,217
Adjusted EBITDA	11,812	8,866	31,443	26,344
Corporate And Eliminations [Member]
Revenue from external customers
Net revenue	(8,780)	(7,797)	(24,951)	(23,297)
Income (loss) before income taxes	(107,765)	(106,240)	(323,874)	(339,902)
Interest expense, net	36,799	37,005	109,915	116,364
Depreciation and amortization	16,132	14,917	43,855	42,320
EBITDA	(54,834)	(54,318)	(170,104)	(181,218)
Equity compensation	1,615	1,135	4,122	2,882
Acquisition accounting adjustments	12	12	34	35
Acquisition-related costs	906	563	3,895	494
Transaction-related costs and advisory fees	1,683	1,500	4,799	4,825
Strategic initiatives, duplicative and transition costs	303	2,188	9,205	3,359
Severance costs	767	3,302	3,626	3,870
Loss on extinguishment of debt and other related costs				24,311
Accretion expense	4,452	7,112	9,220	18,712
Impairment of long-lived assets	3,204		8,490	1,887
Other non-routine, net	(529)	(3,344)	(1,085)	(2,200)
EBITDA Adjustments	12,413	12,468	42,306	58,175
Adjusted EBITDA	(42,421)	(41,850)	(127,798)	(123,043)
Claims Management [Member]
Revenue from external customers
Net revenue	73,314	78,292	215,614	215,933
Claims Management [Member] | Payer [Member]
Revenue from external customers
Net revenue	73,314	78,292	215,614	215,933
Payment Distribution Services [Member]
Revenue from external customers
Net revenue	73,703	63,942	213,766	194,174
Payment Distribution Services [Member] | Payer [Member]
Revenue from external customers
Net revenue	73,703	63,942	213,766	194,174
Patient Billing And Payment Services [Member]
Revenue from external customers
Net revenue	68,360	62,911	205,921	189,396
Patient Billing And Payment Services [Member] | Payer [Member]
Revenue from external customers
Net revenue	68,360	62,911	205,921	189,396
Revenue Cycle Technology [Member]
Revenue from external customers
Net revenue	32,343	29,678	95,254	87,777
Revenue Cycle Technology [Member] | Provider [Member]
Revenue from external customers
Net revenue	32,343	29,678	95,254	87,777
Revenue Cycle Services [Member]
Revenue from external customers
Net revenue	34,979	31,172	101,491	92,273
Revenue Cycle Services [Member] | Provider [Member]
Revenue from external customers
Net revenue	34,979	31,172	101,491	92,273
Physician Services [Member]
Revenue from external customers
Net revenue	12,041	9,237	30,619	27,030
Physician Services [Member] | Provider [Member]
Revenue from external customers
Net revenue	12,041	9,237	30,619	27,030
Pharmacy [Member]
Revenue from external customers
Net revenue	31,649	30,363	92,808	80,331
Pharmacy [Member] | Pharmacy [Member]
Revenue from external customers
Net revenue	31,649	30,363	92,808	80,331
Channel Partner [Member]
Revenue from external customers
Net revenue	6,952	4,135	17,041	11,047
Channel Partner [Member] | All Other [Member]
Revenue from external customers
Net revenue	13,152	10,230	34,659	29,689
Channel Partner [Member] | Corporate And Eliminations [Member]
Revenue from external customers
Net revenue	(6,200)	(6,095)	(17,618)	(18,642)
Dental [Member]
Revenue from external customers
Net revenue	8,267	8,080	24,459	24,491
Dental [Member] | All Other [Member]
Revenue from external customers
Net revenue	8,267	8,080	24,459	24,491
Inter-segment Revenues [Member] | Payer [Member]
Revenue from external customers
Net revenue	2,490	1,625	7,062	4,399
Inter-segment Revenues [Member] | Pharmacy [Member]
Revenue from external customers
Net revenue	90	77	271	256
Inter-segment Revenues [Member] | Corporate And Eliminations [Member]
Revenue from external customers
Net revenue	$ (2,580)	$ (1,702)	$ (7,333)	$ (4,655)

XML

Interest Rate Swap (Effect Of Derivative Instrument On The Accompanying Consolidated Statements Of Operations) (Details) (Designated as Hedging Instrument [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Designated as Hedging Instrument [Member]
Derivatives in Cash Flow Hedging Relationships
Gain/ (loss) related to effective portion of derivative recognized in other comprehensive loss	$ 595	$ (2,305)	$ (2,150)	$ 2,096
Gain/ (loss) related to effective portion of derivative reclassified from accumulated other comprehensive loss to interest expense	$ (652)	$ (652)	$ (1,935)	$ (1,935)

XML

Goodwill And Intangible Assets (Aggregate Future Amortization Expense For Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Goodwill And Intangible Assets [Abstract]
2014 (remainder)	$ 25,574
2015	101,888
2016	101,301
2017	97,399
2018	92,788
Thereafter	1,111,825
Intangible assets, net	$ 1,530,775	$ 1,632,688

XML

Supplemental Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 23,927	$ 76,538	$ 61,563	$ 31,763
Accounts receivable, net of allowance for doubtfull accounts	231,950	214,247
Deferred income tax assets	16,974	6,317
Prepaid expenses and other current assets	33,085	27,019
Total current assets	305,936	324,121
Property and equipment, net	239,635	269,470
Goodwill	1,584,655	1,502,434
Intangible assets, net	1,530,775	1,632,688
Other assets, net	19,656	19,169
Total assets	3,680,657	3,747,882
Current liabilities:
Accounts payable	12,263	8,367
Accrued expenses	143,807	131,149
Deferred revenues	10,233	10,881
Current portion of long-term debt	24,493	31,330
Total current liabilities	190,796	181,727
Long-term debt, excluding current portion	1,998,569	1,999,026
Deferred income tax liabilities	416,986	436,263
Tax receivable agreement obligations to related parties	159,716	150,496
Other long-term liabilities	13,576	11,824
Commitments and contingencies
Equity	901,014	968,546	981,996	1,032,151
Total liabilities and equity	3,680,657	3,747,882
Emdeon Inc. [Member]
Current assets:
Cash and cash equivalents	740	2,794	722	754
Deferred income tax assets	100
Prepaid expenses and other current assets	3,972	3,441
Total current assets	4,812	6,235
Property and equipment, net	7	10
Investment in consolidated subsidiaries	1,718,809	1,764,213
Intangible assets, net	135,750	142,500
Other assets, net	138,648	64,536
Total assets	1,998,026	1,977,494
Current liabilities:
Accrued expenses	16,589	8,205
Current portion of long-term debt	5,577	5,775
Total current liabilities	22,166	13,980
Due to affiliates	138,176	69,142
Long-term debt, excluding current portion	776,954	775,330
Tax receivable agreement obligations to related parties	159,716	150,496
Commitments and contingencies
Equity	901,014	968,546
Total liabilities and equity	1,998,026	1,977,494
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	23,187	73,744	60,841	31,009
Accounts receivable, net of allowance for doubtfull accounts	231,950	214,247
Deferred income tax assets	16,874	6,317
Prepaid expenses and other current assets	29,113	23,578
Total current assets	301,124	317,886
Property and equipment, net	239,628	269,460
Due from affiliates	138,176	69,142
Goodwill	1,584,655	1,502,434
Intangible assets, net	1,395,025	1,490,188
Other assets, net	16,030	14,949
Total assets	3,674,638	3,664,059
Current liabilities:
Accounts payable	12,263	8,367
Accrued expenses	127,218	122,944
Deferred revenues	10,233	10,881
Current portion of long-term debt	18,916	25,555
Total current liabilities	168,630	167,747
Long-term debt, excluding current portion	1,221,615	1,223,696
Deferred income tax liabilities	552,008	496,579
Other long-term liabilities	13,576	11,824
Commitments and contingencies
Equity	1,718,809	1,764,213
Total liabilities and equity	3,674,638	3,664,059
Consolidating Adjustments [Member]
Current assets:
Due from affiliates	(138,176)	(69,142)
Investment in consolidated subsidiaries	(1,718,809)	(1,764,213)
Other assets, net	(135,022)	(60,316)
Total assets	(1,992,007)	(1,893,671)
Current liabilities:
Due to affiliates	(138,176)	(69,142)
Deferred income tax liabilities	(135,022)	(60,316)
Commitments and contingencies
Equity	(1,718,809)	(1,764,213)
Total liabilities and equity	$ (1,992,007)	$ (1,893,671)

XML

Legal Proceedings (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Legal Proceedings [Abstract]
Settlement amount	$ 8,000	$ 8,000
Recognized loss from an underpayment of fees to a vendor	$ 500	$ 3,000

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2014

Basis of Presentation [Abstract]

Basis of Presentation

2. Basis of Presentation

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) Guidelines, Rules and Regulations (“Regulation S-X”) and, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of results for the unaudited interim periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The results of operations for the interim period are not necessarily indicative of the results to be obtained for the full fiscal year. All material intercompany accounts and transactions have been eliminated in the unaudited condensed consolidated financial statements.

Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The Company changed the classification of rebate payments to its channel partners from cost of operations to a reduction of revenue to the extent that such rebate payments for any given channel partner were less than or equal to revenue otherwise earned from the respective channel partner. To conform to the current period presentation, rebate payments to channel partners resulted in a reduction of revenue of $6,096 and $18,641for the three and nine months ended September 30, 2013, respectively.

Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors and various other assumptions that the Company believes are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses and disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in the Company’s business environment; therefore, actual results could differ materially from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the reported results of operations; and if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Estimates and assumptions by management affect: the allowance for doubtful accounts; the fair value assigned to assets acquired and liabilities assumed in business combinations; tax receivable agreement obligations; the fair value of interest rate swap obligations; contingent consideration; loss accruals; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses; revenue recognition; contingencies; and the value attributed to equity awards.

During the three months ended September 30, 2014, the Company recognized a change in estimate related to its accounts receivable, the effect of which reduced revenue and increased pretax loss by $4,098.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, which changes the requirements for reporting discontinued operations. Following adoption of this update, discontinued operations generally will be reported for the disposal by sale or otherwise of a component or a group of components that represents a strategic shift that has or will have a major effect on an entity’s operations and financial results. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2014, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, which replaces most prior general and industry specific revenue recognition guidance with a principles-based comprehensive revenue recognition framework. Under this revised framework, a company will recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2016. Early adoption is not permitted. Upon adoption, a company may elect to either retrospectively restate each prior reporting period or reflect the cumulative effect of initially applying the update with an adjustment to retained earnings. The Company is currently assessing the potential effects this update may have on its consolidated financial statements.

In June 2014, the FASB issued ASU No. 2014-12, which clarifies, in the context of share-based payment awards, that a performance target that affects vesting and could be achieved after the requisite service period has been rendered should be treated as a performance condition. Prior to this update, because there was no explicit guidance, there was diversity in practice among companies. This update is effective for fiscal years and interim periods within those years beginning after December 15, 2015, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

XML

Fair Value Measurements (Fair Value Of Financial Instruments Measured On A Recurring Basis) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate swaps	$ (1,891)
Contingent consideration obligations	(15,145)
Total	(17,036)
Quoted in Markets Indentical (Level 1) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate swaps
Contingent consideration obligations
Total
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate swaps	(1,891)
Total	(1,891)
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration obligations	(15,145)
Total	$ (15,145)

XML

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2014

Accumulated Other Comprehensive Income (Loss) [Abstract]

Summary of Accumulated Other Comprehensive Income (Loss)

	Foreign				Accumulated
	Currency				Other
	Translation		Cash Flow		Comprehensive
	Adjustment		Hedge		Income (Loss)
Balance at January 1, 2014	$	(264)	$	(1,079)	$	(1,343)
Change associated with foreign currency translation		(100)		—		(100)
Change associated with current period hedging		—		(2,062)		(2,062)
Reclassification into earnings		—		1,935		1,935
Balance at September 30, 2014	$	(364)	$	(1,206)	$	(1,570)

XML

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Revenue and Total Segment Contribution for the Reportable Segments

	Three Months Ended September 30, 2014
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	73,314	$	—	$	—	$	—	$	—	$	73,314
Payment distribution services		73,703		—		—		—		—		73,703
Patient billing and payment services		68,360		—		—		—		—		68,360
Revenue cycle technology		—		32,343		—		—		—		32,343
Revenue cycle services		—		34,979		—		—		—		34,979
Physician services		—		12,041		—		—		—		12,041
Pharmacy		—		—		31,649		—		—		31,649
Channel Partner		—		—		—		13,152		(6,200)		6,952
Dental		—		—		—		8,267		—		8,267
Inter-segment revenue		2,490		—		90		—		(2,580)		—
Net revenue	$	217,867	$	79,363	$	31,739	$	21,419	$	(8,780)	$	341,608
Income (loss) before income taxes		51,103		26,565		9,846		11,742		(107,765)	$	(8,509)
Interest expense		—		(159)		(5)		—		36,799		36,635
Depreciation and amortization		16,843		12,178		3,254		41		16,132		48,448
EBITDA		67,946		38,584		13,095		11,783		(54,834)		76,574
Equity compensation		254		265		77		21		1,615		2,232
Acquisition accounting adjustments		18		7		152		—		12		189
Acquisition-related costs		461		12		—		8		906		1,387
Transaction-related costs and advisory fees		—		—		—		—		1,683		1,683
Strategic initiatives, duplicative and transition costs		—		7		96		—		303		406
Severance costs		321		801		13		—		767		1,902
Accretion		—		—		—		—		4,452		4,452
Impairment of long-lived assets		—		—		(90)		—		3,204		3,114
Contingent consideration		—		—		1,976		—		—		1,976
Other non-routine, net		523		106		37		—		(529)		137
EBITDA Adjustments		1,577		1,198		2,261		29		12,413		17,478
Adjusted EBITDA	$	69,523	$	39,782	$	15,356	$	11,812	$	(42,421)	$	94,052

	Three Months Ended September 30, 2013
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	78,292	$	—	$	—	$	—	$	—	$	78,292
Payment distribution services		63,942		—		—		—		—		63,942
Patient billing and payment services		62,911		—		—		—		—		62,911
Revenue cycle technology		—		29,678		—		—		—		29,678
Revenue cycle services		—		31,172		—		—		—		31,172
Physician services		—		9,237		—		—		—		9,237
Pharmacy		—		—		30,363		—		—		30,363
Channel Partner		—		—		—		10,230		(6,095)		4,135
Dental		—		—		—		8,080		—		8,080
Inter-segment revenue		1,625		—		77		—		(1,702)		—
Net revenue	$	206,770	$	70,087	$	30,440	$	18,310	$	(7,797)	$	317,810
Income (loss) before income taxes		51,815		20,052		9,725		8,509		(106,240)	$	(16,139)
Interest expense		(2)		—		(3)		—		37,005		37,000
Depreciation and amortization		16,333		11,579		4,309		43		14,917		47,181
EBITDA		68,146		31,631		14,031		8,552		(54,318)		68,042
Equity compensation		285		315		62		292		1,135		2,089
Acquisition accounting adjustments		65		76		94		4		12		251
Acquisition-related costs		884		29		41		2		563		1,519
Transaction-related costs and advisory fees		—		—		—		—		1,500		1,500
Strategic initiatives, duplicative and transition costs		—		—		223		16		2,188		2,427
Severance costs		84		105		18		—		3,302		3,509
Accretion		—		—		—		—		7,112		7,112
Impairment of long-lived assets		—		25		—		—		—		25
Contingent consideration		—		—		1,879		—		—		1,879
Other non-routine, net		101		136		2		—		(3,344)		(3,105)
EBITDA Adjustments		1,419		686		2,319		314		12,468		17,206
Adjusted EBITDA	$	69,565	$	32,317	$	16,350	$	8,866	$	(41,850)	$	85,248

	Nine Months Ended September 30, 2014
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	215,614	$	—	$	—	$	—	$	—	$	215,614
Payment distribution services		213,766		—		—		—		—		213,766
Patient billing and payment services		205,921		—		—		—		—		205,921
Revenue cycle technology		—		95,254		—		—		—		95,254
Revenue cycle services		—		101,491		—		—		—		101,491
Physician services		—		30,619		—		—		—		30,619
Pharmacy		—		—		92,808		—		—		92,808
Channel Partner		—		—		—		34,659		(17,618)		17,041
Dental		—		—		—		24,459		—		24,459
Inter-segment revenue		7,062		—		271		—		(7,333)		—
Net revenue	$	642,363	$	227,364	$	93,079	$	59,118	$	(24,951)	$	996,973
Income (loss) before income taxes		146,600		67,797		(40,942)		31,170		(323,874)	$	(119,249)
Interest expense		(9)		(159)		(6)		—		109,915		109,741
Depreciation and amortization		49,921		36,127		11,479		159		43,855		141,541
EBITDA		196,512		103,765		(29,469)		31,329		(170,104)		132,033
Equity compensation		769		759		198		66		4,122		5,914
Acquisition accounting  adjustments		85		57		546		3		34		725
Acquisition-related costs		1,368		273		(72)		9		3,895		5,473
Transaction-related costs and advisory fees		—		—		—		—		4,799		4,799
Strategic initiatives, duplicative and transition costs		59		230		192		—		9,205		9,686
Severance costs		851		1,227		18		30		3,626		5,752
Accretion		—		—		—		—		9,220		9,220
Impairment of long-lived assets		—		448		73,751		—		8,490		82,689
Contingent consideration		—		—		3,646		—		—		3,646
Other non-routine, net		3,156		465		206		6		(1,085)		2,748
EBITDA Adjustments		6,288		3,459		78,485		114		42,306		130,652
Adjusted EBITDA	$	202,800	$	107,224	$	49,016	$	31,443	$	(127,798)	$	262,685

	Nine Months Ended September 30, 2013
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	215,933	$	—	$	—	$	—	$	—	$	215,933
Payment distribution services		194,174		—		—		—		—		194,174
Patient billing and payment services		189,396		—		—		—		—		189,396
Revenue cycle technology		—		87,777		—		—		—		87,777
Revenue cycle services		—		92,273		—		—		—		92,273
Physician services		—		27,030		—		—		—		27,030
Pharmacy		—		—		80,331		—		—		80,331
Channel Partner		—		—		—		29,689		(18,642)		11,047
Dental		—		—		—		24,491		—		24,491
Inter-segment revenue		4,399		—		256		—		(4,655)		—
Net revenue	$	603,902	$	207,080	$	80,587	$	54,180	$	(23,297)	$	922,452
Income (loss) before income taxes		144,726		54,987		30,740		25,039		(339,902)	$	(84,410)
Interest expense		1		33		(8)		—		116,364		116,390
Depreciation and amortization		48,355		35,607		11,573		88		42,320		137,943
EBITDA		193,082		90,627		42,305		25,127		(181,218)		169,923
Equity compensation		865		906		140		844		2,882		5,637
Acquisition accounting adjustments		236		402		53		15		35		741
Acquisition-related costs		1,821		91		47		4		494		2,457
Transaction-related costs and advisory fees		—		—		—		—		4,825		4,825
Strategic initiatives, duplicative and transition costs		130		—		781		85		3,359		4,355
Severance costs		434		319		252		263		3,870		5,138
Loss on extinguishment of debt and other related costs		—		—		—		—		24,311		24,311
Accretion		—		—		—		—		18,712		18,712
Impairment of long-lived assets		—		—		—		—		1,887		1,887
Contingent consideration		—		—		1,879		—		—		1,879
Other non-routine, net		218		544		7		6		(2,200)		(1,425)
EBITDA Adjustments		3,704		2,262		3,159		1,217		58,175		68,517
Adjusted EBITDA	$	196,786	$	92,889	$	45,464	$	26,344	$	(123,043)	$	238,440

XML

Fair Value Measurements (Reconciliation Of The Fair Value Of The Liabilities That Use Significant Unobservable Inputs (Level 3)) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total changes included in contingent consideration	$ 1,976	$ 1,879	$ 3,646	$ 1,879
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	(13,169)	(5,887)	(5,484)	(296)
Adjustment of provisional amounts		223
Issuances of contingent consideration			(6,015)	(5,495)
Settlement of contingent consideration		105		232
Total changes included in contingent consideration	(1,976)	(1,879)	(3,646)	(1,879)
Balance at end of period	$ (15,145)	$ (7,438)	$ (15,145)	$ (7,438)

XML

Supplemental Condensed Consolidating Financial Information (Tables)

9 Months Ended

Sep. 30, 2014

Supplemental Condensed Consolidating Financial Information [Abstract]

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

	As of September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	740	$	23,187	$	—	$	23,927
Accounts receivable, net of allowance for doubtful accounts		—		231,950		—		231,950
Deferred income tax assets		100		16,874		—		16,974
Prepaid expenses and other current assets		3,972		29,113		—		33,085
Total current assets		4,812		301,124		—		305,936
Property and equipment, net		7		239,628		—		239,635
Due from affiliates		—		138,176		(138,176)		—
Investment in consolidated subsidiaries		1,718,809		—		(1,718,809)		—
Goodwill		—		1,584,655		—		1,584,655
Intangible assets, net		135,750		1,395,025		—		1,530,775
Other assets, net		138,648		16,030		(135,022)		19,656
Total assets	$	1,998,026	$	3,674,638	$	(1,992,007)	$	3,680,657
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	12,263	$	—	$	12,263
Accrued expenses		16,589		127,218		—		143,807
Deferred revenues		—		10,233		—		10,233
Current portion of long-term debt		5,577		18,916		—		24,493
Total current liabilities		22,166		168,630		—		190,796
Due to affiliates		138,176		—		(138,176)		—
Long-term debt, excluding current portion		776,954		1,221,615		—		1,998,569
Deferred income tax liabilities		—		552,008		(135,022)		416,986
Tax receivable agreement obligations to related parties		159,716		—		—		159,716
Other long-term liabilities		—		13,576		—		13,576
Commitments and contingencies
Equity		901,014		1,718,809		(1,718,809)		901,014
Total liabilities and equity	$	1,998,026	$	3,674,638	$	(1,992,007)	$	3,680,657

Condensed Consolidating Balance Sheet

	As of December 31, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	2,794	$	73,744	$	—	$	76,538
Accounts receivable, net of allowance for doubtful accounts		—		214,247		—		214,247
Deferred income tax assets		—		6,317		—		6,317
Prepaid expenses and other current assets		3,441		23,578		—		27,019
Total current assets		6,235		317,886		—		324,121
Property and equipment, net		10		269,460		—		269,470
Due from affiliates		—		69,142		(69,142)		—
Investment in subsidiaries		1,764,213		—		(1,764,213)		—
Goodwill		—		1,502,434		—		1,502,434
Intangible assets, net		142,500		1,490,188		—		1,632,688
Other assets, net		64,536		14,949		(60,316)		19,169
Total assets	$	1,977,494	$	3,664,059	$	(1,893,671)	$	3,747,882
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	8,367	$	—	$	8,367
Accrued expenses		8,205		122,944		—		131,149
Deferred revenues		—		10,881		—		10,881
Current portion of long-term debt		5,775		25,555		—		31,330
Total current liabilities		13,980		167,747		—		181,727
Due to affiliates		69,142		—		(69,142)		—
Long-term debt, excluding current portion		775,330		1,223,696		—		1,999,026
Deferred income tax liabilities		—		496,579		(60,316)		436,263
Tax receivable agreement obligations to related parties		150,496		—		—		150,496
Other long-term liabilities		—		11,824		—		11,824
Commitments and contingencies		—		—		—		—
Total equity		968,546		1,764,213		(1,764,213)		968,546
Total liabilities and equity	$	1,977,494	$	3,664,059	$	(1,893,671)	$	3,747,882

Condensed Consolidating Statement of Operations

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	341,608	$	—	$	341,608
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		202,305		—		202,305
Development and engineering		—		8,156		—		8,156
Sales, marketing, general and administrative		1,290		43,741		—		45,031
Depreciation and amortization		2,251		46,197		—		48,448
Accretion		4,452		—		—		4,452
Impairment of long-lived assets		—		3,114		—		3,114
Operating income (loss)		(7,993)		38,095		—		30,102
Equity in earnings of consolidated subsidiaries		(10,110)		—		10,110		—
Interest expense, net		23,418		13,217		—		36,635
Contingent consideration		—		1,976		—		1,976
Income (loss) before income tax provision (benefit)		(21,301)		22,902		(10,110)		(8,509)
Income tax provision (benefit)		(8,299)		12,792		—		4,493
Net income (loss)	$	(13,002)	$	10,110	$	(10,110)	$	(13,002)

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	317,810	$	—	$	317,810
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		191,695		—		191,695
Development and engineering		—		7,878		—		7,878
Sales, marketing, general and administrative		1,997		42,107		—		44,104
Depreciation and amortization		2,251		44,930		—		47,181
Accretion		7,112		—		—		7,112
Impairment of long-lived assets		—		25		—		25
Operating income (loss)		(11,360)		31,175		—		19,815
Equity in earnings of consolidated subsidiaries		(3,766)		—		3,766		—
Interest expense, net		23,579		13,421		—		37,000
Contingent consideration		—		1,879		—		1,879
Other		(2,925)		—		—		(2,925)
Income (loss) before income tax provision (benefit)		(28,248)		15,875		(3,766)		(16,139)
Income tax provision (benefit)		(11,983)		12,109		—		126
Net income (loss)	$	(16,265)	$	3,766	$	(3,766)	$	(16,265)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	996,973	$	—	$	996,973
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		597,843		—		597,843
Development and engineering		—		24,771		—		24,771
Sales, marketing, general and administrative		13,775		136,964		—		150,739
Depreciation and amortization		6,753		134,788		—		141,541
Accretion		9,220		—		—		9,220
Impairment of long-lived assets		—		82,689		—		82,689
Operating income (loss)		(29,748)		19,918		—		(9,830)
Equity in earnings of consolidated subsidiaries		51,018		—		(51,018)		—
Interest expense, net		70,224		39,517		—		109,741
Contingent consideration		—		3,646		—		3,646
Other		(111)		(3,857)		—		(3,968)
Income (loss) before income tax provision (benefit)		(150,879)		(19,388)		51,018		(119,249)
Income tax provision (benefit)		(75,363)		31,630		—		(43,733)
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	922,452	$	—	$	922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		563,146		—		563,146
Development and engineering		—		23,201		—		23,201
Sales, marketing, general and administrative		7,023		116,446		—		123,469
Depreciation and amortization		6,753		131,190		—		137,943
Accretion		18,712		—		—		18,712
Impairment of long-lived assets		—		1,887		—		1,887
Operating income (loss)		(32,488)		86,582		—		54,094
Equity in earnings of consolidated subsidiaries		(6,216)		—		6,216		—
Interest expense, net		70,621		45,769		—		116,390
Loss on extinguishment of debt		485		22,675		—		23,160
Contingent consideration		—		1,879		—		1,879
Other		(2,925)		—		—		(2,925)
Income (loss) before income tax provision (benefit)		(94,453)		16,259		(6,216)		(84,410)
Income tax provision (benefit)		(36,465)		10,043		—		(26,422)
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)

Condensed Consolidating Statement of Comprehensive Income (Loss)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(13,002)	$	10,110	$	(10,110)	$	(13,002)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		732		—		—		732
Foreign currency translation adjustment		—		(127)		—		(127)
Equity in other comprehensive earnings		(127)		—		127		—
Other comprehensive income (loss)		605		(127)		127		605
Total comprehensive income (loss)	$	(12,397)	$	9,983	$	(9,983)	$	(12,397)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(16,265)	$	3,766	$	(3,766)	$	(16,265)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(1,064)		—		—		(1,064)
Foreign currency translation adjustment		—		35		—		35
Equity in other comprehensive earnings		35		—		(35)		—
Other comprehensive income (loss)		(1,029)		35		(35)		(1,029)
Total comprehensive income (loss)	$	(17,294)	$	3,801	$	(3,801)	$	(17,294)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(127)		—		—		(127)
Foreign currency translation adjustment		—		(100)		—		(100)
Equity in other comprehensive earnings		(100)		—		100		—
Other comprehensive income (loss)		(227)		(100)		100		(227)
Total comprehensive income (loss)	$	(75,743)	$	(51,118)	$	51,118	$	(75,743)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		2,511		—		—		2,511
Foreign currency translation adjustment		—		(65)		—		(65)
Equity in other comprehensive earnings		(65)		—		65		—
Other comprehensive income (loss)		2,446		(65)		65		2,446
Total comprehensive income (loss)	$	(55,542)	$	6,151	$	(6,151)	$	(55,542)

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Operating activities
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		6,753		134,788		-		141,541
Accretion		9,220		-		-		9,220
Equity compensation		255		5,659		-		5,914
Deferred income tax expense (benefit)		(74,817)		29,931		-		(44,886)
Amortization of debt discount and issuance costs		2,003		3,801		-		5,804
Contingent consideration		-		3,646		-		3,646
Impairment of long lived assets		-		82,689		-		82,689
Equity in earnings of consolidated subsidiaries		51,018		-		(51,018)		-
Other		(1,094)		(2,031)		-		(3,125)
Changes in operating assets and liabilities:
Accounts receivable		-		(12,656)		-		(12,656)
Prepaid expenses and other		(462)		(4,028)		-		(4,490)
Accounts payable		-		644		-		644
Accrued expenses, deferred revenue, and other liabilities		9,377		(9,752)		-		(375)
Due to/from affiliates		69,034		(69,034)		-		-
Net cash provided (used in) by operating activities		(4,229)		112,639		-		108,410
Investing activities
Purchases of property and equipment		-		(37,673)		-		(37,673)
Payments for acquisitions, net of cash acquired		-		(87,909)		-		(87,909)
Proceeds from sale of cost method investment		36		-		-		36
Other		-		(133)		-		(133)
Investment in subsidiary		50		-		(50)		-
Net cash provided by (used in) investing activities		86		(125,715)		(50)		(125,679)
Financing activities
Distributions from (to) Emdeon Inc. net		-		(50)		50		-
Debt principal payments		(207)		(9,452)		-		(9,659)
Payment of debt assumed from acquisition		-		(23,262)		-		(23,262)
Proceeds from Revolving Facility		-		65,000		-		65,000
Payments on Revolving Facility		-		(65,000)		-		(65,000)
Repayment of deferred financing arrangements		-		(4,717)		-		(4,717)
Repurchase of Parent common stock		(960)		-		-		(960)
Capital contribution from Parent		3,256		-		-		3,256
Net cash provided by (used in) financing activities		2,089		(37,481)		50		(35,342)
Net decrease in cash and cash equivalents		(2,054)		(50,557)		-		(52,611)
Cash and cash equivalents at beginning of period		2,794		73,744		-		76,538
Cash and cash equivalents at end of period	$	740	$	23,187	$	-	$	23,927

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Operating activities
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		6,753		131,190		-		137,943
Accretion expense		18,712		-		-		18,712
Equity compensation expense		178		5,459		-		5,637
Deferred income tax expense (benefit)		(33,425)		5,541		-		(27,884)
Amortization of debt discount and issuance costs		1,865		4,720		-		6,585
Contingent consideration		-		1,879		-		1,879
Loss on extinguishment of debt		478		22,350		-		22,828
Impairment of long lived assets		-		1,887		-		1,887
Gain on sale of cost method investment		(2,925)		-		-		(2,925)
Equity in earnings of consolidated subsidiaries		(6,216)		-		6,216		-
Other		(819)		-		-		(819)
Changes in operating assets and liabilities:
Accounts receivable		-		(15,582)		-		(15,582)
Prepaid expenses and other		(4,732)		2,928		-		(1,804)
Accounts payable		-		685		-		685
Accrued expenses, deferred revenue, and other liabilities		14,509		6,476		-		20,985
Tax receivable agreement obligations to related parties		(103)		-		-		(103)
Due to/from affiliates		1,923		(1,923)		-		-
Net cash provided by (used in) operating activities		(61,790)		171,826		-		110,036
Investing activities
Purchases of property and equipment		-		(52,806)		-		(52,806)
Payments for acquisitions, net of cash acquired		-		(18,291)		-		(18,291)
Proceeds from sale of cost method investment		5,820		-		-		5,820
Investment in subsidiaries, net		56,149		-		(56,149)		-
Net cash provided by (used in) investing activities		61,969		(71,097)		(56,149)		(65,277)
Financing activities
Distributions from (to) Emdeon Inc., net		-		(56,149)		56,149		-
Debt principal payments		(211)		(9,481)		-		(9,692)
Payment of debt assumed from acquisition		-		(218)		-		(218)
Payment of loan costs		-		(2,178)		-		(2,178)
Repayment of deferred financing arrangements		-		(2,103)		-		(2,103)
Repurchase of Parent common stock		-		(250)		-		(250)
Other		-		(518)		-		(518)
Net cash provided by (used in) financing activities		(211)		(70,897)		56,149		(14,959)
Net increase (decrease) in cash and cash equivalents		(32)		29,832		-		29,800
Cash and cash equivalents at beginning of period		754		31,009		-		31,763
Cash and cash equivalents at end of period	$	722	$	60,841	$	-	$	61,563

XML

Basis of Presentation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Reclassifications [Abstract]
Reclassfication adjustment, reduction in revenue	$ 6,096	$ 18,641
Uncollectible Receivables [Member]
Change in Accounting Estimate [Line Items]
Reduction in revenue and pretax loss	$ 4,098

XML

Nature of Business and Organization

9 Months Ended

Sep. 30, 2014

Nature of Business and Organization [Abstract]

Nature of Business and Organization

1. Nature of Business and Organization

Nature of Business

Emdeon Inc. (the “Company”), through its subsidiaries, is a provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers, pharmacies and patients of the United States healthcare system. The Company’s product and service offerings integrate and automate key business and administrative functions for healthcare payers, providers and pharmacies throughout the patient encounter, including pre-care patient eligibility and benefits verification and enrollment, clinical information exchange, claims management and adjudication, payment integrity, payment distribution, payment posting and denial management and patient billing and payment processing.

Organization

The Company was formed as a Delaware limited liability company in September 2006 and converted into a Delaware corporation in September 2008 in anticipation of the Company’s August 2009 initial public offering (the “IPO”).

On November 2, 2011, pursuant to an Agreement and Plan of Merger among the Company, Beagle Parent Corp. (“Parent”) and Beagle Acquisition Corp. (“Merger Sub”), Merger Sub merged with and into the Company with the Company surviving the merger (the “Merger”). Subsequent to the Merger, the Company became an indirect wholly-owned subsidiary of Parent, which is controlled by affiliates of The Blackstone Group L.P. (“Blackstone”).

XML

Business Combinations (Summary Of Information Related To Acquisitions) (Details) (USD $) In Thousands, unless otherwise specified			3 Months Ended	9 Months Ended					9 Months Ended			3 Months Ended	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013 Goold [Member]	Sep. 30, 2014 Goold [Member]	Sep. 30, 2013 Goold [Member]	Sep. 30, 2014 Goold [Member] Non-compete agreements [Member]	Sep. 30, 2014 Goold [Member] Customer relationships [Member]	Sep. 30, 2014 Goold [Member] Backlog and other [Member]	Sep. 30, 2014 Vieosoft [Member]	Sep. 30, 2014 Vieosoft [Member] Non-compete agreements [Member]	Sep. 30, 2014 Vieosoft [Member] Backlog and other [Member]	Sep. 30, 2014 Capario [Member]	Sep. 30, 2014 Capario [Member]	Sep. 30, 2014 Capario [Member] Tradename [Member]	Sep. 30, 2014 Capario [Member] Non-compete agreements [Member]	Sep. 30, 2014 Capario [Member] Customer relationships [Member]
Total Consideration Fair Value at Acquisition Date:
Cash paid at closing				$ 19,391					$ 800				$ 89,422
Contingent consideration				5,553					6,015
Other				(5)									(227)
Total consideration transferred				24,939					6,815				89,195
Allocation of the Consideration Transferred:
Cash				1,101					21			2,292	2,292
Accounts receivable				3,435								5,046	5,046
Deferred income tax assets												275	275
Prepaid expenses and other current assets				647								1,112	1,112
Property and equipment				7,695								9,580	9,580
Identifiable intangible assets						280	5,160	460		1,320	2,060			900	2,740	38,510
Goodwill	1,584,655	1,502,434		14,300					6,159			76,062	76,062
Accounts payable				(541)								(2,020)	(2,020)
Accrued expenses				(2,076)					(194)			(9,068)	(9,068)
Deferred Revenue				(101)
Current maturities of long-term debt				(218)					(1,877)			(2,600)	(2,600)
Deferred income tax liabilities				(5,203)					(674)			(14,642)	(14,642)
Long-term debt												(18,785)	(18,785)
Other long-term liabilities												(207)	(207)
Total consideration transferred				24,939					6,815				89,195
Acquisition costs in sales, marketing, general and administrative expense:
Acquisition costs in sales, marketing, general and administrative expense			$ 18		$ 280				$ 111			$ 234	$ 862

XML

Interest Rate Swap (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Disclosure Interest Rate Swap Narrative [Abstract]
Interest rate derivatives designated as cash flow hedges, notional amount	$ 640,000
Estimated reclassification as increase to interest expense	2,570
Termination value of derivatives	$ 2,595

XML

Supplemental Condensed Consolidating Financial Information (Condensed Consolidating Statement Of Operations) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Income Statements [Line Items]
Revenue	$ 341,608	$ 317,810	$ 996,973	$ 922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)	202,305	191,695	597,843	563,146
Development and engineering	8,156	7,878	24,771	23,201
Sales, marketing, general and administrative	45,031	44,104	150,739	123,469
Depreciation and amortization	48,448	47,181	141,541	137,943
Accretion	4,452	7,112	9,220	18,712
Impairment of long-lived assets	3,114	25	82,689	1,887
Operating income (loss)	30,102	19,815	(9,830)	54,094
Interest Expense	36,635	37,000	109,741	116,390
Loss on extinguishment of debt				23,160
Contingent consideration	1,976	1,879	3,646	1,879
Other		(2,925)	(3,968)	(2,925)
Income (loss) before income tax provision (benefit)	(8,509)	(16,139)	(119,249)	(84,410)
Income tax provision (benefit)	4,493	126	(43,733)	(26,422)
Net income (loss)	(13,002)	(16,265)	(75,516)	(57,988)
Emdeon Inc. [Member]
Condensed Income Statements [Line Items]
Revenue
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)
Development and engineering
Sales, marketing, general and administrative	1,290	1,997	13,775	7,023
Depreciation and amortization	2,251	2,251	6,753	6,753
Accretion	4,452	7,112	9,220	18,712
Impairment of long-lived assets
Operating income (loss)	(7,993)	(11,360)	(29,748)	(32,488)
Equity in earnings of consolidated subsidiaries	(10,110)	(3,766)	51,018	(6,216)
Interest Expense	23,418	23,579	70,224	70,621
Loss on extinguishment of debt				485
Contingent consideration
Other		(2,925)	(111)	(2,925)
Income (loss) before income tax provision (benefit)	(21,301)	(28,248)	(150,879)	(94,453)
Income tax provision (benefit)	(8,299)	(11,983)	(75,363)	(36,465)
Net income (loss)	(13,002)	(16,265)	(75,516)	(57,988)
Guarantor Subsidiaries [Member]
Condensed Income Statements [Line Items]
Revenue	341,608	317,810	996,973	922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)	202,305	191,695	597,843	563,146
Development and engineering	8,156	7,878	24,771	23,201
Sales, marketing, general and administrative	43,741	42,107	136,964	116,446
Depreciation and amortization	46,197	44,930	134,788	131,190
Impairment of long-lived assets	3,114	25	82,689	1,887
Operating income (loss)	38,095	31,175	19,918	86,582
Interest Expense	13,217	13,421	39,517	45,769
Loss on extinguishment of debt				22,675
Contingent consideration	1,976	1,879	3,646	1,879
Other			(3,857)
Income (loss) before income tax provision (benefit)	22,902	15,875	(19,388)	16,259
Income tax provision (benefit)	12,792	12,109	31,630	10,043
Net income (loss)	10,110	3,766	(51,018)	6,216
Consolidating Adjustments [Member]
Costs and expenses:
Equity in earnings of consolidated subsidiaries	10,110	3,766	(51,018)	6,216
Income (loss) before income tax provision (benefit)	(10,110)	(3,766)	51,018	(6,216)
Net income (loss)	$ (10,110)	$ (3,766)	$ 51,018	$ (6,216)

XML

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 23,927	$ 76,538
Accounts receivable, net of allowance for doubtful accounts of $4,310 and $3,856 at September 30, 2014 and December 31, 2013, respectively	231,950	214,247
Deferred income tax assets	16,974	6,317
Prepaid expenses and other current assets	33,085	27,019
Total current assets	305,936	324,121
Property and equipment, net	239,635	269,470
Goodwill	1,584,655	1,502,434
Intangible assets, net	1,530,775	1,632,688
Other assets, net	19,656	19,169
Total assets	3,680,657	3,747,882
Current liabilities:
Accounts payable	12,263	8,367
Accrued expenses	143,807	131,149
Deferred revenues	10,233	10,881
Current portion of long-term debt	24,493	31,330
Total current liabilities	190,796	181,727
Long-term debt, excluding current portion	1,998,569	1,999,026
Deferred income tax liabilities	416,986	436,263
Tax receivable agreement obligations to related parties	159,716	150,496
Other long-term liabilities	13,576	11,824
Commitments and contingencies
Equity:
Common stock (par value, $.01), 100 shares authorized and outstanding at September 30, 2014 and December 31, 2013, respectively
Additional paid-in capital	1,147,586	1,139,375
Accumulated other comprehensive income (loss)	(1,570)	(1,343)
Accumulated deficit	(245,002)	(169,486)
Total equity	901,014	968,546
Total liabilities and equity	$ 3,680,657	$ 3,747,882

XML

Fair Value Measurement (Assets and Liabilities Measured at Fair Value on a Non-recurring Basis) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Impairment of Long-lived assets to be Held and Used	$ 3,114	$ 25	$ 82,689	$ 1,887
Maximum [Member] | DCF [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability of new contract execution			90.00%
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Long-lived assets to be Held and Used, Relavant asset group	13,066		13,066
Impairment of Long-lived assets to be Held and Used			73,220
Impairment of Long-lived assets to be Disposed Of			8,848
Significant Unobservable Inputs (Level 3) [Member] | DCF [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability of contract extension			80.00%
Significant Unobservable Inputs (Level 3) [Member] | Maximum [Member] | DCF [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Expected annual revenue range			3,590
Risk free interest rate			1.60%
Significant Unobservable Inputs (Level 3) [Member] | Minimum [Member] | DCF [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability of new contract execution			20.00%
Expected annual revenue range			3,080
Significant Unobservable Inputs (Level 3) [Member] | Property and Equipment [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Impairment of Long-lived assets to be Disposed Of			930
Significant Unobservable Inputs (Level 3) [Member] | Customer relationships [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Impairment of Long-lived assets to be Disposed Of			$ 72,290

XML

Condensed Consolidated Statements of Equity (Unaudited) (USD $) In Thousands, except Share data	Common stock	Additional Paid-in Capital USD ($)	Retained Earnings USD ($)	Accumulated Other Comprehensive Income (Loss) USD ($)	Total USD ($)
Balance at Dec. 31, 2012		$ 1,130,968	$ (95,028)	$ (3,789)	$ 1,032,151
Balance, shares at Dec. 31, 2012	100
Equity compensation expense		5,637			5,637
Repurchase of Parent common stock		(250)			(250)
Net income (loss)			(57,988)		(57,988)
Foreign currency translation adjustment				(65)	(65)
Change in fair value of interest rate swap, net of taxes				2,511	2,511
Balance at Sep. 30, 2013		1,136,355	(153,016)	(1,343)	981,996
Balance, shares at Sep. 30, 2013	100
Balance at Dec. 31, 2013		1,139,375	(169,486)	(1,343)	968,546
Balance, shares at Dec. 31, 2013	100
Equity compensation expense		5,914			5,914
Issuance of shares in connection with equity compensation plans, net of taxes		1,257			1,257
Repurchase of Parent common stock		(960)			(960)
Capital contribution from Parent		2,000			2,000
Net income (loss)			(75,516)		(75,516)
Foreign currency translation adjustment				(100)	(100)
Change in fair value of interest rate swap, net of taxes				(127)	(127)
Balance at Sep. 30, 2014		$ 1,147,586	$ (245,002)	$ (1,570)	$ 901,014
Balance, shares at Sep. 30, 2014	100

XML

Goodwill And Intangible Assets (Goodwill Activity) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets [Line Items]
Beginning balance	$ 1,502,434
Acquisitions	82,221
Ending balance	1,584,655
Payer [Member]
Goodwill and Intangible Assets [Line Items]
Beginning balance	827,455
Acquisitions	18,792
Ending balance	846,247
Provider [Member]
Goodwill and Intangible Assets [Line Items]
Beginning balance	401,845
Acquisitions	34,211
Ending balance	436,056
Pharmacy [Member]
Goodwill and Intangible Assets [Line Items]
Beginning balance	160,561
Acquisitions	6,159
Ending balance	166,720
All Other [Member]
Goodwill and Intangible Assets [Line Items]
Beginning balance	112,573
Acquisitions	23,059
Ending balance	$ 135,632

XML

Basis of Presentation (Policy)

9 Months Ended

Sep. 30, 2014

Basis of Presentation [Abstract]

Principles of Consolidation

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) Guidelines, Rules and Regulations (“Regulation S-X”) and, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of results for the unaudited interim periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The results of operations for the interim period are not necessarily indicative of the results to be obtained for the full fiscal year. All material intercompany accounts and transactions have been eliminated in the unaudited condensed consolidated financial statements.

Reclassifications

Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The Company changed the classification of rebate payments to its channel partners from cost of operations to a reduction of revenue to the extent that such rebate payments for any given channel partner were less than or equal to revenue otherwise earned from the respective channel partner. To conform to the current period presentation, rebate payments to channel partners resulted in a reduction of revenue of $6,096 and $18,641for the three and nine months ended September 30, 2013, respectively.

Accounting Estimates

Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors and various other assumptions that the Company believes are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses and disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in the Company’s business environment; therefore, actual results could differ materially from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the reported results of operations; and if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Estimates and assumptions by management affect: the allowance for doubtful accounts; the fair value assigned to assets acquired and liabilities assumed in business combinations; tax receivable agreement obligations; the fair value of interest rate swap obligations; contingent consideration; loss accruals; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses; revenue recognition; contingencies; and the value attributed to equity awards.

During the three months ended September 30, 2014, the Company recognized a change in estimate related to its accounts receivable, the effect of which reduced revenue and increased pretax loss by $4,098.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, which changes the requirements for reporting discontinued operations. Following adoption of this update, discontinued operations generally will be reported for the disposal by sale or otherwise of a component or a group of components that represents a strategic shift that has or will have a major effect on an entity’s operations and financial results. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2014, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, which replaces most prior general and industry specific revenue recognition guidance with a principles-based comprehensive revenue recognition framework. Under this revised framework, a company will recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. This update is effective for fiscal years and interim periods beginning in those years after December 15, 2016. Early adoption is not permitted. Upon adoption, a company may elect to either retrospectively restate each prior reporting period or reflect the cumulative effect of initially applying the update with an adjustment to retained earnings. The Company is currently assessing the potential effects this update may have on its consolidated financial statements.

In June 2014, the FASB issued ASU No. 2014-12, which clarifies, in the context of share-based payment awards, that a performance target that affects vesting and could be achieved after the requisite service period has been rendered should be treated as a performance condition. Prior to this update, because there was no explicit guidance, there was diversity in practice among companies. This update is effective for fiscal years and interim periods within those years beginning after December 15, 2015, with early adoption permitted. The Company does not expect the adoption of this update to have a material effect on its consolidated financial statements.

XML

Goodwill And Intangible Assets (Intangible Assets Subject to Amortization) (Details) (USD $) In Thousands, unless otherwise specified			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Customer relationships [Member]	Sep. 30, 2014 Tradenames [Member]	Sep. 30, 2014 Non-compete agreements [Member]	Sep. 30, 2014 Data Sublicense Agreement [Member]	Sep. 30, 2014 Other [Member]
Finite Lived Intangible Assets [Line Items]
Weighted Average Remaining Life			16 years 2 months 12 days	16 years 2 months 12 days	2 years 2 months 12 days	3 years	6 years
Gross Carrying Amount	$ 1,810,455		$ 1,602,232	$ 157,430	$ 17,140	$ 31,000	$ 2,653
Accumulated Amortization	(279,680)		(232,575)	(23,235)	(8,260)	(15,275)	(335)
Intangible assets, net	$ 1,530,775	$ 1,632,688	$ 1,369,657	$ 134,195	$ 8,880	$ 15,725	$ 2,318

XML

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill And Intangible Assets [Abstract]

Schedule of Goodwill Activity

	Payer		Provider		Pharmacy		All Other		Total
Balance at December 31, 2013	$	827,455	$	401,845	$	160,561	$	112,573	$	1,502,434
Acquisitions		18,792		34,211		6,159		23,059		82,221
Balance at September 30, 2014	$	846,247	$	436,056	$	166,720	$	135,632	$	1,584,655

Intangible Assets Subject to Amortization

	Weighted		Gross
	Average		Carrying		Accumulated
	Remaining Life		Amount		Amortization		Net
Customer relationships		16.2	$	1,602,232	$	(232,575)	$	1,369,657
Trade names		16.2		157,430		(23,235)		134,195
Non-compete agreements		2.2		17,140		(8,260)		8,880
Data sublicense agreement		3.0		31,000		(15,275)		15,725
Other		6.0		2,653		(335)		2,318
Total			$	1,810,455	$	(279,680)	$	1,530,775

Aggregate Future Amortization Expense for Intangible Assets

2014 (remainder)	$	25,574
2015		101,888
2016		101,301
2017		97,399
2018		92,788
Thereafter		1,111,825
	$	1,530,775

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net income (loss)	$ (75,516)	$ (57,988)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	141,541	137,943
Accretion	9,220	18,712
Equity compensation	5,914	5,637
Deferred income tax expense (benefit)	(44,886)	(27,884)
Amortization of debt discount and issuance costs	5,804	6,585
Contingent consideration	3,646	1,879
Gain on sale of cost method investment		(2,925)
Loss on extinguishment of debt		22,828
Impairment of long-lived assets	82,689	1,887
Other	(3,125)	(819)
Changes in operating assets and liabilities:
Accounts receivable	(12,656)	(15,582)
Prepaid expenses and other	(4,490)	(1,804)
Accounts payable	644	685
Accrued expenses, deferred revenue and other liabilities	(375)	20,985
Tax receivable agreement obligations to related parties		(103)
Net cash provided by (used in) operating activities	108,410	110,036
Investing activities
Purchases of property and equipment	(37,673)	(52,806)
Payments for acquisitions, net of cash acquired	(87,909)	(18,291)
Proceeds from sale of cost method investment	36	5,820
Other	(133)
Net cash provided by (used in) investing activities	(125,679)	(65,277)
Financing activities
Debt principal payments	(9,659)	(9,692)
Payment of debt assumed from acquisition	(23,262)	(218)
Proceeds from Revolving Facility	65,000
Payments on Revolving Facility	(65,000)
Payment of loan costs		(2,178)
Repayment of deferred financing arrangements	(4,717)	(2,103)
Repurchase of Parent common stock	(960)	(250)
Capital contribution from Parent	3,256
Other		(518)
Net cash provided by (used in) financing activities	(35,342)	(14,959)
Net increase (decrease) in cash and cash equivalents	(52,611)	29,800
Cash and cash equivalents at beginning of period	76,538	31,763
Cash and cash equivalents at end of period	$ 23,927	$ 61,563

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 4,310	$ 3,856
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100	100
Common stock, shares outstanding	100	100

XML

Income Taxes

9 Months Ended

Sep. 30, 2014

Income Taxes [Abstract]

Income Taxes

10. Income Taxes

In January 2014, the Company effected a change in the tax status of EBS Master LLC (“EBS Master”) from a partnership to a corporation. Prior to the tax status change, the Company recognized a deferred tax liability for the difference in the book and tax basis of its investment in EBS Master (i.e. outside basis). Following the tax status change, the Company’s deferred tax balances reflect the differences in the book and tax bases of the individual assets and liabilities included in the corporation. In addition, as a result of the change in tax status, the Company was required to revise the apportionment of its income taxes among various state taxing jurisdictions.

Income taxes were also affected by the establishment of a valuation allowance related to state deferred tax assets for three of the Company’s subsidiaries.After giving effect to this change in tax status and these other items, income taxes for the nine months ended September 30, 2014 amounted to an income tax benefit of $43,733and an effective tax rate of 36.7%. The income tax benefit for the nine months ended September 30, 2013, which does not reflect the change in tax status, was $26,422and resulted in an effective tax rate of 31.3%.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Emdeon Inc.
Entity Central Index Key	0001444598
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		100

XML

Tax Receivable Agreement Obligation to Related Parties

9 Months Ended

Sep. 30, 2014

Tax Receivable Agreement Obligation to Related Parties [Abstract]

Tax Receivable Agreement Obligation to Related Parties

11. Tax Receivable Agreement Obligation to Related Parties

In connection with the IPO, the Company entered into tax receivable agreements which obligated the Company to make payments to certain current and former owners of the Company, including affiliates of Hellman and Friedman (“H&F”) and certain members of management, equal to 85% of the applicable cash savings that the Company realizes as a result of tax attributes arising from certain previous transactions. The Company will retain the benefit of the remaining 15% of these tax savings.

In November 2011, H&F and certain current and former members of management exchanged all of their remaining EBS Master Units (“EBS Units”) for cash and a combination of cash and shares of Parent, respectively, and the former majority owner of the Company assigned its rights under the tax receivable agreements to affiliates of Blackstone (Blackstone, together with H&F and certain current and former members of management are sometimes referred to collectively as the “TRA Members”). Additionally, effective December 31, 2011, the Company simplified its corporate structure. The tax attributes of the exchange of EBS Units and corporate restructuring are expected to provide the Company with additional cash savings, 85% of which are payable to the TRA Members. Collectively, the Company expects the tax attributes of the above referenced events to result in cumulative payments under the tax receivable agreements of approximately $352,521.  $160,690 of this amount, which reflected the initial fair value of the tax receivable agreement obligations plus recognized accretion, was reflected as an obligation on the accompanying unaudited condensed consolidated balance sheet at September 30, 2014.

During the nine months ended September 30, 2014, the Company changed its estimate of the timing and amount of future cash flows attributable to the tax receivable agreements as a result of the effective tax rate change resulting from the change in tax status of EBS Master from a partnership to a corporation and the acquisitions of Vieosoft and Capario. These revised estimates resulted in a decrease to pretax net loss of $5,756 for the nine months ended September 30, 2014.

XML

Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements of Operations [Abstract]
Revenue	$ 341,608	$ 317,810	$ 996,973	$ 922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)	202,305	191,695	597,843	563,146
Development and engineering	8,156	7,878	24,771	23,201
Sales, marketing, general and administrative	45,031	44,104	150,739	123,469
Depreciation and amortization	48,448	47,181	141,541	137,943
Accretion	4,452	7,112	9,220	18,712
Impairment of long-lived assets	3,114	25	82,689	1,887
Operating income (loss)	30,102	19,815	(9,830)	54,094
Interest expense, net	36,635	37,000	109,741	116,390
Loss on extinguishment of debt				23,160
Contingent consideration	1,976	1,879	3,646	1,879
Other		(2,925)	(3,968)	(2,925)
Income (loss) before income tax provision (benefit)	(8,509)	(16,139)	(119,249)	(84,410)
Income tax provision (benefit)	4,493	126	(43,733)	(26,422)
Net income (loss)	$ (13,002)	$ (16,265)	$ (75,516)	$ (57,988)

XML

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2014

Goodwill And Intangible Assets [Abstract]

Goodwill and Intangible Assets

5. Goodwill and Intangible Assets

Goodwill activity during the nine months ended September 30, 2014 was as follows:

	Payer		Provider		Pharmacy		All Other		Total
Balance at December 31, 2013	$	827,455	$	401,845	$	160,561	$	112,573	$	1,502,434
Acquisitions		18,792		34,211		6,159		23,059		82,221
Balance at September 30, 2014	$	846,247	$	436,056	$	166,720	$	135,632	$	1,584,655

Intangible assets subject to amortization as of September 30, 2014 consisted of the following:

	Weighted		Gross
	Average		Carrying		Accumulated
	Remaining Life		Amount		Amortization		Net
Customer relationships		16.2	$	1,602,232	$	(232,575)	$	1,369,657
Trade names		16.2		157,430		(23,235)		134,195
Non-compete agreements		2.2		17,140		(8,260)		8,880
Data sublicense agreement		3.0		31,000		(15,275)		15,725
Other		6.0		2,653		(335)		2,318
Total			$	1,810,455	$	(279,680)	$	1,530,775

Amortization expense was $75,286 and $78,140 for the nine months ended September 30, 2014 and 2013, respectively. Aggregate future amortization expense for intangible assets is estimated to be:

2014 (remainder)	$	25,574
2015		101,888
2016		101,301
2017		97,399
2018		92,788
Thereafter		1,111,825
	$	1,530,775

During the nine months ended September 30, 2014, the Company recognized an impairment charge related to the pending partial loss of a customer contract. See Note 8 to the unaudited condensed consolidated financial statements included in Item 1 of this Quarterly Report.

XML

Business Combinations

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Business Combinations

4. Business Combinations

In July 2014, the Company acquired all of the equity interests of Capario, Inc. (“Capario”), a technology-enabled provider of revenue cycle management solutions.

In February 2014, the Company acquired all of the equity interests of Vieosoft, Inc. (“Vieosoft”), a development stage enterprise.

In June 2013, the Company acquired all of the equity interests of Goold Health Systems (“Goold”), a technology-enabled provider of pharmacy benefit and related services primarily to state Medicaid agencies across the nation.

The following table summarizes certain information related to these acquisitions. The preliminary values of the consideration transferred, assets acquired and liabilities assumed in the Capario acquisition, including related tax effects, are subject to receipt of a final valuation and a final working capital settlement.

		Capario	Vieosoft		Goold
Total Consideration Fair Value at Acquisition Date:
Cash paid at closing	$	89,422	$	800	$	19,391
Contingent consideration		—		6,015		5,553
Other		(227)		—		(5)
	$	89,195	$	6,815	$	24,939
Allocation of the Consideration Transferred:
Cash	$	2,292	$	21	$	1,101
Accounts receivable		5,046		—		3,435
Deferred income tax assets		275		—		—
Prepaid expenses and other current assets		1,112		—		647
Property and equipment		9,580		—		7,695
Identifiable intangible assets:
Tradename		900		—		—
Noncompetition agreements		2,740		1,320		280
Customer relationships		38,510		—		5,160
Backlog and other		—		2,060		460
Goodwill		76,062		6,159		14,300
Accounts payable		(2,020)		—		(541)
Accrued expenses		(9,068)		(194)		(2,076)
Deferred revenues		—		—		(101)
Current maturities of long-term debt		(2,600)		(1,877)		(218)
Deferred income tax liabilities		(14,642)		(674)		(5,203)
Long-term debt		(18,785)		—		—
Other long-term liabilities		(207)		—		—
Total consideration transferred	$	89,195	$	6,815	$	24,939
Acquisition costs in sales, marketing, general and administrative expense:
For the three months ended September 30, 2014	$	234	$	—	$	—
For the three months ended September 30, 2013	$	—	$	—	$	18
For the nine months ended September 30, 2014	$	862	$	111	$	—
For the nine months ended September 30, 2013	$	—	$	—	$	280

	Capario		Vieosoft		Goold
Other Information:
Gross contractual accounts receivable	$	5,112	$	—	$	3,435
Amount not expected to be collected	$	66	$	—	$	—
Goodwill expected to be deductible for tax purposes	$	—	$	—	$	—
Contingent Consideration Information:
Contingent consideration range		N/A		$0-$43,104		$0-15,000
Measurement period				February 12, 2014 to December 31, 2017		July 1, 2013 to September 30, 2014
Basis of measurement		N/A		Milestone achievement, revenue performance		Award of contracts with annual revenue exceeding targeted amount
Type of measurement		N/A		Level 3		Level 3
Key assumptions at the acquisition date:
Probability of achieving milestone objectives		N/A		90%		N/A
Probability of achieving minimum gross profit margin		N/A		5% for 2015  -90% for 2017		N/A
Probability of winning new contracts		N/A		N/A		10%-50%
Probability of retaining contracts that expire during the measurement period		N/A		N/A		90%
Range of baseline revenue retention for existing customers		N/A		N/A		75% -125%
Expected payment date(s)		N/A		2015 -  2017		12/15/2014
Discount rate(s)		N/A		5.2% to 53.2%		15.4%
Increase (decrease) to net loss:
For the three months ended September 30, 2014		N/A	$	647	$	1,329
For the nine months ended September 30, 2014		N/A	$	1,305	$	2,341
For the three months ended September 30, 2013		N/A		N/A	$	1,879
For the nine months ended September 30, 2013		N/A		N/A	$	1,879

The Company generally recognizes goodwill attributable to the assembled workforce and expected synergies among the operations of acquired entities and the Company’s existing operations. In the case of the Company’s acquisitions of operating companies, synergies generally have resulted from the elimination of duplicative facilities and personnel costs and cross selling opportunities among the Company’s existing customer base.

Goodwill is generally deductible for federal income tax purposes when a business combination is treated as an asset purchase. Goodwill is generally not deductible for federal income tax purposes when the business combination is treated as a stock purchase.

XML

Business Combinations (Tables)

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Summary of Information Related To Acquisitions

		Capario	Vieosoft		Goold
Total Consideration Fair Value at Acquisition Date:
Cash paid at closing	$	89,422	$	800	$	19,391
Contingent consideration		—		6,015		5,553
Other		(227)		—		(5)
	$	89,195	$	6,815	$	24,939
Allocation of the Consideration Transferred:
Cash	$	2,292	$	21	$	1,101
Accounts receivable		5,046		—		3,435
Deferred income tax assets		275		—		—
Prepaid expenses and other current assets		1,112		—		647
Property and equipment		9,580		—		7,695
Identifiable intangible assets:
Tradename		900		—		—
Noncompetition agreements		2,740		1,320		280
Customer relationships		38,510		—		5,160
Backlog and other		—		2,060		460
Goodwill		76,062		6,159		14,300
Accounts payable		(2,020)		—		(541)
Accrued expenses		(9,068)		(194)		(2,076)
Deferred revenues		—		—		(101)
Current maturities of long-term debt		(2,600)		(1,877)		(218)
Deferred income tax liabilities		(14,642)		(674)		(5,203)
Long-term debt		(18,785)		—		—
Other long-term liabilities		(207)		—		—
Total consideration transferred	$	89,195	$	6,815	$	24,939
Acquisition costs in sales, marketing, general and administrative expense:
For the three months ended September 30, 2014	$	234	$	—	$	—
For the three months ended September 30, 2013	$	—	$	—	$	18
For the nine months ended September 30, 2014	$	862	$	111	$	—
For the nine months ended September 30, 2013	$	—	$	—	$	280

Summary of Other and Contingent Consideration Information Related to Acquisitions

	Capario		Vieosoft		Goold
Other Information:
Gross contractual accounts receivable	$	5,112	$	—	$	3,435
Amount not expected to be collected	$	66	$	—	$	—
Goodwill expected to be deductible for tax purposes	$	—	$	—	$	—
Contingent Consideration Information:
Contingent consideration range		N/A		$0-$43,104		$0-15,000
Measurement period				February 12, 2014 to December 31, 2017		July 1, 2013 to September 30, 2014
Basis of measurement		N/A		Milestone achievement, revenue performance		Award of contracts with annual revenue exceeding targeted amount
Type of measurement		N/A		Level 3		Level 3
Key assumptions at the acquisition date:
Probability of achieving milestone objectives		N/A		90%		N/A
Probability of achieving minimum gross profit margin		N/A		5% for 2015  -90% for 2017		N/A
Probability of winning new contracts		N/A		N/A		10%-50%
Probability of retaining contracts that expire during the measurement period		N/A		N/A		90%
Range of baseline revenue retention for existing customers		N/A		N/A		75% -125%
Expected payment date(s)		N/A		2015 -  2017		12/15/2014
Discount rate(s)		N/A		5.2% to 53.2%		15.4%
Increase (decrease) to net loss:
For the three months ended September 30, 2014		N/A	$	647	$	1,329
For the nine months ended September 30, 2014		N/A	$	1,305	$	2,341
For the three months ended September 30, 2013		N/A		N/A	$	1,879
For the nine months ended September 30, 2013		N/A		N/A	$	1,879

XML

Segment Reporting

9 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Segment Reporting

12. Segment Reporting

Effective January 1, 2014, the Company completed an internal reorganization of its reporting structure which resulted in a change in the composition of its operating segments. Additionally, the Company periodically makes other changes to the composition of its operating segments. Prior period segment information is restated to reflect the organizational structure and any other changes made.

Management views the Company’s operating results in three reportable segments: (a) payer services, (b) provider services and (c) pharmacy services. Listed below are the results of operations for each of the reportable segments. In addition to these reportable segments, the Company reports financial information for two additional operating segments that is presented on an aggregate basis. This information is reflected in the manner utilized by management to make operating decisions, assess performance and allocate resources. Segment assets are not presented to management for purposes of operational decision making, and therefore are not included in the accompanying tables. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies in the notes to the Company’s audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the SEC.

Payer Services Segment

The payer services segment provides payment cycle solutions that simplify the administration of healthcare related to insurance eligibility and benefit verification, claims management, payment integrity and payment distribution. Additionally, the payer services segment provides patient billing and payment and consulting services.

Provider Services Segment

The provider services segment provides revenue cycle management solutions, government program eligibility and enrollment services and revenue optimization solutions primarily to hospitals, physician practices, laboratories and other healthcare providers that simplify providers’ revenue cycle and workflow, reduce related costs and improve cash flow.

Pharmacy Services Segment

The pharmacy services segment provides electronic prescribing services, other electronic solutions and benefit administration services to pharmacies, pharmacy benefit management companies, government agencies and other payers related to prescription benefit claim filing, adjudication and management.

All Other

All Other consists of two operating segments, one of which provides revenue cycle management solutions through channel partners and one of which provides revenue cycle solutions, either directly or through channel partners, to dental practices.

Corporate and Eliminations

Inter-segment revenue and expenses primarily represent claims management and patient billing and payment services provided between segments.

Corporate and eliminations includes management, administrative and other shared corporate services functions such as information technology, legal, finance, human resources, marketing and product management, as well as eliminations to remove inter-segment revenue and expenses. These administrative and other shared services costs are excluded from the adjusted EBITDA measure for each respective operating segment.

The revenue and adjusted EBITDA for the operating segments are as follows:

	Three Months Ended September 30, 2014
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	73,314	$	—	$	—	$	—	$	—	$	73,314
Payment distribution services		73,703		—		—		—		—		73,703
Patient billing and payment services		68,360		—		—		—		—		68,360
Revenue cycle technology		—		32,343		—		—		—		32,343
Revenue cycle services		—		34,979		—		—		—		34,979
Physician services		—		12,041		—		—		—		12,041
Pharmacy		—		—		31,649		—		—		31,649
Channel Partner		—		—		—		13,152		(6,200)		6,952
Dental		—		—		—		8,267		—		8,267
Inter-segment revenue		2,490		—		90		—		(2,580)		—
Net revenue	$	217,867	$	79,363	$	31,739	$	21,419	$	(8,780)	$	341,608
Income (loss) before income taxes		51,103		26,565		9,846		11,742		(107,765)	$	(8,509)
Interest expense		—		(159)		(5)		—		36,799		36,635
Depreciation and amortization		16,843		12,178		3,254		41		16,132		48,448
EBITDA		67,946		38,584		13,095		11,783		(54,834)		76,574
Equity compensation		254		265		77		21		1,615		2,232
Acquisition accounting adjustments		18		7		152		—		12		189
Acquisition-related costs		461		12		—		8		906		1,387
Transaction-related costs and advisory fees		—		—		—		—		1,683		1,683
Strategic initiatives, duplicative and transition costs		—		7		96		—		303		406
Severance costs		321		801		13		—		767		1,902
Accretion		—		—		—		—		4,452		4,452
Impairment of long-lived assets		—		—		(90)		—		3,204		3,114
Contingent consideration		—		—		1,976		—		—		1,976
Other non-routine, net		523		106		37		—		(529)		137
EBITDA Adjustments		1,577		1,198		2,261		29		12,413		17,478
Adjusted EBITDA	$	69,523	$	39,782	$	15,356	$	11,812	$	(42,421)	$	94,052

	Three Months Ended September 30, 2013
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	78,292	$	—	$	—	$	—	$	—	$	78,292
Payment distribution services		63,942		—		—		—		—		63,942
Patient billing and payment services		62,911		—		—		—		—		62,911
Revenue cycle technology		—		29,678		—		—		—		29,678
Revenue cycle services		—		31,172		—		—		—		31,172
Physician services		—		9,237		—		—		—		9,237
Pharmacy		—		—		30,363		—		—		30,363
Channel Partner		—		—		—		10,230		(6,095)		4,135
Dental		—		—		—		8,080		—		8,080
Inter-segment revenue		1,625		—		77		—		(1,702)		—
Net revenue	$	206,770	$	70,087	$	30,440	$	18,310	$	(7,797)	$	317,810
Income (loss) before income taxes		51,815		20,052		9,725		8,509		(106,240)	$	(16,139)
Interest expense		(2)		—		(3)		—		37,005		37,000
Depreciation and amortization		16,333		11,579		4,309		43		14,917		47,181
EBITDA		68,146		31,631		14,031		8,552		(54,318)		68,042
Equity compensation		285		315		62		292		1,135		2,089
Acquisition accounting adjustments		65		76		94		4		12		251
Acquisition-related costs		884		29		41		2		563		1,519
Transaction-related costs and advisory fees		—		—		—		—		1,500		1,500
Strategic initiatives, duplicative and transition costs		—		—		223		16		2,188		2,427
Severance costs		84		105		18		—		3,302		3,509
Accretion		—		—		—		—		7,112		7,112
Impairment of long-lived assets		—		25		—		—		—		25
Contingent consideration		—		—		1,879		—		—		1,879
Other non-routine, net		101		136		2		—		(3,344)		(3,105)
EBITDA Adjustments		1,419		686		2,319		314		12,468		17,206
Adjusted EBITDA	$	69,565	$	32,317	$	16,350	$	8,866	$	(41,850)	$	85,248

	Nine Months Ended September 30, 2014
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	215,614	$	—	$	—	$	—	$	—	$	215,614
Payment distribution services		213,766		—		—		—		—		213,766
Patient billing and payment services		205,921		—		—		—		—		205,921
Revenue cycle technology		—		95,254		—		—		—		95,254
Revenue cycle services		—		101,491		—		—		—		101,491
Physician services		—		30,619		—		—		—		30,619
Pharmacy		—		—		92,808		—		—		92,808
Channel Partner		—		—		—		34,659		(17,618)		17,041
Dental		—		—		—		24,459		—		24,459
Inter-segment revenue		7,062		—		271		—		(7,333)		—
Net revenue	$	642,363	$	227,364	$	93,079	$	59,118	$	(24,951)	$	996,973
Income (loss) before income taxes		146,600		67,797		(40,942)		31,170		(323,874)	$	(119,249)
Interest expense		(9)		(159)		(6)		—		109,915		109,741
Depreciation and amortization		49,921		36,127		11,479		159		43,855		141,541
EBITDA		196,512		103,765		(29,469)		31,329		(170,104)		132,033
Equity compensation		769		759		198		66		4,122		5,914
Acquisition accounting  adjustments		85		57		546		3		34		725
Acquisition-related costs		1,368		273		(72)		9		3,895		5,473
Transaction-related costs and advisory fees		—		—		—		—		4,799		4,799
Strategic initiatives, duplicative and transition costs		59		230		192		—		9,205		9,686
Severance costs		851		1,227		18		30		3,626		5,752
Accretion		—		—		—		—		9,220		9,220
Impairment of long-lived assets		—		448		73,751		—		8,490		82,689
Contingent consideration		—		—		3,646		—		—		3,646
Other non-routine, net		3,156		465		206		6		(1,085)		2,748
EBITDA Adjustments		6,288		3,459		78,485		114		42,306		130,652
Adjusted EBITDA	$	202,800	$	107,224	$	49,016	$	31,443	$	(127,798)	$	262,685

	Nine Months Ended September 30, 2013
									Corporate and
	Payer		Provider		Pharmacy		All Other		Eliminations		Consolidated
Revenue from external customers:
Claims management	$	215,933	$	—	$	—	$	—	$	—	$	215,933
Payment distribution services		194,174		—		—		—		—		194,174
Patient billing and payment services		189,396		—		—		—		—		189,396
Revenue cycle technology		—		87,777		—		—		—		87,777
Revenue cycle services		—		92,273		—		—		—		92,273
Physician services		—		27,030		—		—		—		27,030
Pharmacy		—		—		80,331		—		—		80,331
Channel Partner		—		—		—		29,689		(18,642)		11,047
Dental		—		—		—		24,491		—		24,491
Inter-segment revenue		4,399		—		256		—		(4,655)		—
Net revenue	$	603,902	$	207,080	$	80,587	$	54,180	$	(23,297)	$	922,452
Income (loss) before income taxes		144,726		54,987		30,740		25,039		(339,902)	$	(84,410)
Interest expense		1		33		(8)		—		116,364		116,390
Depreciation and amortization		48,355		35,607		11,573		88		42,320		137,943
EBITDA		193,082		90,627		42,305		25,127		(181,218)		169,923
Equity compensation		865		906		140		844		2,882		5,637
Acquisition accounting adjustments		236		402		53		15		35		741
Acquisition-related costs		1,821		91		47		4		494		2,457
Transaction-related costs and advisory fees		—		—		—		—		4,825		4,825
Strategic initiatives, duplicative and transition costs		130		—		781		85		3,359		4,355
Severance costs		434		319		252		263		3,870		5,138
Loss on extinguishment of debt and other related costs		—		—		—		—		24,311		24,311
Accretion		—		—		—		—		18,712		18,712
Impairment of long-lived assets		—		—		—		—		1,887		1,887
Contingent consideration		—		—		1,879		—		—		1,879
Other non-routine, net		218		544		7		6		(2,200)		(1,425)
EBITDA Adjustments		3,704		2,262		3,159		1,217		58,175		68,517
Adjusted EBITDA	$	196,786	$	92,889	$	45,464	$	26,344	$	(123,043)	$	238,440

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Fair Value Measurements

8. Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company’s assets and liabilities that are measured at fair value on a recurring basis consist of the Company’s derivative financial instruments and contingent consideration associated with business combinations. The table below summarizes these items as of September 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

			Quoted in				Significant
	Balance at		Markets		Significant Other		Unobservable
	September 30,		Identical		Observable Inputs		Inputs
Description	2014		(Level 1)		(Level 2)		(Level 3)
Interest rate swaps	$	(1,891)	$	—	$	(1,891)	$	—
Contingent consideration obligations		(15,145)		—		—		(15,145)
Total	$	(17,036)	$	—	$	(1,891)	$	(15,145)

The valuation of the Company’s derivative financial instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivative, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair value of the interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments) using the overnight index swap rate as the discount rate.

The Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements and measures the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs to evaluate the likelihood of default by itself and by its counterparties. As of September 30, 2014, the Company determined that the credit valuation adjustments are not significant to the overall valuation of its derivatives. As a result, the Company determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

The valuation of the Company’s contingent consideration obligations is estimated as the present value of total expected contingent consideration payments which are determined using a Monte Carlo simulation. This analysis reflects the contractual terms of the purchase agreements and utilizes assumptions with regard to future sales, probabilities of achieving such future sales, the likelihood and timing of expected payments and a discount rate. Significant increases with respect to assumptions as to future sales and probabilities of achieving such future sales would result in a higher fair value measurement, while an increase in the discount rate would result in a lower fair value measurement.

The table below presents a reconciliation of the fair value of the liabilities that use significant unobservable inputs (Level 3).

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Balance at beginning of period	$	(13,169)	$	(5,887)	$	(5,484)	$	(296)
Adjustment of provisional amounts		—		223		—		—
Issuance of contingent consideration		—		—		(6,015)		(5,495)
Settlement of contingent consideration		—		105		—		232
Total changes included in contingent consideration		(1,976)		(1,879)		(3,646)		(1,879)
Balance at end of period	$	(15,145)	$	(7,438)	$	(15,145)	$	(7,438)

Assets and Liabilities Measured at Fair Value on a Non-recurring Basis

During the nine months ended September 30, 2014, the Company’s pharmacy services segment received notice that its existing contract with a customer would not be renewed in full upon its expiration. As a result, the Company abandoned a customer related project that was under development and assessed the recoverability of the net assets included in the relevant asset group. The Company recognized an impairment charge to write off the abandoned project and to adjust the carrying value of the asset group to its fair value. This latter impairment charge was generally allocated to the affected long-lived assets on a pro rata basis. Additionally, the Company abandoned certain pharmacy services and provider services segment development projects in connection with execution of certain strategic initiatives during the nine months ended September 30, 2014.

The following table summarizes the affected financial statement captions, the allocation of the impairment charges among those captions and provides certain quantitative information associated with the required fair value measurements.

	Range of Inputs	Fair Value		Impairment
Long-lived assets to be held and used
Relevant asset group	N/A	$	13,066	$	73,220
Balance sheet account:
Customer relationships	N/A		N/A	$	72,290
Property and equipment	N/A		N/A	$	930
Unobservable inputs (discounted cash flow method):
Probability of contract extension	80%		N/A		N/A
Probability of new contract execution	20%-90%		N/A		N/A
Expected annual revenue range	$3,080-$3,590		N/A		N/A
Risk free interest rate	1.6%		N/A		N/A
Long-lived assets to be disposed of
Property and Equipment	N/A	$	—	$	8,848

Assets and Liabilities Measured at Fair Value upon Initial Recognition

The carrying amount and the estimated fair value of financial instruments held by the Company as of September 30, 2014 were:

	Carrying
	Amount		Fair Value
Cash and cash equivalents	$	23,927	$	23,927
Accounts receivable	$	231,950	$	231,950
Senior Credit Facilities (Level 1)	$	1,255,092	$	1,255,926
Senior Notes (Level 2)	$	734,166	$	830,861

The carrying amounts of cash equivalents and accounts receivable approximate fair value because of their short-term maturities. The fair value of long-term debt is based upon market quotes and trades by investors in partial interests of these instruments.

XML

Long-Term Debt

9 Months Ended

Sep. 30, 2014

Long-Term Debt [Abstract]

Long-Term Debt

;6. Long-Term Debt

In November 2011, the Company entered into a credit agreement which was comprised of a senior secured term loan facility (the “Term Loan Facility”), a revolving credit facility (the “Revolving Facility”; together with the Term Loan Facility, the “Senior Credit Facilities”), 11% senior notes due 2019 (the “2019 Notes”) and 11.25% senior notes due 2020 (the “2020 Notes”; together with the 2019 Notes, the “Senior Notes”).

Long-term debt as of September 30, 2014 and December 31, 2013, consisted of the following:

	September 30,		December 31,
	2014		2013
Senior Credit Facilities
$1,301 million Senior Secured Term Loan facility, due November 2, 2018, net of unamortized discount of $13,520 and $15,826 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 4.21%)	$	1,255,092	$	1,262,445
$125 million Senior Secured Revolving Credit facility, expiring on November 2, 2016 and bearing interest at a variable base rate plus a spread rate		—		—
Senior Notes
$375 million 11% Senior Notes due December 31, 2019, net of unamortized discount of $6,966 and $7,664 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.53%)		368,034		367,336
$375 million 11.25% Senior Notes due December 31, 2020, net of unamortized discount of $8,868 and $9,560 at September 30, 2014 and December 31, 2013, respectively (effective interest rate of 11.86%)		366,132		365,440
Obligation under data sublicense agreement		22,543		22,543
Other		11,261		12,592
Less current portion		(24,493)		(31,330)
Long-term debt	$	1,998,569	$	1,999,026

Senior Credit Facilities

The credit agreement governing the Senior Credit Facilities (the “Senior Credit Agreement”) provides that, subject to certain conditions, the Company may request additional tranches of term loans, increase commitments under the Revolving Facility or the Term Loan Facility or add one or more incremental revolving credit facility tranches (provided that the revolving credit commitments outstanding at any time have no more than three different maturity dates) in an aggregate amount not to exceed (a) $300,000 plus (b) an unlimited amount at any time, subject to compliance on a pro forma basis with a first lien net leverage ratio of no greater than 4.00:1.00. Availability of such additional tranches of term loans or revolving credit facilities and/or increased commitments is subject to, among other conditions, the absence of any default under the Senior Credit Agreement and the receipt of commitments by existing or additional financial institutions. Proceeds of the Revolving Facility, including up to $30,000 in the form of borrowings on same-day notice, referred to as swingline loans, and up to $50,000 in the form of letters of credits, are available to provide financing for working capital and general corporate purposes.

Borrowings under the Senior Credit Facilities bear interest at an annual rate equal to an applicable margin plus, at the Company’s option, either (a) a base rate determined by reference to the highest of (i) the applicable prime rate, (ii) the federal funds rate plus 0.50% and (iii) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00%, which base rate, in the case of the Term Loan Facility only, shall be no less than 2.25%, or (b) a LIBOR rate determined by reference to the costs of funds for United States dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, which, in the case of the Term Loan Facility only, shall be no less than 1.25%.  

In April 2012, the Company amended the Senior Credit Agreement to reprice the Senior Credit Facilities and borrow $80,000 of additional term loans. Following this amendment, the LIBOR-based interest rate on the Term Loan Facility was LIBOR plus 3.75%, compared to the previous interest rate of LIBOR plus 5.50%. The new LIBOR-based interest rate on the Revolving Facility was LIBOR plus 3.50% (with a potential step-down to LIBOR plus 3.25% based on the Company’s first lien net leverage ratio), compared to the previous interest rate of LIBOR plus 5.25% (with a potential step-down to LIBOR plus 5.00% based on the Company’s first lien net leverage ratio).

In April 2013, the Company again amended the Senior Credit Agreement to further reprice, and also to modify certain financial covenants under, the Senior Credit Facilities. Following this amendment, the interest rate on the Term Loan Facility is LIBOR plus 2.50%, compared to the previous interest rate of LIBOR plus 3.75%. The new interest rate on the Revolving Facility is LIBOR plus 2.50%, compared to the previous interest rate of LIBOR plus 3.50% (or 3.25% based on a specified first lien net leverage ratio). The Term Loan Facility remains subject to a LIBOR floor of 1.25%, and there continues to be no LIBOR floor on the Revolving Facility. In connection with the April 2013 repricing, the Senior Credit Agreement also was amended to, among other things, eliminate the financial covenant related to the consolidated cash interest coverage ratio and modify the financial covenant related to the net leverage test by maintaining the required first lien net leverage ratio at 5.35 to 1.00 for the remaining term of the Senior Credit Facilities.

These amendments to the Senior Credit Agreement resulted in a loss on extinguishment of debt of $23,160 and other expenses related to fees paid to third parties of $1,151 for the nine months ended September 30, 2013, which have been reflected within sales, marketing, general and administrative expense in the accompanying consolidated statements of operations.

In addition to paying interest on outstanding principal under the Senior Credit Facilities, the Company is required to pay customary agency fees, letter of credit fees and a 0.50% commitment fee in respect of the unutilized commitments under the Revolving Facility.

The Senior Credit Agreement requires that the Company prepay outstanding loans under the Term Loan Facility, subject to certain exceptions, with (a) 100% of the net cash proceeds of any incurrence of debt other than debt permitted under the Senior Credit Agreement, (b) commencing with the fiscal year ended December 31, 2012, 50% (which percentage will be reduced to 25% and 0% based on the Company’s first lien net leverage ratio) of the Company’s annual excess cash flow and (c) 100% of the net cash proceeds of certain asset sales and casualty and condemnation events, subject to reinvestment rights and certain other exceptions.

The Company generally may voluntarily prepay outstanding loans under the Senior Credit Facilities at any time without premium or penalty other than breakage costs with respect to LIBOR loans.

The Company is required to make quarterly payments equal to 0.25% of the aggregate principal amount of the loans under the Term Loan Facility, with the balance due and payable on November 2, 2018. Any principal amount outstanding under the Revolving Facility is due and payable on November 2, 2016.  

Certain of the Company’s United States wholly-owned restricted subsidiaries, together with the Company, are co-borrowers and jointly and severally liable for all obligations under the Senior Credit Facilities. Such obligations of the co-borrowers are unconditionally guaranteed by Beagle Intermediate Holdings, Inc. (a direct wholly-owned subsidiary of Parent), the Company and each of its existing and future United States wholly-owned restricted subsidiaries (with certain exceptions including immaterial subsidiaries). These obligations are secured by a perfected security interest in substantially all of the assets of the co-borrowers and guarantors now owned or later acquired, including a pledge of all of the capital stock of the Company and its United States wholly-owned restricted subsidiaries and 65% of the capital stock of its foreign restricted subsidiaries, subject in each case to the exclusion of certain assets and additional exceptions.

The Senior Credit Agreement requires the Company to comply with a maximum first lien net leverage ratio financial maintenance covenant, to be tested on the last day of each fiscal quarter. A breach of the first lien net leverage ratio covenant is subject to certain equity cure rights. In addition, the Senior Credit Facilities contain a number of negative covenants that, among other things and subject to certain exceptions, restrict the Company’s ability and the ability of its subsidiaries to:

· incur additional indebtedness or guarantees;

· incur liens;

· make investments, loans and acquisitions;

· consolidate or merge;

· sell assets, including capital stock of subsidiaries;

· pay dividends on capital stock or redeem, repurchase or retire capital stock of the Company or any restricted subsidiary, subject to customary covenants, including compliance with leverage ratios and subject to limitation based on net income generated during the term of the Senior Credit Agreement;

· alter the business of the Company;

· amend, prepay, redeem or purchase subordinated debt;

· engage in transactions with affiliates; and

· enter into agreements limiting dividends and distributions of certain subsidiaries.

The Senior Credit Agreement also contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default (including upon change of control).

As of September 30, 2014, the Company believes it was in compliance with all of the applicable debt covenants under the Senior Credit Agreement.

Senior Notes

The 2019 Notes bear interest at an annual rate of 11.00% with interest payable semi-annually on June 30 and December 31 of each year. The 2019 Notes mature on December 31, 2019. The 2020 Notes bear interest at an annual rate of 11.25% with interest payable quarterly on March 31, June 30, September 30 and December 31 of each year. The 2020 Notes mature on December 31, 2020.

The Company may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at any time on or after December 31, 2015 at the applicable redemption price, plus accrued and unpaid interest. In addition, at any time prior to December 31, 2014, the Company may, at its option and on one or more occasions, redeem up to 35% of the aggregate principal amount of the 2019 Notes or the 2020 Notes, at a redemption price equal to 100% of the aggregate principal amount, plus a premium equal to the stated interest rate on the 2019 Notes or the 2020 Notes, respectively, plus accrued and unpaid interest with the net cash proceeds of certain equity offerings; provided that at least 50% of the sum of the aggregate principal amount of the 2019 Notes or 2020 Notes, respectively, originally issued (including any additional notes) remain outstanding immediately after such redemption and the redemption occurs within 180 days of the equity offering. At any time prior to December 31, 2015, the Company may redeem the 2019 Notes, the 2020 Notes or both, in whole or in part, at its option and on one or more occasions, at a redemption price equal to 100% of the principal amount, plus an applicable premium and accrued and unpaid interest. If the Company experiences specific kinds of changes in control, it must offer to purchase the Senior Notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest.

The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of the Company’s existing and future indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness. The Company’s obligations under the Senior Notes are guaranteed on a senior basis by all of its existing and subsequently acquired or organized wholly-owned United States restricted subsidiaries that guarantee the Senior Credit Facilities or its other indebtedness or indebtedness of any affiliate guarantor. The Senior Notes and the related guarantees are effectively subordinated to the Company’s existing and future secured obligations and that of its affiliate guarantors to the extent of the value of the collateral securing such obligations, and are structurally subordinated to all existing and future indebtedness and other liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Notes.

The indentures governing the Senior Notes (the “Indentures”) contain customary covenants that restrict the ability of the Company and its restricted subsidiaries to:

· pay dividends on their capital stock or redeem, repurchase or retire their capital stock, subject to customary covenants, including compliance with a fixed charge coverage ratio and subject to limitation based on net income generated during the term of the Indentures;

· incur additional indebtedness or issue certain capital stock;

· incur certain liens;

· make investments, loans, advances and acquisitions;

· consolidate, merge or transfer all or substantially all of their assets and the assets of their subsidiaries;

· prepay subordinated debt;

· engage in certain transactions with affiliates; and

· enter into agreements restricting the subsidiaries’ ability to pay dividends.

The Indentures also contain certain customary affirmative covenants and events of default.

As of September 30, 2014, the Company believes it was in compliance with all of the applicable debt covenants under the Senior Notes.

Obligation Under Data Sublicense Agreement

In October 2009 and April 2010, the Company acquired certain additional rights to specified uses of its data from the former owner of the Company’s business in order to broaden the Company’s ability to pursue business intelligence and data analytics solutions for payers and providers. The Company previously licensed exclusive rights to this data to the former owner of the Company’s business. In connection with these data rights acquisitions, the Company recorded amortizable intangible assets and corresponding obligations at inception based on the present value of the scheduled annual payments through 2018, which totaled $65,000 in the aggregate (approximately $30,000 remained payable at September 30, 2014). In connection with the Merger, the Company was required to adjust this obligation to its fair value.

Other

From time to time, the Company enters into deferred financing arrangements with certain vendors. The obligations under such arrangements are recorded at the present value of the scheduled payments. Such future payments totaled $12,081 at September 30, 2014.

XML

Interest Rate Swap

9 Months Ended

Sep. 30, 2014

Interest Rate Swap [Abstract]

Interest Rate Swap

7. Interest Rate Swap

Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During the three and nine months ended September 30, 2014, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt pursuant to the Term Loan Facility. As of September 30, 2014, the Company had three outstanding interest rate derivatives with a combined notional amount of $640,000 that were designated as cash flow hedges of interest rate risk.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next twelve months, the Company estimates that an additional $2,570 will be reclassified as an increase to interest expense.

The following table summarizes the fair value of the Company’s derivative instruments at September 30, 2014 and December 31, 2013:

	Fair Values of Derivative Instruments
	Asset (Liability) Derivatives
		September 30,		December 31,
	Balance Sheet Location	2014		2013
Derivatives designated as hedging instruments:
Interest rate swaps	Other assets	$	679	$	899
Interest rate swaps	Accrued expenses		(2,570)		(2,575)
		$	(1,891)	$	(1,676)

Tabular Disclosure of the Effect of Derivative Instruments on the Statement of Operations

The effect of the derivative instruments on the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013, respectively, is summarized in the following table:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Derivatives in Cash Flow Hedging Relationships
Gain/ (loss) related to effective portion of derivative recognized in other comprehensive loss	$	595	$	(2,305)	$	(2,150)	$	2,096
Gain/ (loss) related to effective portion of derivative reclassified from accumulated other comprehensive loss to interest expense	$	(652)	$	(652)	$	(1,935)	$	(1,935)

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where if the Company defaults on any of its indebtedness, including default where repayment of the indebtedness has not been accelerated by the lender, then the Company also could be declared in default on its derivative obligations.

As of September 30, 2014, the termination value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $2,595. If the Company had breached any of these provisions at September 30, 2014, the Company could have been required to settle its obligations under the agreements at this termination value. The Company does not offset any derivative instruments and the derivative instruments are not subject to collateral posting requirements.

XML

Legal Proceedings

9 Months Ended

Sep. 30, 2014

Legal Proceedings [Abstract]

Legal Proceedings

9. Legal Proceedings

The Company finalized and paid $8,000 related to the settlement of a vendor fee dispute during the three months ended September 30, 2014, with $500 and $3,000 of this amount recognized within sales, general, marketing and administrative expense during the three and nine months ended September 30, 2014, respectively.

Additionally, in the normal course of business, the Company is involved in various claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the Company does not believe that their outcomes will have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.

XML

Goodwill And Intangible Assets (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Goodwill And Intangible Assets [Abstract]
Amortization expense of intangible assets	$ 75,286	$ 78,140

XML

Accumulated Other Comprehensive (Loss) Income (Summary Of Accumulated Other Comprehensive Income (Loss)) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at January 1, 2014			$ (1,343)
Change associated with foreign currency translation	(127)	35	(100)	(65)
Change associated with current period hedging			(2,062)
Reclassification into earnings			1,935
Balance at September 30, 2014	(1,570)		(1,570)
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at January 1, 2014			(264)
Change associated with foreign currency translation			(100)
Balance at September 30, 2014	(364)		(364)
Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at January 1, 2014			(1,079)
Change associated with current period hedging			(2,062)
Reclassification into earnings			1,935
Balance at September 30, 2014	$ (1,206)		$ (1,206)

XML

Supplemental Condensed Consolidating Financial Information

9 Months Ended

Sep. 30, 2014

Supplemental Condensed Consolidating Financial Information [Abstract]

Supplemental Condensed Consolidating Financial Information

14. Supplemental Condensed Consolidating Financial Information

In lieu of providing separate annual and interim financial statements for each guarantor of the Senior Notes, Regulation S-X provides companies, if certain criteria are satisfied, with the option to instead provide condensed consolidating financial information for its issuers, guarantors and non-guarantors. In the case of the Company, the applicable criteria include the following: (i) the Senior Notes are fully and unconditionally guaranteed on a joint and several basis, (ii) each of the guarantors of the Senior Notes is a direct or indirect wholly-owned subsidiary of the Company and (iii) any non-guarantors are considered minor as that term is defined in Regulation S-X. Because each of these criteria has been satisfied by the Company, condensed consolidating balance sheets as of September 30, 2014 and December 31, 2013, condensed consolidating statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2014 and 2013, respectively, and condensed consolidating cash flows for the nine months ended September 30, 2014 and 2013, respectively, for the Company, segregating the issuer, the subsidiary guarantors and consolidating adjustments, are reflected below. Prior period amounts have been reclassified to conform to the current year presentation.

Condensed Consolidating Balance Sheet

	As of September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	740	$	23,187	$	—	$	23,927
Accounts receivable, net of allowance for doubtful accounts		—		231,950		—		231,950
Deferred income tax assets		100		16,874		—		16,974
Prepaid expenses and other current assets		3,972		29,113		—		33,085
Total current assets		4,812		301,124		—		305,936
Property and equipment, net		7		239,628		—		239,635
Due from affiliates		—		138,176		(138,176)		—
Investment in consolidated subsidiaries		1,718,809		—		(1,718,809)		—
Goodwill		—		1,584,655		—		1,584,655
Intangible assets, net		135,750		1,395,025		—		1,530,775
Other assets, net		138,648		16,030		(135,022)		19,656
Total assets	$	1,998,026	$	3,674,638	$	(1,992,007)	$	3,680,657
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	12,263	$	—	$	12,263
Accrued expenses		16,589		127,218		—		143,807
Deferred revenues		—		10,233		—		10,233
Current portion of long-term debt		5,577		18,916		—		24,493
Total current liabilities		22,166		168,630		—		190,796
Due to affiliates		138,176		—		(138,176)		—
Long-term debt, excluding current portion		776,954		1,221,615		—		1,998,569
Deferred income tax liabilities		—		552,008		(135,022)		416,986
Tax receivable agreement obligations to related parties		159,716		—		—		159,716
Other long-term liabilities		—		13,576		—		13,576
Commitments and contingencies
Equity		901,014		1,718,809		(1,718,809)		901,014
Total liabilities and equity	$	1,998,026	$	3,674,638	$	(1,992,007)	$	3,680,657

Condensed Consolidating Balance Sheet

	As of December 31, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	2,794	$	73,744	$	—	$	76,538
Accounts receivable, net of allowance for doubtful accounts		—		214,247		—		214,247
Deferred income tax assets		—		6,317		—		6,317
Prepaid expenses and other current assets		3,441		23,578		—		27,019
Total current assets		6,235		317,886		—		324,121
Property and equipment, net		10		269,460		—		269,470
Due from affiliates		—		69,142		(69,142)		—
Investment in subsidiaries		1,764,213		—		(1,764,213)		—
Goodwill		—		1,502,434		—		1,502,434
Intangible assets, net		142,500		1,490,188		—		1,632,688
Other assets, net		64,536		14,949		(60,316)		19,169
Total assets	$	1,977,494	$	3,664,059	$	(1,893,671)	$	3,747,882
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	—	$	8,367	$	—	$	8,367
Accrued expenses		8,205		122,944		—		131,149
Deferred revenues		—		10,881		—		10,881
Current portion of long-term debt		5,775		25,555		—		31,330
Total current liabilities		13,980		167,747		—		181,727
Due to affiliates		69,142		—		(69,142)		—
Long-term debt, excluding current portion		775,330		1,223,696		—		1,999,026
Deferred income tax liabilities		—		496,579		(60,316)		436,263
Tax receivable agreement obligations to related parties		150,496		—		—		150,496
Other long-term liabilities		—		11,824		—		11,824
Commitments and contingencies		—		—		—		—
Total equity		968,546		1,764,213		(1,764,213)		968,546
Total liabilities and equity	$	1,977,494	$	3,664,059	$	(1,893,671)	$	3,747,882

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	341,608	$	—	$	341,608
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		202,305		—		202,305
Development and engineering		—		8,156		—		8,156
Sales, marketing, general and administrative		1,290		43,741		—		45,031
Depreciation and amortization		2,251		46,197		—		48,448
Accretion		4,452		—		—		4,452
Impairment of long-lived assets		—		3,114		—		3,114
Operating income (loss)		(7,993)		38,095		—		30,102
Equity in earnings of consolidated subsidiaries		(10,110)		—		10,110		—
Interest expense, net		23,418		13,217		—		36,635
Contingent consideration		—		1,976		—		1,976
Income (loss) before income tax provision (benefit)		(21,301)		22,902		(10,110)		(8,509)
Income tax provision (benefit)		(8,299)		12,792		—		4,493
Net income (loss)	$	(13,002)	$	10,110	$	(10,110)	$	(13,002)

Condensed Consolidating Statement of Operations

	Three Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	317,810	$	—	$	317,810
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		191,695		—		191,695
Development and engineering		—		7,878		—		7,878
Sales, marketing, general and administrative		1,997		42,107		—		44,104
Depreciation and amortization		2,251		44,930		—		47,181
Accretion		7,112		—		—		7,112
Impairment of long-lived assets		—		25		—		25
Operating income (loss)		(11,360)		31,175		—		19,815
Equity in earnings of consolidated subsidiaries		(3,766)		—		3,766		—
Interest expense, net		23,579		13,421		—		37,000
Contingent consideration		—		1,879		—		1,879
Other		(2,925)		—		—		(2,925)
Income (loss) before income tax provision (benefit)		(28,248)		15,875		(3,766)		(16,139)
Income tax provision (benefit)		(11,983)		12,109		—		126
Net income (loss)	$	(16,265)	$	3,766	$	(3,766)	$	(16,265)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	996,973	$	—	$	996,973
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		597,843		—		597,843
Development and engineering		—		24,771		—		24,771
Sales, marketing, general and administrative		13,775		136,964		—		150,739
Depreciation and amortization		6,753		134,788		—		141,541
Accretion		9,220		—		—		9,220
Impairment of long-lived assets		—		82,689		—		82,689
Operating income (loss)		(29,748)		19,918		—		(9,830)
Equity in earnings of consolidated subsidiaries		51,018		—		(51,018)		—
Interest expense, net		70,224		39,517		—		109,741
Contingent consideration		—		3,646		—		3,646
Other		(111)		(3,857)		—		(3,968)
Income (loss) before income tax provision (benefit)		(150,879)		(19,388)		51,018		(119,249)
Income tax provision (benefit)		(75,363)		31,630		—		(43,733)
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)

Condensed Consolidating Statement of Operations

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Revenue	$	—	$	922,452	$	—	$	922,452
Costs and expenses:
Cost of operations (exclusive of depreciation and amortization below)		—		563,146		—		563,146
Development and engineering		—		23,201		—		23,201
Sales, marketing, general and administrative		7,023		116,446		—		123,469
Depreciation and amortization		6,753		131,190		—		137,943
Accretion		18,712		—		—		18,712
Impairment of long-lived assets		—		1,887		—		1,887
Operating income (loss)		(32,488)		86,582		—		54,094
Equity in earnings of consolidated subsidiaries		(6,216)		—		6,216		—
Interest expense, net		70,621		45,769		—		116,390
Loss on extinguishment of debt		485		22,675		—		23,160
Contingent consideration		—		1,879		—		1,879
Other		(2,925)		—		—		(2,925)
Income (loss) before income tax provision (benefit)		(94,453)		16,259		(6,216)		(84,410)
Income tax provision (benefit)		(36,465)		10,043		—		(26,422)
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(13,002)	$	10,110	$	(10,110)	$	(13,002)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		732		—		—		732
Foreign currency translation adjustment		—		(127)		—		(127)
Equity in other comprehensive earnings		(127)		—		127		—
Other comprehensive income (loss)		605		(127)		127		605
Total comprehensive income (loss)	$	(12,397)	$	9,983	$	(9,983)	$	(12,397)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Three Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(16,265)	$	3,766	$	(3,766)	$	(16,265)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(1,064)		—		—		(1,064)
Foreign currency translation adjustment		—		35		—		35
Equity in other comprehensive earnings		35		—		(35)		—
Other comprehensive income (loss)		(1,029)		35		(35)		(1,029)
Total comprehensive income (loss)	$	(17,294)	$	3,801	$	(3,801)	$	(17,294)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		(127)		—		—		(127)
Foreign currency translation adjustment		—		(100)		—		(100)
Equity in other comprehensive earnings		(100)		—		100		—
Other comprehensive income (loss)		(227)		(100)		100		(227)
Total comprehensive income (loss)	$	(75,743)	$	(51,118)	$	51,118	$	(75,743)

Condensed Consolidating Statement of Comprehensive Income (Loss)

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes		2,511		—		—		2,511
Foreign currency translation adjustment		—		(65)		—		(65)
Equity in other comprehensive earnings		(65)		—		65		—
Other comprehensive income (loss)		2,446		(65)		65		2,446
Total comprehensive income (loss)	$	(55,542)	$	6,151	$	(6,151)	$	(55,542)

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2014
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Operating activities
Net income (loss)	$	(75,516)	$	(51,018)	$	51,018	$	(75,516)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		6,753		134,788		-		141,541
Accretion		9,220		-		-		9,220
Equity compensation		255		5,659		-		5,914
Deferred income tax expense (benefit)		(74,817)		29,931		-		(44,886)
Amortization of debt discount and issuance costs		2,003		3,801		-		5,804
Contingent consideration		-		3,646		-		3,646
Impairment of long lived assets		-		82,689		-		82,689
Equity in earnings of consolidated subsidiaries		51,018		-		(51,018)		-
Other		(1,094)		(2,031)		-		(3,125)
Changes in operating assets and liabilities:
Accounts receivable		-		(12,656)		-		(12,656)
Prepaid expenses and other		(462)		(4,028)		-		(4,490)
Accounts payable		-		644		-		644
Accrued expenses, deferred revenue, and other liabilities		9,377		(9,752)		-		(375)
Due to/from affiliates		69,034		(69,034)		-		-
Net cash provided (used in) by operating activities		(4,229)		112,639		-		108,410
Investing activities
Purchases of property and equipment		-		(37,673)		-		(37,673)
Payments for acquisitions, net of cash acquired		-		(87,909)		-		(87,909)
Proceeds from sale of cost method investment		36		-		-		36
Other		-		(133)		-		(133)
Investment in subsidiary		50		-		(50)		-
Net cash provided by (used in) investing activities		86		(125,715)		(50)		(125,679)
Financing activities
Distributions from (to) Emdeon Inc. net		-		(50)		50		-
Debt principal payments		(207)		(9,452)		-		(9,659)
Payment of debt assumed from acquisition		-		(23,262)		-		(23,262)
Proceeds from Revolving Facility		-		65,000		-		65,000
Payments on Revolving Facility		-		(65,000)		-		(65,000)
Repayment of deferred financing arrangements		-		(4,717)		-		(4,717)
Repurchase of Parent common stock		(960)		-		-		(960)
Capital contribution from Parent		3,256		-		-		3,256
Net cash provided by (used in) financing activities		2,089		(37,481)		50		(35,342)
Net decrease in cash and cash equivalents		(2,054)		(50,557)		-		(52,611)
Cash and cash equivalents at beginning of period		2,794		73,744		-		76,538
Cash and cash equivalents at end of period	$	740	$	23,187	$	-	$	23,927

Condensed Consolidating Statement of Cash Flows

	Nine Months Ended September 30, 2013
			Guarantor		Consolidating
	Emdeon Inc.		Subsidiaries		Adjustments		Consolidated
Operating activities
Net income (loss)	$	(57,988)	$	6,216	$	(6,216)	$	(57,988)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		6,753		131,190		-		137,943
Accretion expense		18,712		-		-		18,712
Equity compensation expense		178		5,459		-		5,637
Deferred income tax expense (benefit)		(33,425)		5,541		-		(27,884)
Amortization of debt discount and issuance costs		1,865		4,720		-		6,585
Contingent consideration		-		1,879		-		1,879
Loss on extinguishment of debt		478		22,350		-		22,828
Impairment of long lived assets		-		1,887		-		1,887
Gain on sale of cost method investment		(2,925)		-		-		(2,925)
Equity in earnings of consolidated subsidiaries		(6,216)		-		6,216		-
Other		(819)		-		-		(819)
Changes in operating assets and liabilities:
Accounts receivable		-		(15,582)		-		(15,582)
Prepaid expenses and other		(4,732)		2,928		-		(1,804)
Accounts payable		-		685		-		685
Accrued expenses, deferred revenue, and other liabilities		14,509		6,476		-		20,985
Tax receivable agreement obligations to related parties		(103)		-		-		(103)
Due to/from affiliates		1,923		(1,923)		-		-
Net cash provided by (used in) operating activities		(61,790)		171,826		-		110,036
Investing activities
Purchases of property and equipment		-		(52,806)		-		(52,806)
Payments for acquisitions, net of cash acquired		-		(18,291)		-		(18,291)
Proceeds from sale of cost method investment		5,820		-		-		5,820
Investment in subsidiaries, net		56,149		-		(56,149)		-
Net cash provided by (used in) investing activities		61,969		(71,097)		(56,149)		(65,277)
Financing activities
Distributions from (to) Emdeon Inc., net		-		(56,149)		56,149		-
Debt principal payments		(211)		(9,481)		-		(9,692)
Payment of debt assumed from acquisition		-		(218)		-		(218)
Payment of loan costs		-		(2,178)		-		(2,178)
Repayment of deferred financing arrangements		-		(2,103)		-		(2,103)
Repurchase of Parent common stock		-		(250)		-		(250)
Other		-		(518)		-		(518)
Net cash provided by (used in) financing activities		(211)		(70,897)		56,149		(14,959)
Net increase (decrease) in cash and cash equivalents		(32)		29,832		-		29,800
Cash and cash equivalents at beginning of period		754		31,009		-		31,763
Cash and cash equivalents at end of period	$	722	$	60,841	$	-	$	61,563

XML

Interest Rate Swap (Tables)

9 Months Ended

Sep. 30, 2014

Interest Rate Swap [Abstract]

Fair Value of Derivative Instrument

	Fair Values of Derivative Instruments
	Asset (Liability) Derivatives
		September 30,		December 31,
	Balance Sheet Location	2014		2013
Derivatives designated as hedging instruments:
Interest rate swaps	Other assets	$	679	$	899
Interest rate swaps	Accrued expenses		(2,570)		(2,575)
		$	(1,891)	$	(1,676)

Effect of Derivative Instrument on the Accompanying Consolidated Statements of Operations

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Derivatives in Cash Flow Hedging Relationships
Gain/ (loss) related to effective portion of derivative recognized in other comprehensive loss	$	595	$	(2,305)	$	(2,150)	$	2,096
Gain/ (loss) related to effective portion of derivative reclassified from accumulated other comprehensive loss to interest expense	$	(652)	$	(652)	$	(1,935)	$	(1,935)

XML

Tax Receivable Agreement Obligations To Related Parties (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Tax Receivable Agreement Obligation to Related Parties [Abstract]
Percentage of cash savings	85.00%
Retained ratio of tax savings	15.00%
Cumulative payments under tax receivable agreement	$ 352,521
Initial fair value of tax receivable agreement	160,690
Change in estimate effect on pretax income/loss	$ 5,756

XML

Interest Rate Swap (Fair Value Of Derivative Instrument) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Derivatives designated as hedging instruments:
Fair Values of Derivative Instruments Asset (Liability) Derivatives	$ (1,891)	$ (1,676)
Other assets [Member] | Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Derivatives designated as hedging instruments:
Fair Values of Derivative Instruments Asset (Liability) Derivatives	(679)	(899)
Accrued expenses [Member] | Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Derivatives designated as hedging instruments:
Fair Values of Derivative Instruments Asset (Liability) Derivatives	$ (2,570)	$ (2,575)

XML

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ (13,002)	$ (16,265)	$ (75,516)	$ (57,988)
Other comprehensive income (loss):
Changes in fair value of interest rate swap, net of taxes	732	(1,064)	(127)	2,511
Foreign currency translation adjustment	(127)	35	(100)	(65)
Other comprehensive income (loss)	605	(1,029)	(227)	2,446
Total comprehensive income (loss)	$ (12,397)	$ (17,294)	$ (75,743)	$ (55,542)

XML

Concentration of Credit Risk

9 Months Ended

Sep. 30, 2014

Concentration of Credit Risk [Abstract]

Concentration of Credit Risk

3. Concentration of Credit Risk

The Company’s revenue is primarily generated in the United States. Changes in economic conditions, government regulations or demographic trends, among other matters, in the United States could adversely affect the Company’s revenue and results of operations.

The Company maintains its cash and cash equivalent balances in either insured depository accounts or money market mutual funds. The money market mutual funds are limited to investments in low-risk securities such as United States or government agency obligations, or repurchase agreements secured by such securities.

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Fair Value of Financial Instruments Measured on a Recurring Basis

			Quoted in				Significant
	Balance at		Markets		Significant Other		Unobservable
	September 30,		Identical		Observable Inputs		Inputs
Description	2014		(Level 1)		(Level 2)		(Level 3)
Interest rate swaps	$	(1,891)	$	—	$	(1,891)	$	—
Contingent consideration obligations		(15,145)		—		—		(15,145)
Total	$	(17,036)	$	—	$	(1,891)	$	(15,145)

Reconciliation of the Fair Value of the Liabilities That Use Significant Unobservable Inputs (Level 3)

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013
Balance at beginning of period	$	(13,169)	$	(5,887)	$	(5,484)	$	(296)
Adjustment of provisional amounts		—		223		—		—
Issuance of contingent consideration		—		—		(6,015)		(5,495)
Settlement of contingent consideration		—		105		—		232
Total changes included in contingent consideration		(1,976)		(1,879)		(3,646)		(1,879)
Balance at end of period	$	(15,145)	$	(7,438)	$	(15,145)	$	(7,438)

Quantitative Information about Level 3 Fair Value Measurements

	Range of Inputs	Fair Value		Impairment
Long-lived assets to be held and used
Relevant asset group	N/A	$	13,066	$	73,220
Balance sheet account:
Customer relationships	N/A		N/A	$	72,290
Property and equipment	N/A		N/A	$	930
Unobservable inputs (discounted cash flow method):
Probability of contract extension	80%		N/A		N/A
Probability of new contract execution	20%-90%		N/A		N/A
Expected annual revenue range	$3,080-$3,590		N/A		N/A
Risk free interest rate	1.6%		N/A		N/A
Long-lived assets to be disposed of
Property and Equipment	N/A	$	—	$	8,848

Carrying Amount and the Estimated Fair Value of Financial Instruments

	Carrying
	Amount		Fair Value
Cash and cash equivalents	$	23,927	$	23,927
Accounts receivable	$	231,950	$	231,950
Senior Credit Facilities (Level 1)	$	1,255,092	$	1,255,926
Senior Notes (Level 2)	$	734,166	$	830,861

XML

Long-Term Debt (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended		9 Months Ended	1 Months Ended		9 Months Ended									1 Months Ended			9 Months Ended			1 Months Ended			9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014 Senior Notes [Member]	Apr. 30, 2013 Senior Credit Facilities [Member]	Apr. 30, 2012 Senior Credit Facilities [Member]	Sep. 30, 2014 Senior Credit Facilities [Member]	Sep. 30, 2014 Senior Credit Facilities [Member] LIBOR [Member]	Sep. 30, 2014 Senior Credit Facilities [Member] Federal Funds Rate [Member]	Sep. 30, 2014 11% Senior Notes Due December 31, 2019 [Member] Senior Notes [Member]	Sep. 30, 2014 11.25% Senior Notes Due December 31, 2020 [Member] Senior Notes [Member]	Sep. 30, 2014 Senior Secured Term Loan Facility, Due November 2, 2018 [Member] Senior Credit Facilities [Member]	Sep. 30, 2014 Senior Secured Revolving Credit Facility, Expiring On November 2, 2016 [Member] Senior Credit Facilities [Member]	Sep. 30, 2014 Maximum [Member] Senior Credit Facilities [Member]	Sep. 30, 2014 Revolving Credit Facility [Member] Senior Credit Facilities [Member]	Apr. 30, 2013 Revolving Credit Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Apr. 30, 2012 Revolving Credit Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Mar. 31, 2012 Revolving Credit Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Sep. 30, 2014 Same Day Notice [Member] Senior Credit Facilities [Member]	Sep. 30, 2014 Letters Of Credit [Member] Senior Credit Facilities [Member]	Sep. 30, 2014 Term Loan Facility [Member] Senior Credit Facilities [Member]	Apr. 30, 2013 Term Loan Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Apr. 30, 2012 Term Loan Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Mar. 31, 2012 Term Loan Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Sep. 30, 2014 Term Loan Facility [Member] Senior Credit Facilities [Member] LIBOR [Member]	Sep. 30, 2014 Data Sublicense Agreement [Member]	Apr. 30, 2010 Data Sublicense Agreement [Member]	Oct. 31, 2009 Data Sublicense Agreement [Member]
Debt Instrument [Line Items]
Stated interest rate									11.00%	11.25%
Accordion credit						$ 300,000
Net leverage ratio				5.35									4.00
Proceeds from credit facility																		30,000	50,000
Basis spread on variable rate							1.00%	0.50%							2.50%	3.50%	5.25%				2.50%	3.75%	5.50%
Effective interest rate minimum							2.25%																	1.25%
Proceeds from issuance of debt					80,000
Potential step down basis spread on variable rate																3.25%	5.00%
LIBOR floor rate																					1.25%
Loss on extinguishment of debt	(23,160)					23,160
Third party fees						1,151
Commitment fee percentage						0.50%
Net cash proceeds of incurrence of debt, percentage						100.00%
Percentage of annual excess cash flow						50.00%
Percentage of annual excess cash flow based on first lien net leverage ratio						25.00%
Reduced percentage of annual excess cash flow based on first lien net leverage ratio						0.00%
Net cash proceeds of asset sales and casualty and condemnation events						100.00%
Quarterly payment on original principal amount of loans																				0.25%
Maturity date									Dec. 31, 2019	Dec. 31, 2020	Nov. 02, 2018	Nov. 02, 2016		Nov. 02, 2016						Nov. 02, 2018
Percentage of capital stock of foreign restricted subsidiaries						65.00%
Principal amount redemption, percentage			35.00%
Repurchase price percent equal of the principal amount, plus accrued and unpaid interest			101.00%
Aggregate redemption price plus any accured and unpaid interest, percentage			100.00%
Principal amount redemption, minimum percentage			50.00%
Redemption period			180 days
Redemption period end date			Dec. 31, 2015
Payments due related to an asset acquired																									30,000	65,000	65,000
Deferred Financing obligations recorded at the present value of the scheduled payments		$ 12,081

XML

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2014

Accumulated Other Comprehensive Income (Loss) [Abstract]

Accumulated Other Comprehensive Income (Loss)

13. Accumulated Other Comprehensive Income (Loss)

The following is a summary of the accumulated other comprehensive income (loss) balances, net of taxes, as of and for the nine months ended September 30, 2014.

	Foreign				Accumulated
	Currency				Other
	Translation		Cash Flow		Comprehensive
	Adjustment		Hedge		Income (Loss)
Balance at January 1, 2014	$	(264)	$	(1,079)	$	(1,343)
Change associated with foreign currency translation		(100)		—		(100)
Change associated with current period hedging		—		(2,062)		(2,062)
Reclassification into earnings		—		1,935		1,935
Balance at September 30, 2014	$	(364)	$	(1,206)	$	(1,570)